











































participants	 that	 underwent	 either	 a	 hyperinsulinaemic-hypoglycaemic	 (2.5	
mmol/l)	 (n=8),	 euglycaemic	 (6.0	 mmol/l)	 (n=8)	 or	 sham-saline	 clamp	 (n=8)	
(normoglycaemic	conditions).	To	determine	if	antecedent	hypoglycaemia	modified	
innate	 immune	 responses,	 all	 participants	 then	 received	 a	 low	 dose	 (0.3	 ng/kg)	
intravenous	 endotoxin	 challenge	 48	 hours	 later.	 I	 studied	 in	 vivo	 monocyte	
mobilisation	 and	 monocyte-platelet	 interactions.	 In	 comparison	 to	 controls,	
hypoglycaemia	 increased	 total	 leukocytes	 and	 significantly	 mobilised	 pro-
inflammatory	CD16+	monocytes.	Platelet	aggregation	 to	agonist,	 and	 formation	of	
monocyte-platelet	 aggregates,	 increased	 following	hypoglycaemia	with	 significant	
aggregation	 of	 CD16+	 monocytes	 and	 platelets.	 Compared	 to	 euglycaemia,	





In	mice,	 I	 developed	 a	 unique	model	 of	 recurrent	 insulin	 induced	hypoglycaemia	
(n=10)	 or	 sham-saline	 injection	 (n=10)	 in	 high	 fat	 diet	 fed	 Apolipoprotein	 E	
deficient	mice		(ApoE	-/-)	that	had	pre-established	atherosclerotic	plaques.		I	show	
that	 8	 episodes	 of	 a	 modest	 recurrent	 hypoglycaemic	 stimulus	 over	 4	 weeks	
compared	 to	 sham-saline	 injection	 resulted	 in	 a	 trend	 towards	 increased	 total	
atherosclerotic	burden	in	whole	aortae.		
	
I	 conclude	 that	 hypoglycaemia	mobilises	monocytes,	 increases	 platelet	 reactivity,	
promotes	 interaction	 between	 platelets	 and	 pro-inflammatory	monocyte	 subsets,	
and	 changes	 the	 subsequent	 immune	 response	 to	 endotoxin	 in	 humans.	 In	mice,	
data	 suggest	 pro-atherosclerotic	 effects	 of	 recurrent	 hypoglycaemia	 that	 abolish	




































































































































have	 obtained	 permission	 from	 original	 copyright	 owners	 to	 reproduce	 or	 adapt	
material	presented	herein.	My	contribution	 to	both	human	and	murine	 studies	 is	
explicitly	indicated	below.	
	
Human	 studies:	 I	 conducted	 all	 human	 studies.	 I	 drafted	 all	 study	 experimental	
protocols	 and	 with	 the	 help	 of	 my	 supervisors	 (Professor	 Sabroe	 and	 Professor	
Heller)	 obtained	 ethics	 and	 local	 trust	 (NHS)	 approval.	 I	 was	 responsible	 for	
recruiting	 all	 participants,	 screening	 participants	 and	 then	 performing	 all	 trial	
visits	 until	 each	 participant	 successfully	 exited	 the	 study.	 Thus,	 I	 independently	








visit	 to	 ensure	 their	 safety	 (during	 hypoglycaemic	 and	 euglycaemic	 clamps)	 and	
following	 intravenous	endotoxin	challenge,	 I	received	support	 in	preparing	whole	
blood	 for	 flow	cytometry	and	platelet	assays	during	 trial	visits.	This	 support	was	
provided	by	two	Sheffield	Hallam	University	placement	students	(Danielle	Lambert	
and	 Lewis	 Birch)	 over	 the	 course	 of	 the	 study,	 that	 I	 trained	 and	 supervised.	
Additional	trial	support	was	provided	during	the	demanding	endotoxin	visits	(x	4	





Murine	 studies:	 I	 obtained	 a	 home	 office	 personal	 licence	 and	 conducted	 all	




Ariaans	 and	 Carl	 Wright	 in	 animal	 cardiac	 puncture	 prior	 to	 performing	 these	
independently.	 I	 performed	 animal	 sacrifice	 and	 dissection	 independently.	 I	
received	instruction	in	sectioning	and	assistance	in	sectioning	of	animal	tissue	from	





































































this	 work.	 Firstly,	 I	 would	 like	 to	 thank	 my	 supervisory	 team:	 Professor	 Sheila	
Francis,	 Professor	 Simon	 Heller,	 Professor	 Ian	 Sabroe	 and	 Dr	 Lynne	 Prince.		
Without	 their	 persistent	 encouragement	 and	 support	 this	 work	 would	 not	 have	
been	 possible.	 Dr	 Elaine	 Chow	 provided	 me	 with	 invaluable	 training	 on	 clamp	
techniques	allowing	me	to	generate	preliminary	data	for	my	fellowship	application.	
Susan	Hudson,	Chloe	Husband,	Helena	Renberg-Fawcett	as	nursing	colleagues	and	
Dr	 Alan	 Bernjak	 and	 Dr	 Peter	 Novodvorsky	 have	 played	 an	 instrumental	 role	 in	
helping	me	set	up	the	hyperinsulinaemic	and	low-dose	endotoxin	challenge	studies.	
I	 must	 acknowledge	 Danielle	 Lambert,	 Lewis	 Birch,	 Dr	 Linda	 Kay,	 Fiona	Wright,	
Carl	Wright,	 Jessica	Willis	 and	Dr	Mark	 Ariaans	 for	 providing	 excellent	 technical	
support	during	the	course	of	my	studies.	Dr	Richard	Jacques	from	the	University	of	
Sheffield	 School	 of	 Health	 and	 Related	 Research	 (ScHARR)	 provided	 statistical	
advice	for	which	I	am	grateful.	
	
I	 am	 also	 grateful	 to	 Professor	 Rob	 Storey	 and	 Dr	 Mark	 Thomas	 for	 their	
collaborative	input.	Dr	Jessica	Johnston	taught	me	core	histological	techniques	for	
which	 I	 am	 grateful.	 Professor	 Rory	 McCrimmon	 and	 Dr	 Alison	 McNeilly	 at	 the	
University	 of	 Dundee	 provided	 valuable	 input	 in	 designing	 and	 conducting	 my	
murine	model	of	recurrent	hypoglycaemia.	I	would	also	like	to	extend	my	gratitude	
to	 the	 Medical	 Research	 Council	 for	 funding	 this	 project	 as	 part	 of	 a	 clinical	
research	 training	 fellowship.	 I	 am	 eternally	 grateful	 to	 all	 study	 participants	 and	
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The	 earliest	 accurate	 description	 of	 diabetes	 mellitus	 arguably	 comes	 from	
Aretaeus	of	Cappadocia	(80-138	AD).	Aretaeus	astutely	observed	that	patients	with	
diabetes	 had	 excessive	 thirst	 and	 urinated	 frequently.	 The	 Persian	 polymath	
Avicenna	(980-1037)	gave	a	more	detailed	clinical	account	of	diabetes	including	a	
peculiar	sweetness	 to	urine	 from	patients	with	diabetes	 in	his	 influential	 text	 the	
Canon	of	Medicine.	Thomas	Crawley	in	1788	first	suggested	that	the	pancreas	gland	
was	implicated	in	the	pathophysiology	of	diabetes.	It	was	not	until	1921,	however,	
that	 Canadian	 scientists	 Banting	 and	 Best	 first	 extracted	 insulin	 from	 dogs	 to	
successfully	treat	diabetes	(Banting,	Campbell	and	Fletcher,	1923).	
	
	Today,	 diabetes	poses	 a	 significant	 global	 threat	 to	human	health,	wellbeing	 and	
prosperity.	The	number	of	adults	with	diabetes	has	risen	from	108	million	in	1980	
to	 422	 million	 in	 2014	 and	 alarmingly	 this	 number	 is	 projected	 to	 exceed	 500	
million	 by	 2035	 (Mathers	 et	 al.,	 2006).	 There	 are	 3.6	 million	 people	 living	 with	




the	presence	of	 typical	diabetes	 symptoms	 (polyuria,	 polydipsia	 and	unexplained	
weight	 loss	 for	 T1D)	 plus:	 a	 random	 venous	 plasma	 glucose	 ≥	 11.1	mmol/l	 or	 a	
fasting	plasma	glucose	concentration	≥	7.0	mmol/l	or	a	 two	hour	plasma	glucose	
concentration	 ≥	 11.1	mmol/l	 following	 a	 75g	 anhydrous	 glucose	 challenge	 in	 an	




an	 HbA1c	 of	 	 >	 6.5%	 (48	 mmol/mol)	 is	 sufficient	 for	 the	 diagnosis	 of	 diabetes	
(WHO,	 2011).	 T1D	 is	 characterised	 by	 an	 absolute	 deficiency	 of	 insulin.	 In	 T2D,	
which	accounts	for	between	90-95%	of	diabetes,	a	combined	resistance	to	insulin	
both	in	skeletal	muscle	and	the	liver,	in	addition	to	defective	insulin	production	by	
pancreatic	 β	 cells	 is	 present	 (DeFronzo,	 2004).	 The	 underlying	 biochemical	
abnormality	 in	both	T1D	and	T2D	 is	persistent	hyperglycaemia,	which	 leads	 to	 a	
myriad	of	 complications	 affecting	both	 small	 and	 large	blood	 vessels	 in	 the	body	
termed	 micro	 and	 macrovascular	 complications	 respectively.	 Within	
macrovascular	 complications,	 the	 leading	 cause	 of	 death	 for	 all	 patients	 with	
diabetes	is	cardiovascular	disease	(CVD),	usually	due	to	acute	myocardial	infarction	
(AMI)	or	 cerebrovascular	accident	 (CVA)	 (Morrish	et	al.,	 2001;	Laing	et	al.,	 2003;	
Tu	et	al.,	2008).		
	
Much	 investigation	 has	 focussed	 on	 hyperglycaemia	 and	 the	 benefit	 of	 good	
glycaemic	control	in	reducing	micro	and	macrovascular	complications	in	diabetes.	
Whilst	the	role	of	tight	glycaemic	control	in	reducing	microvascular	complications	
is	 well	 established	 (UK	 Prospective	 Diabetes	 Study	 Group,	 1998	 a,b),	 the	
contribution	 of	 tight	 glucose	 control	 in	 reducing	 macrovascular	 complications	
remains	 less	 certain.	 Three	 large	 randomised	 controlled	 trials:	 Action	 to	 Control	
Cardiovascular	 Risk	 in	 Diabetes	 (ACCORD),	 Action	 in	 Diabetes	 and	 Vascular	
Disease:	 Preterax	 and	 Diamicron	 Modified	 Release	 Controlled	 Evaluation	
(ADVANCE	study)	and	the	Veteran’s	Affairs	Diabetes	Trial	(VADT)	(Gerstein	et	al.,	
2008;	Patel	et	al.,	2008;	Duckworth	et	al.,	2009)	have	recently	tested	the	effects	of	
intensive	 glucose	 control	 on	 major	 cardiovascular	 (CV)	 end	 points	 in	 T2D.	
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Participants	 underwent	 randomisation	 to	 achieve	 intensive	 glucose	 control,	
defined	 by	 a	 glycated	 haemoglobin	A1c	 (HbA1c)	 of	 <6.0%	 in	ACCORD	 and	VADT	









In	 this	 introductory	 chapter,	 I	will	 first	discuss	 the	epidemiology,	physiology	and	
clinical	 consequences	 of	 hypoglycaemia.	 As	 an	 association	 between	 severe	
hypoglycaemia	and	increased	CV	mortality	is	more	consistently	reported	in	T2D,	I	
will	then	provide	a	critical	review	of	trials	of	intensive	glycaemic	control	in	T2D	in	
light	 of	 hypoglycaemia	 emerging	 as	 a	 potential	 causal	 factor	 for	 CV	 events	 from	
these	 data.	 Existing	 literature	 on	 mechanistic	 links	 between	 hypoglycaemia	 and	
CVD	 will	 then	 be	 reviewed.	 I	 will	 then	 detail	 the	 aetiology	 of	 atherosclerosis	
focusing	 on	 the	 role	 of	 the	 innate	 immune	 system	 prior	 to	 discussing	 the	 use	 of	
intravenous	 endotoxin	 challenge	 as	 a	 model	 of	 sterile	 inflammation	 in	 humans.	








An	 ADA	 working	 group	 (American	 Diabetes	 Association	 2005)	 has	 defined	
symptomatic	hypoglycaemia	as	the	presence	of	typical	symptoms	of	hypoglycaemia	
with	 a	 glucose	 measurement	 <	 3.9	mmol/l	 and	 severe	 hypoglycaemia	 as	 any	
episode	 requiring	 the	 assistance	 of	 another	 person	 to	 recover.	 These	 definitions	
have	 limitations,	 however,	 and	 universal	 application	 is	 difficult.	 For	 example,	
paediatricians	 generally	 include	 hypoglycaemic	 episodes	 that	 cause	 coma	 or	
seizures	 in	 their	 definition	 for	 severe	 hypoglycaemia	 as	 young	 children	 always	








agreed	 a	 position	 statement	 that	 proposes	 the	 inclusion	 of	 a	 third	 glucose	 level,	
denoting	 ‘clinically	 important’	 (in	 addition	 to	 <	 3.9	mmol/l	 and	 severe	
hypoglycaemia)	 at	 <	 3.0	mmol/l	 for	 the	 classification	 of	 hypoglycaemia	 (The	
International	 Hypoglycaemia	 Study	 Group	 2017).	 However,	 these	 new	 proposed	
criteria	for	hypoglycaemia	have	yet	to	be	agreed	more	widely.	Thus,	in	this	section	I	




to	 recover)	 is	 currently	 widely	 accepted.	 It	 is	 important	 to	 note	 that	 data	 from	
clinical	 trials	 report	 rates	 of	 hypoglycaemia,	 including	 severe,	 which	 are	 many	
times	 lower	 than	rates	collected	 from	observational	data.	 In	 the	Diabetes	Control	
and	 Complications	 Trial	 (DCCT),	 which	 is	 considered	 to	 have	 resulted	 in	 an	
epidemic	of	severe	hypoglycaemia	in	the	intensive	arm,	reported	rates	expressed	in	
episodes	per	patient	year	were	considerably	 lower	 than	rates	 from	observational	
studies	 (Diabetes	 Control	 and	 Complications	 Trial	 Research	 Group	 et	 al.,	 1993).	
More	recent	clinical	trials	have	reported	even	lower	rates	of	severe	hypoglycaemia	
(Bergenstal	et	al.,	 2010).	 In	 contrast,	 data	 reported	 in	observational	 studies	have	
shown	 virtually	 no	 reduction	 in	 rates	 of	 severe	 hypoglycaemia	 over	 the	 last	 20	
years,	despite	 the	 introduction	of	 insulin	analogues	and	continuous	subcutaneous	
insulin	 infusion	 (CSII)	 (Table	 1.1)(MacLeod	 et	 al.	 1993;	 ter	 Braak	 et	 al.	 2000;	
Pedersen-Bjergaard	et	al.	2004;	UK	Hypoglycaemia	Study	Group	2007;	Kristensen	
et	 al.	 2012).	 These	 data	 suggest	 that	 clinicians	 are	 either	 failing	 to	 exploit	
technological	 developments	 or	 that	 other	 factors	 often	 determine	 hypoglycaemic	
risk.	 Prospective	 population	 based	 studies	 which	 have	 examined	 hypoglycaemic	
rates	 indicate	 that	 rates	 of	 severe	 hypoglycaemia	 in	 insulin	 treated	T2D	patients	
are	generally	a	third	of	the	rates	seen	in	patients	with	T1D	(Donnelly	et	al.,	2005).	
Interestingly,	 comparable	 rates	of	hypoglycaemia	have	been	reported	 in	T1D	and	
T2D	once	patients	were	matched	for	duration	of	insulin	treatment	(Hepburn	et	al.,	
1993).	 Data	 from	 another	 prospective	 study	 also	 showed	 that	 severe	
hypoglycaemia	 rates	 rise	 in	 both	 T1D	 and	 T2D	 with	 increasing	 duration	
of	treatment	 (UK	 Hypoglycaemia	 Study	 Group	 2007).	 These	 findings	 may	 be	




free	 insulin	 levels.	 Finally,	 as	 T2D	 is	 much	 more	 common	 than	 T1D	 with	 an	
increasing	incidence	predicted	in	the	coming	years	(Hossain,	Kawar	and	El	Nahas,	
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1.2.2	Physiology	of	hypoglycaemia	
The	 brain	 relies	 on	 glucose	 as	 an	 obligate	 fuel	 and	 this	 explains	 both	 the	
vulnerability	 of	 patients	 to	 hypoglycaemia	 and	 the	 array	 of	 defences	 that	 have	
evolved	 as	 stress	 responses.	 These	 physiological	 responses	 are	 termed	 counter-
regulatory	 (opposing	 the	 regulatory	 effect	 of	 insulin)(Figure	 1.1).	 Two	 key	
responses	 are	 triggered	 by	 hypoglycaemia:	 1)	 Increased	 endogenous	 glucose	
production	 via	 glycogenolysis	 and	 gluconeogenesis;	 2)	 A	 behavioural	 response	
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prompting	 the	 individual	 to	 consume	 food.	 In	 individuals	 without	 diabetes,	 the	
initial	 response	 to	 glucose	 values	 falling	 below	 4.6	 mmol/l	 is	 a	 reduction	 in	
endogenous	insulin	secretion	(Cryer,	Davis	and	Shamoon,	2003).	Since	individuals	
with	 T1D	 and	 insulin-treated	 T2D	 depend	 on	 injected	 insulin	 boluses	 in	 the	
absence	of	endogenous	insulin	secretion,	their	ability	to	defend	themselves	against	
hypoglycaemia	requires	additional	mechanisms.	Initially,	as	glucose	concentrations	
fall	 below	 3.8	 mmol/l,	 endogenous	 glucagon	 secretion	 from	 pancreatic	 α	 cells	
induces	both	glycogenolysis	and	gluconeogenesis	 (Cryer,	2008).	As	blood	glucose	
falls	 further,	 the	 adrenal	medulla	 secretes	 adrenaline	 (and	 to	 a	 lesser	 extent	 also	
noradrenaline)	 which	 promotes	 hepatic	 glucose	 release	 through	 similar	























Experimental	 data	 indicate	 that	 counter-regulatory	 responses	 to	 hypoglycaemia	
whilst	 intact	 at	 diagnosis	 of	 T1D,	 are	 gradually	 lost	 with	 increasing	 disease	
duration	 (Bolli	 et	 al.,	 1983;	White	 et	 al.,	 1983).	 Counter-regulatory	 responses	 to	
hypoglycaemia	have	been	less	extensively	studied	in	individuals	with	T2D	but	the	
same	drivers	which	increase	vulnerability	in	T1D	may	also	operate	in	longstanding	




of	 iatrogenic	 hypoglycaemia	 which	 attenuate	 the	 autonomic	 response	 to	
subsequent	hypoglycaemia	(Amiel	et	al.,	1988;	Heller	and	Cryer,	1991;	Davis	et	al.,	
2009).	Recurrent,	episodic	hypoglycaemic	events	of	 sufficient	depth	and	duration	
progressively	 blunt	 and	 impair	 normal	 counter-regulatory	 responses	 to	
hypoglycaemia	 predisposing	 patients	 to	 a	 vicious	 cycle	 of	 ever	 more	 frequent	
hypoglycaemic	 episodes	 with	 a	 falling	 glucose	 threshold	 to	 trigger	 counter-
regulation	(Cryer,	1993).	Cryer	has	termed	this	sequence	of	events	hypoglycaemia-
associated	autonomic	failure	(HAAF)(Cryer,	1992).		
There	 is,	 however,	 good	 evidence	 to	 suggest	 that	 reduced	 neuroendocrine	 and	







The	 UKPDS	 study	 was	 an	 influential	 prospective,	 multicentre,	 randomised	
controlled	trial	that	showed	that	intensive	glycaemic	control	{average	HbA1c	of	7%	
(52	 mmol/mol)}	 in	 newly	 diagnosed	 T2D	 significantly	 reduced	 microvascular	
complications	 with	 a	 non-significant	 reduction	 in	 the	 relative	 risk	 of	myocardial	
infarction	(p	=	0.052)	(UK	Prospective	Diabetes	Study	Group,	1998	a,b).	A	10	year	
follow-up	of	the	UKPDS	cohort	examined	if	intensive	glycaemic	control	had	effects	
on	macrovascular	 outcomes	 in	 the	 longer	 term	despite	HbA1c	 levels	which	were	
comparable	between	the	intensive	and	the	control	arms	of	the	original	trial	in	the	
additional	10	years	of	 follow	up	 (Holman	et	al.,	 2008).	 In	 this	 study,	 a	 significant	
reduction	in	the	risk	of	myocardial	infarction	(p	=	0.01)	was	observed.	
	
Three,	 multicentre,	 randomised	 controlled	 trials	 (ACCORD,	 ADVANCE,	 VADT)	
aimed	 to	definitively	 test	 the	hypothesis	 that	 intensive	glycaemic	control	 reduces	
CV	 mortality	 in	 T2D	 (Gerstein	 et	 al.,	 2008;	 Patel	 et	 al.,	 2008;	 Duckworth	 et	 al.,	
2009).	 Collectively,	 the	 above	 studies	 recruited	 23,182	participants	 globally	with	
known	T2D	and	pre-existing	CVD	or	established	cardiovascular	(CV)	risk	factors.	In	
all	trials	no	significant	reduction	in	major	CV	events	was	observed.	In	the	ACCORD	
trial,	 5,128	 participants	 were	 randomised	 to	 intensive	 glucose	 control	 (HbA1c	 <	
6.0%	 (42.1	 mmol/mol)	 and	 5,123	 participants	 randomised	 to	 the	 standard	
treatment	 arm	 (HbA1c	 7-7.9%	 (53-62.8	 mmol/mol)	 (Gerstein	 et	 al.,	 2008).	
Surprisingly,	 significant	 excess	mortality	 (257	deaths)	was	noted	 in	 the	 intensive	
glucose	 arm	 compared	 to	 standard	 treatments	 (203	 deaths)	 (hazard	 ratio	 1.22;	
95%	CI,	 1.01	 to	 1.46;	 p	 =	 0.01).	 This	 observation	 led	 to	 early	 trial	 closure	 at	 3.5	
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years	 of	 follow-up.	 Possible	 explanations	 for	 this	 result	 include,	 weight	 gain,	
specific	 medications	 and	 the	 play	 of	 chance.	 A	 statistically	 significant	 excess	 CV	
mortality	was	not	noted	in	the	ADVANCE	and	VADT	cohorts.	
	
Interestingly,	 in	 ACCORD,	 ADVANCE	 and	 VADT	 an	 increased	 incidence	 of	
hypoglycaemia	 in	 the	 intensive	 glycaemic	 control	 arms	was	 seen	 (Gerstein	 et	al.,	
2008;	 Patel	 et	 al.,	 2008;	 Duckworth	 et	 al.,	 2009).	 Participants	 in	 the	 intensive	
treatment	arms	of	the	ACCORD	and	VADT	trials	had	higher	rates	of	hypoglycaemia	
compared	to	standard	treatment	(ACCORD	16.2%	vs.	5.1%;	VADT	21.2%	vs.	9.9%)	
in	 comparison	 to	 ADVANCE	 (2.7%	 vs.	 1.5%)	 (Figure	 1.2).	 The	 finding	 of	 excess	
mortality	 in	 the	ACCORD	trial	but	not	 in	ADVANCE	and	VADT	 is	 intriguing	and	 is	
likely	 explained	 by	 intrinsic	 differences	 in	 the	 study	 participants	 such	 as	weight,	
differences	 in	side	effects	 to	different	diabetes	drugs	and	pre-existing	duration	of	
diabetes	 (Table	 1.2).	 In	 the	 ACCORD	 trial,	 severe	 hypoglycaemia	 was	 associated	
with	 increased	mortality	 across	 both	 the	 intensive	 and	 standard	 treatment	 arms	
(Gerstein	et	al.,	2008).		CV	death	accounted	for	a	nearly	a	third	of	all	deaths	in	the	
ACCORD	study	(Gerstein	et	al.,	2008).	 In	 the	 intensive	 treatment	arm	of	ACCORD,	
annual	 unadjusted	mortality	was	2.8%	 in	 those	 that	 had	 one	 or	more	 episode	 of	
severe	 hypoglycaemia	 compared	 to	 1.2%	 in	 those	 with	 no	 episodes	 of	 severe	
hypoglycaemia	 (hazard	 ratio,	 1.41;	 95%	 CI,	 1.03-1.93)(Bonds	 et	 al.,	 2010).	
However,	 the	 risk	 of	 death	 following	 hypoglycaemia	was	 comparatively	 lower	 in	
the	intensive	glucose	control	arm	compared	to	standard	control	(hazard	ratio,	1.41;	
95%	CI,	1.03-1.93	vs.	hazard	ratio,	2.30;	95%	CI	1.46-3.65).	Furthermore,	there	is	a	




intensive	 glucose	 control	 arm	 (hazard	 ratio,	 0.76,	 95%	CI,	 0.67-0.92;	 0.004).	 In	 a	
meta-analysis	of	thirteen	trials	(n=34,533)	studying	intensive	glycaemic	control	in	
T2D	 a	 similar	 trend	 towards	 a	 reduction	 in	 the	 risk	 of	 non-fatal	 AMI	 in	 those	
randomised	 to	 intensive	 glucose	 control	was	 noted	 (Boussageon	 et	al.,	 2011).	 In	
summary,	 trial	 data	 suggest	 that	 intensive	 glucose	 control	 is	 potentially	
cardioprotective	 against	 non-fatal	 AMI	 and	 this	 protection	 appears	 to	 be	
preferentially	 conferred	 to	 those	 that	 have	 a	 low	 CVD	 burden	 to	 begin	 with.	 CV	
benefits	 of	 intensive	 glucose	 control	 in	 some,	 however,	 appear	 to	 be	
counterbalanced	 by	 a	 significant	 increase	 in	 the	 risk	 of	 fatal	 AMI	 in	 others	 with	
intensive	 glucose	 control	 being	 associated	 with	 a	 much	 higher	 risk	 of	 severe	
hypoglycaemia.	
	
It	 is	 extremely	 challenging	 to	 confirm	 or	 refute	 a	 causal	 link	 between	
hypoglycaemia	and	observed	CV	mortality.	One	reason	is	that	these	trials	were	not	
originally	 designed	 to	 examine	 the	 relationship	 between	 hypoglycaemia	 and	 CV	
outcomes.	 The	 ACCORD	 investigators	 have	 argued	 that	 there	 is	 scant	 evidence	
linking	severe	hypoglycaemia	to	increased	CV	mortality	in	the	intensive	glycaemic	
control	 arm	 of	 their	 trial,	 since	 they	 observed	 no	 direct	 relationship	 between	
severe	 hypoglycaemic	 episodes	 and	 subsequent	 deaths	 (Riddle	 et	 al.,	 2010).	
Nevertheless,	 the	 potential	 role	 of	 hypoglycaemia	 in	 exacerbating	 CV	 risk	 in	
patients	randomised	 to	 intensive	glucose	control	 in	ACCORD	was	underestimated	
(Frier,	 Schernthaner	 and	 Heller,	 2011).	 Hypoglycaemia	 may	 have	 been	 under-
reported	in	the	intensive	treatment	arm	since	repeated	episodes	of	hypoglycaemia	
lead	 to	 reduced	 hypoglycaemia	 awareness.	 Furthermore,	 a	 causal	 hypoglycaemic	
event	may	have	 led	 to	 pathophysiological	 changes	 leading	 to	 increased	mortality	
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downstream	of	 the	event.	 Indeed,	 it	 is	 striking	 that	 in	all	 three	of	 these	major	CV	
outcome	trials,	a	severe	hypoglycaemic	event	predicted	mortality,	not	at	 the	 time	
but	 weeks	 or	 months	 after	 the	 event	 (Gerstein	 et	 al.,	 2008;	 Patel	 et	 al.,	 2008;	
Duckworth	 et	 al.,	 2009;	 Bonds	 et	 al.,	 2010;	 Zoungas	 et	 al.,	 2010).	 Furthermore,	
some	 excess	 deaths	 in	 the	 intensive	 treatment	 arm	 of	 ACCORD	 may	 have	 been	
erroneously	coded	as	being	due	 to	coronary	events	with	no	possibility	of	glucose	
measurement	 post-mortem	 (Frier,	 Schernthaner	 and	 Heller,	 2011).	 Also,	 it	 is	
noteworthy	 that	only	severe	hypoglycaemic	events	were	measured	 in	 these	 large	
studies	as	such	events	are	much	easier	to	record	than	non-severe	hypoglycaemia.	
 
Whilst	 it	 is	 challenging	 to	 establish	 causation	 rather	 than	 association,	 due	 to	
potential	 confounding,	 hypoglycaemia	 is	 probably	 associated	 with	 excess	 CV	
mortality	in	those	with	comorbidities	such	as	liver	disease,	chronic	kidney	disease	
and	general	 frailty	 that	are	 likely	to	 lead	to	hypoglycaemic	events	(Zoungas	et	al.,	
2010).	 Hence,	 hypoglycaemia	 might	 merely	 be	 a	 marker	 for	 susceptibility,	 as	
opposed	 to	 being	 a	 direct	 cause	 of	mortality.	However,	 a	 recent	 large	 systematic	
review	 and	meta-analysis	 using	 specific	 statistical	 adjustments,	 concluded	 that	 it	
was	 unlikely	 that	 comorbidities	 alone	 explained	 the	 relationship	 between	
hypoglycaemia	 and	 CV	 disease	 (Goto	 et	 al.,	 2013).	 The	 authors	 studied	 the	
relationship	 in	 studies	 involving	 nearly	 a	 million	 participants	 and	 demonstrated	







Figure	 1-2	 Percentage	 of	 participants	 with	 severe	 hypoglycaemic	 events	 in	
the	 ACCORD,	 ADVANCE	 and	 VADT	 trials	 adapted	 from	 (Frier,	 Schernthaner	
and	Heller,	 2011).	 Abbreviations:	 ACCORD,	 action	 to	 control	 cardiovascular	
risk	in	diabetes;	ADVANCE,	action	in	diabetes	and	vascular	disease:	preterax	






























Table	 1.2	 Clinical	 characteristics	 and	 differences	 in	 primary	 CVD	 endpoint,	
overall	mortality	and	CV	mortality	between	intensive	glycaemic	control	and	
standard	 arms	 of	 ACCORD,	 ADVANCE	 and	 VADT	 adapted	 from	 (Frier,	
Schernthaner	 and	 Heller,	 2011).	 Abbreviations:	 ACCORD,	 action	 to	 control	
cardiovascular	 risk	 in	 diabetes;	 ADVANCE,	 action	 in	 diabetes	 and	 vascular	
disease:	 preterax	 and	 diamicron	 modified	 release	 controlled	 evaluation;	
VADT,	 veteran’s	 affairs	 diabetes	 trial,	 BMI,	 body	 mass	 index;	 CVD,	
cardiovascular	disease;	CV,	cardiovascular;	ns,	non-significant.	
 ACCORD	 ADVANCE	 VADT	
n	 10,251	 11,140	 1,791	
Age	(years)	 62	 66	 60	
Men/Women	(%)	 61/39	 58/42	 97/3	
Duration	of	study	(years)	 3.5	 5.0	 5.6	
BMI	(kg/m2)	 32.2	±	5.5		 28.0	±	5.0	 31.3	±	3.5	
Duration	of	diabetes	(years)	 10	 8	 11.5	
CVD	(%)	 35	 32	 40	
Primary	CVD	end	point	 ↓10%	(p=0.16)	 ↓6%	(p=0.37) ↓13%	
(p=0.12) 
Mortality	(overall)	 ↑22%	(p=0.04)	 ↓7%	(p=NS) ↑6.5%	
(p=ns) 




In	 the	 previous	 section	 I	 have	 highlighted	 clinical	 trial	 data	 suggesting	












Adrenaline	 acting	 via	 β1	 adrenoreceptors	 increases	 heart	 rate	 and	 agonism	 of	 α	
and	 β2	 adrenoreceptors	 increases	 blood	 pressure	 (Lohmann,	 Loesment	 and	
Kaehler,	1990).	In	healthy	volunteers,	a	study	using	radionuclide	ventriculography	
demonstrated	 that	 hypoglycaemia	 associated	 catecholamine	 release	 increased	
cardiac	 output	 via	 increased	myocardial	 contractility	 thus	 increasing	myocardial	
oxygen	 demand	 (Fisher	 et	 al.,	 1987).	 In	 those	 with	 diabetes	 and	 pre-existing	
coronary	artery	disease	(CAD)	or	established	CV	risk	factors,	increased	myocardial	
oxygen	 demand	 may	 outstrip	 supply,	 resulting	 in	 cardiac	 tissue	 ischaemia	 and	
eventually	infarction.	Also,	in	healthy	individuals	undergoing	acute	hypoglycaemia,	
the	arterial	 tree	demonstrates	a	degree	of	elasticity	which	ensures	 that	 the	blood	
flow	wave	generated	from	increased	myocardial	contraction	during	systole	returns	
to	the	heart	during	early	diastole	thus	enhancing	coronary	artery	perfusion	which	
occurs	mainly	 in	 diastole	 (Sommerfield	 et	al.,	 2007).	 In	 individuals	with	 T1D	 for	
more	 than	 15	 years,	 a	 loss	 of	 vessel	 wall	 elasticity	 due	 to	 progressive	 stiffening	
means	that	blood	flow	generated	during	early	systole	returns	back	to	the	heart	in	
late	 systole	 as	 opposed	 to	 early	 diastole	 thus	potentially	 compromising	 coronary	
artery	 perfusion	 (Sommerfield	 et	 al.,	 2007).	 Interestingly,	 in	 a	 study	 using	
myocardial	 contrast	 echocardiography,	 acute	 hypoglycaemia	 also	 reduced	
myocardial	blood	flow	in	19	healthy	volunteers	and	28	subjects	with	T1D	without	
CAD	 (Rana	 et	 al.,	 2011).	 The	 exact	 mechanisms	 are	 not	 clear,	 but	 the	 authors	





Electrocardiographic	 (ECG)	 changes	 of	 cardiac	 ischaemia	 have	 been	 previously	
reported	in	a	patient	with	hypoglycaemia	induced	coma	(Markel,	Keidar	and	Yasin,	
1994).	Others	 have	 reported	 hypoglycaemia	 induced	 angina	 pectoris	 in	 a	 patient	
with	diabetes	and	CAD	(Duh	and	Feinglos,	1994).		In	a	study	of	6	patients	with	T2D	
without	 known	 cardiac	 disease,	 induction	 of	 hypoglycaemia	 resulted	 in	 cardiac	
ischaemia	 in	 5	 patients	 as	 evidenced	 by	 ST	 segment	 depression	 and	 T-wave	
flattening	 (Lindström	 et	al.,	 1992).	 Another	 study	 enrolled	 21	 patients	with	 both	
CAD	and	T2D	and	performed	simultaneous	continuous	glucose	monitoring	(CGM)	
and	 cardiac	Holter	monitoring	 over	 a	 continuous	72	hour	 period	 (Desouza	et	al.,	
2003).	In	the	54	recorded	episodes	of	hypoglycaemia	(<	3.9	mmol/l),	10	episodes	
were	associated	with	symptoms	of	chest	pain	of	which	4	had	clear	ECG	changes	of	
ischaemia	 whilst	 neither	 chest	 pain	 nor	 ECG	 changes	 were	 document	 in	
normoglycaemia	 (Desouza	 et	al.,	 2003).	 For	 ethical	 reasons,	 there	 is	 a	 paucity	 of	
experimental	 data	 prospectively	 verifying	 case	 reports	 and	 relatively	 small	
observational	 studies	 of	 hypoglycaemia	 induced	 cardiac	 ischaemia.	 However,	 it	




Hypoglycaemia	 can	 be	 pro-arrhythmogenic	 via	 a	 number	 of	 mechanisms	 and	
hypoglycaemia	 has	 thus	 been	 implicated	 in	 sudden	 cardiac	 death.	 Nocturnal	
sudden	 death	 in	 young	 patients	 with	 T1D	 that	 are	 previously	 well	 is	 well	
documented	 and	 termed	 ‘dead-in-bed-syndrome’	 (Campbell,	 1991;	 Tattersall	 and	
Gill,	 1991).	 It	 has	 been	 postulated	 that	 nocturnal	 hypoglycaemia	 generated	
arrhythmias	 may	 be	 responsible	 for	 the	 dead-in-bed	 syndrome.	 There	 is	
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circumstantial	 evidence	 linking	 hypoglycaemia	 to	 sudden	death	 in	 a	 patient	with	
T1D	 who	 was	 having	 CGM	 and	 insulin	 administration	 via	 an	 insulin	 pump	
(Tanenberg	et	al.	2010).	The	subject	studied	by	Tanenberg	et	al.	had	a	propensity	
to	 nocturnal	 hypoglycaemia	 and	 was	 found	 dead	 after	 an	 overnight	 dip	 of	
interstitial	blood	glucose	 to	1.8	mmol/l.	 In	addition,	 a	number	of	 epidemiological	
studies	have	supported	the	existence	of	the	dead-in-bed	phenomenon	(Sartor	and	





Hypoglycaemia	 may	 predispose	 to	 tachyarrhythmias,	 through	 effects	 on	 QT	
interval	 (usually	 expressed	 as	QT	 interval	 corrected	 for	heart	 rate	 -	QTc)	 and	on	
electrolytes.	 Mechanistically,	 hypoglycaemia	 is	 known	 to	 cause	 QT	 interval	
prolongation	 and	 increase	 QT	 dispersion	 (QTd)	 during	 cardiac	 electrical	
repolarisation	 (Robinson	 et	 al.,	 2003;	 Koivikko	 et	 al.,	 2008).	 QT	 changes	 during	
hypoglycaemia	 can	 account	 for	 ventricular	 tachycardia	 and	 atrial	 fibrillation	
(Collier	 et	 al.,	 1987;	 Chelliah,	 2000).	 QTc	 prolongation	 in	 hypoglycaemia	 is	
mediated	by	catecholamines,	hypokalaemia	(caused	by	catecholamine	and	 insulin	
mediated	 shift	 of	 potassium	 into	 the	 intracellular	 compartment)	 and	 direct	
inhibitory	effect	of	hypoglycaemia	on	the	current	through	the	human	ether-a-go-go	
related	 gene	 channel	 (Zhang	 et	 al.,	 2003;	 Nordin,	 2010).	 Out	 of	 these	 three	
mechanisms,	 catecholamine	 effect	 is	 thought	 to	 be	 the	 most	 important	 one	 as	
evidenced	 by	 the	 fact	 that	 selective	 β	 blockade	with	 atenolol	 has	 been	 shown	 to	









tone	 following	 counter-regulation	 to	 hypoglycaemia	 may	 account	 for	 observed	
bradyarrhythmias	(Chow	et	al.,	2014).	Chow	et	al.	also	found	that	bradycardia	and	
atrial	 and	 ventricular	 ectopic	 beats	 occurred	 more	 frequently	 during	 nocturnal	





modulate	 the	 protective	 counter-regulatory	 response	 to	 hypoglycaemia	 by	
reducing	the	threshold	of	glucose	for	initiation	of	counter-regulation	in	early	sleep	
with	 late	nocturnal	 sleep	 reducing	 the	 induction	of	 counter-regulatory	hormones	
(Jones	et	al.,	1998).	Taken	together,	these	data	imply	that	hypoglycaemia	mediated	




Platelets	 play	 an	 important	 role	 in	 thrombotic	 cardiac	 complications	 associated	
with	 diabetes.	 Hypoglycaemia	 can	 influence	 both	 platelet	 activation	 and	
aggregation	 (Hutton	 et	 al.,	 1979;	 Wright	 et	 al.,	 2010).	 In	 those	 with	 T1D,	
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hypoglycaemia	 has	 been	 shown	 to	 reduce	 platelet	 counts	 (Dalsgaard-Nielsen,	
Madsbad	 and	 Hilsted,	 1982).	 Increased	 platelet	 activation	 in	 vivo	 during	
hypoglycaemia	has	been	demonstrated	by	 increased	 soluble	P-selectin	 (Gogitidze	
Joy	et	al.,	2010;	Joy	et	al.,	2015),	β	thromboglobulin	(Trovati	et	al.,	1986;	Takeda	et	
al.,	1988)	and	increased	monocyte	platelet	aggregates	(MPAs)	(Wright	et	al.,	2010).	
Additionally,	 increased	 plasma	 sCD40L	 concentrations	 have	 been	 shown	 in	
response	 to	 acute	 hypoglycaemia	 (Wright	 et	al.,	 2010).	 Hypoglycaemia	 increases	
platelet	 reactivity	 to	 agonists	 in	 vitro	 (Trovati	 et	 al.,	 1986).	 Increased	 platelet	
activation	and	aggregation	are	thought	to	be	mediated	by	an	adrenergic	response	
to	 hypoglycaemia	 (Hutton	 et	 al.,	 1979).	 Recent	 work	 from	 our	 group	 has	 also	
shown	that	 in	T2D,	hypoglycaemia	 increases	platelet	 reactivity	but	 these	changes	
are	short	lived	and	last	up	to	24	hours	following	hyperinsulinaemic	hypoglycaemia	





Systemic	 inflammation	 is	 critical	 to	 the	 aetiology	 of	 atherosclerosis.	 Acute	
hypoglycaemia	 induced	 by	 an	 insulin	 bolus	 in	 healthy	 volunteers	 resulted	 in	 an	
increase	 in	 the	 pro-inflammatory	 cytokines:	 TNF-α,	 IL-1β,	 IL-6	 and	 IL-8	 (Razavi	
Nematollahi	 et	 al.,	 2009).	 There	 was	 also	 an	 increase	 in	 markers	 of	 lipid	
peroxidation,	 reactive	 oxygen	 species	 (ROS)	 and	 a	 significant	 leukocytosis	 in	
response	 to	 hypoglycaemia	 (Razavi	 Nematollahi	 et	 al.,	 2009).	 Acute	 leukocytosis	





accompanied	 by	 a	 simultaneous	 increase	 in	 the	 counter-regulatory	 hormones	
adrenaline,	 noradrenaline	 and	 cortisol,	 implying	 hormonal	 mediation	 of	 pro-
inflammatory	 changes	 in	 response	 to	 hypoglycaemia	 (Razavi	 Nematollahi	 et	 al.,	
2009).	 These	 data	 are	 limited,	 however,	 as	 they	 are	 not	 representative	 of	
hypoglycaemia	 as	 encountered	 in	 clinical	 practice	 on	 account	 of	 supra-
physiological	 doses	 of	 insulin	 used	 to	 rapidly	 lower	 blood	 glucose.	 Latterly,	 the	
effects	of	acute	hypoglycaemia	on	pro-inflammatory	markers	in	healthy	individuals	
and	 those	 with	 TID	 have	 been	 investigated	 more	 robustly	 by	 using	
hyperinsulinaemic	 hypoglycaemic	 and	 euglycaemic	 clamps	 that	 allowed	 the	
investigators	 to	 control	 for	 the	anti-inflammatory	effects	of	 insulin	 (Dotson	et	al.,	
2008;	Gogitidze	 Joy	et	al.,	 2010).	Moderate	hypoglycaemia	 at	 2.9	mmol/l	 for	120	
minutes	increased	levels	of	IL-6	in	both	healthy	volunteers	and	in	those	with	T1D	
(Gogitidze	 Joy	et	al.,	 2010).	 Levels	 of	 IL-6	 also	 increased	 significantly	 following	 a	
hypoglycaemic	 stimulus	 at	 2.7	 mmol/l	 for	 110	 minutes	 in	 healthy	 volunteers	
(Dotson	 et	 al.,	 2008).	 The	 acute	 phase	 C	 reactive	 protein	 (CRP)	 has	 also	 been	
implicated	 as	 a	 predictor	 of	 acute	 coronary	 syndrome	 (ACS)	 in	 epidemiological	
studies	(Ridker	et	al.,	2002;	Danesh	et	al.,	2004).	 In	a	study	of	healthy	volunteers	
and	 those	 with	 T1D,	 hypoglycaemia	 increased	 CRP	 levels	 for	 up	 to	 24	 hours	
(Galloway	 et	 al.,	 2000).	 A	 more	 recent	 study	 however	 demonstrated	 that	 an	
increase	 in	 CRP	 following	 hypoglycaemia	 was	 more	 acute	 and	 only	 confined	 to	
healthy	volunteers	(Wright	et	al.,	2010).	
	





formation	 and	 atherosclerosis	 (Chi	 &	 Melendez	 et	 al.	 2007).	 Significantly	 higher	
levels	 of	 ICAM-1,	 VCAM-1	 and	 E-selectin	 have	 been	 demonstrated	 during	
hypoglycaemia	 compared	 to	 euglycaemia	 in	 both	 healthy	 volunteers	 and	 T1D	
patients	(Gogitidze	Joy	et	al.,	2010;	Joy	et	al.,	2015).	Furthermore,	in	a	rat	model	of	
T2D,	 recurrent	 hypoglycaemia	 (once	 every	 3	 days	 for	 5	 weeks)	 upregulated	
endothelial	 expression	 of	 ICAM-1	 and	 VCAM-1	 and	 increased	 the	 number	 of	





endothelial	 cells	 following	 hypoglycaemia	 (Wang	 et	 al.,	 2012).	 Also,	 recently	
generated	 evidence	 suggests	 that	 endogenous	 NO	 mediated	 endothelial	
vasodilation	is	reduced	following	an	episode	of	acute	hypoglycaemia	in	man	(Joy	et	





al.,	 2012).	 Together,	 these	 findings	 support	 an	 earlier	 observation	 that	 recurrent	
hypoglycaemia	 aggravates	 pre-clinical	 atherosclerosis	 in	 T1D	 compared	 to	
matched	 controls	 that	 do	 not	 suffer	 recurrent	 hypoglycaemia	 (Giménez	 et	 al.,	







Figure	 1-3	 Putative	 mechanisms	 linking	 hypoglycaemia	 and	 CVD.	
Hypoglycaemia	 is	 characterised	 by	 sympatho-adrenal	 activation.	 Abnormal	
cardiac	repolarisation	and	deranged	autonomic	function	as	well	as	the	acute	
haemodynamic	 consequences	 of	 hypoglycaemia	 can	 induce	 CV	 events	 via	
arrhythmias	 (1)	 and	 cardiac	 ischaemia	 (2).	 Enhanced	 coagulation	 and	
impaired	fibrinolysis	(3)	in	addition	to	platelet	activation	and	aggregation	(6)	
promotes	 atherothrombosis.	 An	 acute	 leukocytosis	 and	 production	 of	 pro-






Atherosclerosis	gives	 rise	 to	CV	disease	and	CAD	which	are	 the	 leading	causes	of	
death	 worldwide	 (Weber	 and	 Noels,	 2011).	 The	 aetiology	 of	 atherosclerosis	 is	
complex,	and	multifactorial,	but	at	its	core	involves	a	progressive	narrowing	of	the	
lumen	in	large	and	medium-sized	arteries	due	to	accumulation	of	lipids	and	fibrous	





appears	at	preferential	 sites	 in	 the	arterial	 tree	such	as	points	of	bifurcation	as	a	
likely	 consequence	 of	 cellular	 responses	 to	 altered	 fluid	 dynamics	 at	 these	 sites	
(Moore	 and	 Tabas,	 2011).	 Injury	 to	 vessels	 through	 risk	 factors	 such	 as	
hypercholesterolaemia	 and	 hypertension	 initiates	 the	 process	 as	 it	 allows	
accumulation	of	low-density	lipoproteins	(LDL)	in	the	subendothelial	matrix	(Lusis,	
2000).	Within	 the	 arterial	 intima,	 LDL	particles	 undergo	 oxidation	 leading	 to	 the	
release	of	phospholipids	including	lysophosphatidylcholine	resulting	in	endothelial	
cell	 activation	 (Weber	 and	 Noels,	 2011).	 Endothelial	 activation	 then	 facilitates	
leukocyte	 capture,	 activation	 and	 firm	 arrest	 at	 the	 site	 of	 vessel	 injury	 prior	 to	
transendothelial	diapedesis	in	a	sequence	of	events	termed	the	leukocyte	adhesion	
cascade	 (Ley	 et	al.,	 2007).	 The	 various	 leukocytes	 recruited	 in	 this	 inflammatory	
cascade	 include:	monocytes,	 neutrophils,	 dendritic	 cells,	 T	 cells,	 B	 cells	 and	mast	
cells	(Weber,	Zernecke	and	Libby,	2008).	
	
E-selectin,	 L-selectin	 and	 P-selectin	 bind	 rapidly	 to	 respective	 ligands	 thereby	
mediating	 capture	 and	 rolling	 of	 leukocytes	 and	 platelets	 on	 the	 vascular	
endothelium	 (Alon	 et	 al.,	 1995).	 Initial	 capture	 or	 tethering	 is	 mediated	 via	 P-
selectin	which	is	expressed	on	the	endothelium	or	L-selectin	which	is	ubiquitously	




and	 their	 counter	 ligands.	 The	 activated	 endothelium	 is	 characterised	 by	
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expression	 of	 adhesion	 molecules	 including	 VCAM-1	 and	 ICAM-1	 which	 bind	 to	





type	 2	 (CCR2)	 (Boring	 et	 al.,	 1998).	 Other	 chemokines	 including	 c-c	 motif	
chemokine	ligand	5	(CCL5	or	RANTES)	and	IFN-inducible	T	cell	α-chemoattractant	
(I-TAC	 or	 CXCL11)	 recruit	 T	 lymphocytes	 to	 human	 atherosclerotic	 lesions	 by	
binding	 to	 CCR1	 and	CXCR3	 respectively	 (Mach	et	al.,	 1999).	Notably,	 fractalkine	
(CX3CL1)	which	is	a	membrane	bound	chemokine,	plays	a	key	role	in	atherogenesis	
by	recruitment	of	CX3CR1	expressing	 leukocytes	 including	monocytes,	T	cells	and	
natural	 killer	 (NK)	 cells	 (Imai	 et	 al.,	 1997;	 Lesnik,	 Haskell	 and	 Charo,	 2003).		
Monocyte	 traffic	 and	 recruitment	 into	 the	 atherosclerotic	 plaque	 is	 discussed	 in	
more	detail	in	section	1.4.2.	
	
In	 addition	 to	 leukocytes,	 platelets	 also	 adhere	 to	 activated	 endothelium	 and	
contribute	to	 the	 initiation	of	 the	atherosclerotic	 lesion	 formation	as	a	key	player	
(Massberg	et	al.,	2002).	Modification	of	LDL	in	the	vessel	wall	is	not	only	confined	
to	oxidation,	but	also	includes	lipolysis,	proteolysis	and	aggregation	(Lusis,	2000).	
Lipid	 oxidised	 LDL	 (oxLDL)	 appears	 to	 be	 particularly	 important	 in	 driving	
inflammatory	cell	infiltration	into	arterial	intima	(Lusis,	2000).	Under	the	influence	
of	 macrophage-colony	 stimulating	 factor	 (M-CSF)	 and	 granulocyte-macrophage	
colony	stimulating	factor	(GM-CSF)	produced	by	endothelial	and	several	other	cells,	





Macrophage	 formation	 is	 a	 critical	 step	 in	 the	 pathogenesis	 of	 atherosclerosis	 as	
macrophages	 internalise	 oxLDL	 to	 form	 foam	 cells	 leading	 to	 production	 of	 pro-
inflammatory	 cytokines	 including	 IL-1β	 and	 this	 augments	 upregulation	 of	 cell	
adhesion	 molecules	 with	 greater	 leukocyte	 traffic	 into	 the	 lesion	 (Hansson,	
Robertson	 and	 Söderberg-Nauclér,	 2006).	 In	 due	 course,	 a	 more	 mature	 plaque	
lesion	develops	which	contains	a	central	necrotic	core	covered	by	a	fibrous	cap	and	
regions	 infiltrated	 by	 inflammatory	 cells	 producing	 pro-inflammatory	 mediators	
(Hansson,	 Robertson	 and	 Söderberg-Nauclér,	 2006).	 Rupture	 of	 atherosclerotic	
plaques	 leads	 to	exposure	of	 the	necrotic	 core	 resulting	 in	atherothrombosis	and	
the	 clinical	 syndromes	 of	 AMI	 and	 CVA.	 Unstable	 plaque	 in	 the	 presence	 of	
activated	platelets	may	also	be	more	 likely	 to	 result	 in	 coronary	artery	occlusion	




As	 the	 focus	 of	 this	 thesis	 is	 to	 investigate	 the	 effects	 of	 hypoglycaemia	 on	
inflammation	 as	 a	 driver	 for	 atherosclerosis,	 I	 will	 now	 describe	 the	 role	 of	 the	
immune	system	in	pathogenesis	of	atherosclerosis.	In	particular,	I	will	concentrate	
on	monocytes	as	plaque	macrophages	that	are	derived	from	circulating	monocytes	
constitute	 the	majority	of	 leukocytes	 in	 the	atherosclerotic	plaque	(Lundberg	and	








































Figure	 1-4	 Summarises	 the	 pathophysiology	 of	 lesion	 formation	 in	
atherosclerosis.		Upon	injury	to	the	vessel	wall,	such	as	due	to	high	circulating	
levels	 of	 LDL	 cholesterol,	 there	 is	 subendothelial	 accumulation	 of	
lipoproteins,	 resulting	 in	 endothelial	 cell	 activation.	 The	 activated	
endothelium	 expresses	 selectins	 and	 upregulates	 cell	 adhesion	 molecules.	
These	 facilitate	 the	 capture	 and	 arrest	 of	 leukocytes	 including	 monocytes	
onto	 the	 endothelium	 through	 adhesion	 cell	molecule-integrin	 interactions.	
Under	 the	 influence	 of	 chemokines,	 monocytes	 transmigrate	 into	 the	
subendothelial	 space.	 Infiltrated	 monocytes	 then	 differentiate	 into	
macrophages	 in	 a	 process	 facilitated	 by	 GM-CSF	 and	 M-CSF	 which	 are	
produced	by	activated	endothelial	and	other	cells.		Within	the	arterial	intima,	
LDL	 particles	 undergo	 oxidation	 to	 form	 OxLDL	 that	 are	 phagocytosed	 by	
macrophages	via	scavenger	receptors	resulting	in	the	formation	of	foam	cells.	
Pro-inflammatory	 cytokines	 and	 growth	 factors	 produced	 by	 foam	 cells	
encourage	migration	of	vascular	smooth	muscle	cells	 from	the	tunica	media	
into	 the	 intima.	 Over	 time,	 an	 accumulation	 of	 lipid	 rich	 foam	 cells	 and	
vascular	 smooth	 muscle	 cells	 in	 addition	 to	 the	 synthesis	 of	 collagen	 and	
extracellular	 matrix	 causes	 the	 intima	 to	 thicken	 and	 bulge	 towards	 the	
arterial	 lumen.	 	 Furthermore,	 apoptosis	 and	 necrosis	 of	 foam	 cells	 and	
vascular	 smooth	 muscle	 cells	 encourages	 the	 formation	 of	 a	 lipid	 rich	
necrotic	core	and	release	of	matrix	metalloproteinases	which	destabilise	the	
plaque.	 Erosion	 and	 fissuring	 of	 the	 fibrous	 plaque	 allows	 the	 highly	
thrombogenic	contents	of	 the	necrotic	core	to	come	into	direct	contact	with	
circulating	 blood.	 Platelets	 rapidly	 activate	 and	 aggregate	 at	 this	 site	
resulting	in	the	formation	of	a	thrombus	and	this	can	significantly	narrow	the	
vessel	 lumen	 thus	 leading	 to	an	acute	myocardial	 infarction.	Abbreviations:	







launches	 a	 defence	 of	 arteries	 challenged	 by	 a	 host	 of	 inflammatory	 stimuli.	
Activation	 of	 the	 innate	 immune	 system	 is	 dependent	 on	 a	 number	 of	 pattern-
recognition	receptors	 (PRR)	 (Lundberg	and	Hansson,	2010).	Broadly,	PRR	can	be	
sub-classified	 into	 endocytic	 receptors	 and	 signalling	 receptors.	 Endocytic	
receptors	largely	mediate	antigen	uptake	with	ligand	binding	to	these	receptors	not	




inflammatory	 pathways	 by	 upregulation	 of	 a	 number	 of	 pro-inflammatory	 genes	
(Lundberg	and	Hansson,	2010).	 In	atherosclerosis,	 endocytic	 scavenger	 receptors	
that	 recognise	 oxLDL	 and	 mediate	 its	 internalisation	 include:	 CL-P1,	 LOX-1,	
CXCL16,	 CD36,	MARCO,	 SRA-1	 and	 SRA-II	 (Greaves	 and	 Gordon,	 2009).	 Thus,	 by	





developing	 atherosclerotic	 lesion	 (Akira,	 Uematsu	 and	Takeuchi,	 2006;	 Lundberg	
and	Hansson,	2010).	 	In	cells	expressing	TLR,	stimulation	with	the	respective	TLR	
ligands	 triggers	 intracellular	 signalling	 pathways	 including	 mitogen	 activated	
protein	 kinase	 (MAPK).	 This	 culminates	 in	 the	 activation	 of	 a	 number	 of	 pro-
inflammatory	 transcription	 factors	 including	 nuclear	 factor	 (NF)	 κB,	 activating	
protein	 (AP)-1	 and	 interferon	 regulating	 factors	 (IRF)	 (Lundberg	 and	 Hansson,	
2010).	In	both	normal	and	atherosclerotic	human	vasculature,	expression	of	a	wide	
repertoire	 of	 TLR	 including	 TLR1,	 TLR2,	 TLR3,	 TLR4,	 TLR5,	 TLR7	 and	 TLR9	 has	
been	demonstrated	(Edfeldt	et	al.,	2002;	Curtiss	and	Tobias,	2009).	Evidence	from	





proteins	 that	 can	 organise	 into	 high	molecular	 weight	 inflammasomes	 (Hansson	
and	Hermansson,	 2011).	 The	 latter	 have	been	described	 as	 ‘molecular	platforms’	
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and	upon	activation	 trigger	secretion	of	pro-inflammatory	cytokines	 including	 IL-




experiments,	 the	 latter	 authors	 also	 reported	 that	 mice	 deficient	 in	 NLRP3	







































atherosclerotic	 changes	 through	 different	 inflammatory	 pathways.	 Ligation	
of	TLRs	with	OxLDL	activates	intracellular	signalling	pathways	that	culminate	
in	 activation	 of	 the	 transcription	 factors	 NF-κB,	 IRF	 and	 AP-1	 which	 then	
drive	 up	 regulation	 of	 genes	 encoding	 pro-inflammatory	 cytokines,	
chemokines,	proteases	(collagenases,	elastases,	cathepsins),	reactive	oxygen	
and	nitrogen	species	and	eicosanoids,	principally	leukotriene	B4	all	of	which	
collectively	 promote	 inflammation	 and	 atherosclerosis.	 OxLDL	 can	 also	 be	
internalised	by	scavenger	receptors	including	CD36	and	SRA	which	results	in	
accumulation	 of	 intracellular	 cholesterols	 crystals	 promoting	macrophages	
into	foam	cells.	Cholesterol	crystals	can	trigger	activation	of	inflammasomes	
including	 NLRP3	 that	 further	 augment	 inflammation	 by	 producing	 pro-
inflammatory	 cytokines	 including	 IL-1β.	 Abbreviations:	 TLR,	 toll-like	
receptors;	 SRA,	 scavenger	 receptor	 class	 A;	 oxLDL,	 oxidised	 low	 density	
lipoprotein;	NF-κB,	nuclear	factor	κB;	IRF,	interferon	regulating	factors;	AP-1,	







Monocytes	 are	 a	 subset	 of	 circulating	 leukocytes	 and	 differentiate	 into	
macrophages	and	dendritic	cells	(DC)	in	tissues	(Shi	and	Pamer,	2011).	Monocytes	
have	 been	 studied	 extensively	 in	 the	 context	 of	 atherosclerosis	 both	 in	 murine	
models	and	humans	given	their	role	as	major	players	in	the	innate	immune	system	




Monocytes	 comprise	 4%	 and	 10%	 of	 all	 blood	 leukocytes	 in	 mice	 and	 humans,	
respectively	 (Dutta	 and	 Nahrendorf,	 2015).	 Considerable	 heterogeneity	 exists	
within	 and	 between	 species	 in	 circulating	 blood	monocytes	 based	 on	 chemokine	
receptor	expression	and	presence	of	cell	surface	molecules	(Shi	and	Pamer,	2011;	
Wong	 et	 al.,	 2012).	 In	mice,	 the	main	 subset	 of	 CD115+	monocytes	 express	 high	
levels	 of	 Ly-6c	 and	 CCR2,	 but	 low	 levels	 of	 CX3CR1	 and	 are	 termed	 Ly-6chigh	
monocytes	 (Shi	 and	 Pamer,	 2011).	 The	 latter	 have	 been	 termed	 ‘inflammatory’	
monocytes	 based	 on	 data	 demonstrating	 their	 rapid	 recruitment	 to	 sites	 of	
inflammation	 and	 production	 of	 pro-inflammatory	 cytokines	 including	 IL-1β	 and	
TNF-α	 (Dutta	 and	 Nahrendorf,	 2015).	 A	 second	 major	 subset	 of	 monocytes	
identified	in	mice	express	low	levels	of	Ly-6c	and	CCR2,	but	high	levels	of	CX3CR1	
and	are	termed	Ly-6clow	monocytes	(Dutta	and	Nahrendorf,	2015).	Less	prevalent	
then	Ly-6chigh	 cells,	 Ly-6clow	monocytes	 are	 thought	 to	 reside	 in	 the	blood	 stream	
and	 patrol	 the	 endothelium	 through	 long-range	 crawling	 allowing	 these	 cells	 to	
scavenge	 lipids,	 cellular	debris	 and	microorganisms	 (Auffray	et	al.,	 2007).	Recent	




CD16	 (Fc	 γ	 receptor	 type	 III)	 termed	 classical	 monocytes	 (CM:	 CD14++	 CD16-,	
‘Mon1’),	 intermediate	 monocytes	 (IM:	 CD14++	 CD16+,	 ‘Mon2’)	 and	 non-classical	
monocytes	(NCM:	CD14+	CD16++,	 ‘Mon3’)	(Ziegler-Heitbrock	et	al.,	2010;	Weber	et	
al.,	2016).	Classical	monocytes	comprise	85%	of	circulating	human	monocytes,	the	
remaining	 15%	 being	 comprised	 of	 intermediate	 and	 non-classical	 monocytes	
(Wong	et	al.,	 2012).	Classical	monocytes	 in	addition	 to	being	most	abundant	also	
express	CCR2	and	are	thought	to	be	homologous	to	mouse	Ly-6chigh	cells	(Shi	and	
Pamer,	 2011).	 Intermediate	 monocytes	 have	 pro-inflammatory	 roles	 and	 non-




studies	 (Passlick,	 Flieger	 and	 Loms	 Ziegler-Heitbrock,	 1989)	 before	 the	 current	
nomenclature	was	 devised	 and	when	 less	 sophisticated	 flow	 cytometric	 analyses	
were	 available	 thus	 limiting	 the	 ability	 to	 dissect	 these	 populations.	 Once	
stimulated	 with	 TLR	 ligands,	 CD16+	 cells	 produce	 pro-inflammatory	 cytokines	
including	TNF-α	 (Grage-Griebenow	et	al.,	 2001).	Furthermore,	 selective	depletion	
of	these	cells	both	in	vitro	and	in	vivo	by	the	anti-inflammatory	effects	of	high	dose	
glucocorticoids	 	 has	 traditionally	 justified	 their	 pro-inflammatory	 categorisation	
(Dayyani	et	al.,	2003).	
	
A	 number	 of	 detailed	 gene	 expression	 profiling	 studies	 have	 furthered	 our	




et	 al.,	 2007;	 Ancuta	 et	 al.,	 2009;	 Zhao	 et	 al.,	 2009;	 Wong	 et	 al.,	 2011).	 	 Certain	
defining	features	that	are	subset	specific	emerge	from	these	data.	CMs	possess	the	
widest	repertoire	of	sensing	receptor	genes	and	genes	involved	in	tissue	repair	and	
immune	 responses	 (Wong	 et	 al.,	 2011).	 The	 relatively	 higher	 expression	 of	 pro-
inflammatory	 genes	 including	 S100A8/9	 and	 S100AI2	 genes	 which	 encode	 the	
phagocyte-specific	 S100	 proteins	may	 underpin	 the	 ability	 of	 CMs	 to	 orchestrate	
inflammation	(Roth	et	al.,	2003).	The	transcription	factor	AP-1	is	also	most	highly	
expressed	by	CMs	at	a	gene	 level	(Wong	et	al.,	2011).	This	 is	perhaps	reflected	 in	
the	 ability	 of	 CMs	 to	 produce	 the	 widest	 array	 of	 chemokines	 and	 cytokines	 in	
response	to	LPS	stimulation	in	vitro	including:	G-CSF,	CCL2,	RANTES,	IL-6,	IL-8,	IL-
1β,	 TNF-α	 and	 IL-10	 (Wong	 et	 al.,	 2011).	 Microarray	 studies	 suggest	 a	 close	
resemblance	 in	 the	 expressed	 subsets	 of	 genome	 of	 IMs	 and	NCMs	 (Wong	 et	al.,	
2011).	 There	 are,	 however,	 genetic	 differences	 between	 these	monocyte	 subsets.	
Major	histocompatibility	complex	(MHC)	class	 II	expression	 is	 for	example	higher	
in	 IMs	 relative	 to	 NCMs	 (Wong	 et	 al.,	 2011).	 These	 findings	 support	 an	 earlier	
observation	 that	 IMs	 have	 a	 greater	 role	 in	 antigen	 processing	 and	 presentation,	
specifically	to	T-cells	in	addition	to	IL-12	production	capacity	(Grage-Griebenow	et	
al.,	 2001).	 In	 addition,	 IMs	 have	 an	 enrichment	 of	 genes	 related	 to	 angiogenesis	
(TIE2,	 CD105)	 (Zawada	 et	 al.,	 2011).	 At	 least	 one	 study	 has,	 however,	 suggested	
that	 upon	 LPS	 stimulation	 in	 vitro,	 IMs	 are	 the	 primary	 producers	 of	 the	 anti-
inflammatory	 cytokine	 IL-10	 (Skrzeczyńska-Moncznik	 et	 al.,	 2008)	 contrary	 to	 a	
more	 recent	 investigation	 (Wong	 et	 al.,	 2011)	 demonstrating	 that	 CMs	 were	
unequivocally	 the	 most	 prolific	 producers	 of	 IL-10	 following	 LPS.	 Discrepant	
reporting	 on	 the	 cytokine	 production	 capacity	 of	 human	 monocyte	 subsets	 is	 a	
likely	 reflection	 of	 methodological	 differences.	 For	 example,	 isolation	 of	 human	
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monocytes	 subsets	 can	 be	 performed	 using	 a	 variety	 of	 clones	 of	 the	 anti-CD14	
monoclonal	antibody.		There	exist	clonal	differences	in	that	with	certain	anti-CD14	
clones,	for	example	ME52,	LPS	stimulation	of	CD14	is	significantly	inhibited	(Power	
et	 al.,	 2004).	 Arguably,	 intracellular	 staining	 for	 cytokines	 in	 whole	 blood	which	
avoids	 the	pitfalls	of	cellular	activation	and	 inhibition	due	 to	 isolation	 techniques	
yields	the	most	reliable	data	(Wong	et	al.,	2011).	 In	contrast	 to	 IMs,	NCMs	have	a	
greater	expression	of	genes	involved	in	re-arrangement	of	the	cellular	cytoskeleton	
(Wong	et	al.,	2011).		This	supports	the	role	of	these	cells	in	in	vivo	patrolling	(Cros	
et	 al.,	 2010).	 In	 response	 to	 LPS	 in	 vitro,	 NCMs	 have	 also	 been	 shown	 to	 be	 the	
highest	 producers	 of	 pro-inflammatory	 cytokines	 TNF-α	 and	 IL-1β	 (Belge	 et	 al.,	
2002;	Wong	et	al.,	2011).		These	data	indicate	that	NCMs	have	a	pro-inflammatory	
role	 that	 extends	 beyond	 tissue	 patrolling	 and	 surveillance	 of	 nucleic	 acids	 and	



















6-sulfo	 LacNAc;	 G-CSF,	 granulocyte	 colony	 stimulating	 factor;	 IL-10,	
interleukin	10;	RANTES,	regulated	on	activation,	normal	T	cell	expressed	and	







and	 inflammation	 are	 largely	 derived	 from	 studies	 in	 rodents.	 Within	 the	 bone	
marrow,	 haematopoietic	 stem	 cells	 (HSC)	 give	 rise	 to	 common	 myeloid	

























































receptor	 gene	 in	 mice	 results	 in	 diminished	 monocyte	 counts	 and	 reduced	





into	 inflammatory	 DCs	 or	 inflammatory	 macrophages	 (Shi	 and	 Pamer,	 2011).	
Interestingly,	 Ly-6chigh	monocytes	 can	 generate	 Ly-6clow	monocytes	 under	 steady	
state	conditions	and	the	latter	ordinarily	patrol	the	endothelium	with	a	half	life	of	
approximately	 2.5	 days,	 although	 may	 differentiate	 into	 alternatively	 activated	
macrophages	 with	 an	 anti-inflammatory	 phenotype	 and	 play	 a	 part	 in	 wound	
healing	(Yona	et	al.,	2013).	In	the	absence	of	inflammation,	Ly-6chigh	monocytes	can	
return	to	the	bone	marrow	and	have	a	short	life	span	with	a	typical	half	life	of	<	1	
day	 whilst	 in	 circulation	 (Shi	 and	 Pamer,	 2011).	 The	 spleen	 acts	 an	 important	
reservoir	 of	 Ly-6chigh	 monocytes	 and	 can	 rapidly	 deploy	 these	 cells	 to	 sites	 of	
inflammation	 (Swirski	 et	 al.,	 2009).	 It	 appears	 that	 in	 addition	 to	 hosting	 bone	
marrow	 derived	 monocytes,	 the	 spleen	 plays	 a	 part	 in	 active	 production	 of	
monocytes	 from	 HSC	 in	 splenic	 niche	 sites	 (Robbins	 et	 al.,	 2012).	 Monocytes	
originating	in	the	spleen	through	extramedullary	haematopoiesis	have	been	shown	
to	 contribute	 directly	 to	 the	 atherosclerotic	 lesion	 via	 fate	 mapping	 studies	
(Robbins	 et	 al.,	 2012).	 The	 latter	 authors	 also	 report	 that	 functionally,	 spleen	
derived	 monocytes	 displayed	 an	 inflammatory	 profile	 resembling	 bone	 marrow	
derived	 cells	 characterised	 by	 production	 of	 pro-inflammatory	 cytokines,	
generation	of	ROS	and	production	of	proteases.	Furthermore,	these	cells	ultimately	
formed	 foam	 cells	 through	 ingesting	 lipids.	 In	 ApoE	 -/-	 mice,	 Dutta	 et	 al.	
Dr	Ahmed	Iqbal,	Department	of	Infection,	Immunity	and	Cardiovascular	Disease	
	 52	
demonstrated	 that	 an	 episode	 of	 AMI	 accelerates	 pre-established	 atherosclerosis	
(Dutta	 et	 al.,	 2012).	 The	 authors	 showed	 a	 sustained	 systemic	 monocytosis	 in	
response	to	AMI	that	was	mediated	by	an	increased	sympathetic	drive.	Sympathetic	
nervous	 signaling	 in	 the	bone	marrow	via	β3	 adrenergic	 receptors	 released	HSC.	
The	 latter	 seeded	 the	 spleen	 resulting	 in	 increased	 monocyte	 numbers	 via	




There	 is	 a	 paucity	 of	 data	 detailing	 the	 fate	 and	 life-span	 of	 human	 monocyte	
subsets.	 Nevertheless,	 approaches	 involving	 radio-isotope	 labelling	 of	 human	
leukocytes	 in	 vivo	 have	 advanced	 our	 understanding	 in	 this	 field	 (Busch	 et	 al.,	
2007).	 In	 a	 recent	 study,	 Patel	 et	 al.	 using	 in	 vivo	 deuterium	 labelling	 studied	
human	monocyte	subset	kinetics	in	30	healthy	volunteers	(Patel	et	al.,	2017).	The	
authors	 report	 that	 under	 homeostatic	 conditions,	 CMs	 arise	 from	 monocyte	
precursors	in	the	bone	marrow	and	circulate	systemically	for	approximately	1	day.	





A	 classical	 cascade	 involving	 selectins,	 cell	 adhesion	 molecules	 and	 chemokines	
orchestrates	 monocyte	 traffic	 and	 recruitment	 into	 the	 atherosclerotic	 plaque.	
During	atherosclerosis,	recruitment	of	both	Ly-6chigh	and	Ly-6clow	monocytes	in	the	
plaque	 has	 been	 reported	 with	 comparatively	 less	 evidence	 to	 characterise	




Initially,	 monocytes	 undergo	 P-selectin	 and	 E-selectin	 dependent	 rolling	 on	 the	
endothelium	 (Shi	 and	 Pamer,	 2011).	 P-selectin	 is	 expressed	 on	 activated	
endothelium	and	platelets	and	can	bind	neutrophils,	monocytes	and	 lymphocytes	
via	its	ligand	P-selectin	glycoprotein	ligand	1	(PSGL1)	which	is	expressed	by	these	
cells.	 E-selectin	 also	 interacts	 with	 PSGL1	 (Katayama	 et	 al.,	 2003)	 and	 notably		
LDLR	-/-	mice	with	a	combined	deficiency	of	P-selectin	and	E-selectin	had	significant	
protection	 from	 atherosclerosis	 (Dong	 et	 al.,	 1998).	 Ly-6chigh	 monocytes	




Firm	 adhesion	 of	 monocytes	 onto	 the	 activated	 endothelium	 is	 facilitated	 by	
integrins	 on	 the	 surface	 of	 monocytes	 that	 bind	 to	 endothelial	 cell	 adhesion	
molecules	 (Ley	 et	 al.,	 2007).	 The	 vey	 late	 antigen-4	 (VLA-4)	 and	 lymphocyte	
function	 associated	 antigen-1	 (LFA-1)	 are	 highly	 expressed	 on	 circulating	
monocytes	 and	 interact	 with	 VCAM-1	 and	 ICAM-1	 respectively	 (Woollard	 and	
Geissmann,	 2010).	 Human	 monocytes	 have	 been	 shown	 to	 express	 the	 integrin	
CD11c	which	 is	not	present	on	murine	monocytes	 (Geissmann,	 Jung	and	Littman,	
2003),	 however,	 genetic	 analysis	 of	 human	 NCMs	 has	 revealed	 upregulation	 of	
patrolling	 associated	 integrins	 including	 LFA-1	 (G.	 Thomas	 et	 al.,	 2015).	 Several	
studies	 have	 highlighted	 an	 important	 role	 for	 both	 VCAM-1	 and	 ICAM-1	 in	




Chemokines	 which	 are	 secreted	 by	 endothelial	 cells,	 smooth	 muscle	 cells,	
fibroblasts	and	macrophages	interact	with	their	respective	receptors	on	monocytes	
to	facilitate	extravasation	of	monocytes	into	the	atherosclerotic	plaque.	In	Ly-6chigh	
monocytes,	 CCR2,	 CX3CR1	 and	 CCR5	 direct	 traffic	 into	 lesions	 (Woollard	 and	
Geissmann,	2010).		In	ApoE	-/-	mice,	combined	inhibition	of	CCL2,	CX3CR1	and	CCR5	
led	 to	 a	 90%	 reduction	 in	 atherosclerosis	 with	 an	 abrogation	 of	 monocytosis	
normally	 associated	 with	 hyperlipidaemia	 in	 these	 animals	 (Combadiere	 et	 al.,	
2008).	 In	CD16+	monocytes,	CX3CR1	expression	has	been	shown	 to	preferentially	





A	 number	 of	 observational	 studies	 have	 suggested	 that	 leukocytosis	 is	 a	 poor	
prognostic	 indicator	 in	 stable	CAD	and	 following	AMI	and	CVA	(Brown,	Giles	and	
Croft,	 2001;	 Madjid	 et	 al.,	 2004;	 Ohira	 et	 al.,	 2006).	 Epidemiological	 studies	
investigating	 an	 association	 between	 total	monocyte	 counts	 and	 risk	 of	 acute	 CV	
events	 have	 yielded	 conflicting	 results	 that	 can	 possibly	 be	 explained	 by	
methodological	 differences	 and	 confounding	 factors.	 Some	 studies	 suggest	 that	 a	
higher	total	monocyte	count	is	a	strong	independent	predictor	of	future	CV	events	




A	 number	 of	 observational	 studies	 have	 also	 examined	 the	 relationship	 between	
different	 monocyte	 subsets	 and	 CV	 risk.	 Whilst	 differences	 in	 flow	 cytometric	
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gating	 strategies	 between	 studies	 makes	 it	 challenging	 to	 directly	 compare	 the	
absolute	 numbers	 and	 percentages	 of	 individual	 subsets,	 an	 association	 between	
CD16+	IMs	and	NCMs	and	CV	risk	is	emerging	(Schlitt	et	al.,	2004;	Heine	et	al.,	2008;	
Wildgruber	 et	al.,	 2009;	 Poitou	 et	al.,	 2011;	 Rogacev	 et	al.,	 2011;	 Hilgendorf	 and	
Swirski,	 2012).	 One	 of	 the	 largest	 observational	 studies	 investigating	 the	 role	 of	
monocyte	 subsets	 in	 predicting	 CV	 events	 prospectively	 studied	 951	 patients	
referred	 for	 elective	 coronary	 angiography	 over	 a	 mean	 follow-up	 of	 2.6	 years	
(Rogacev	et	al.,	2012).	In	this	high-risk	population,	the	primary	endpoint,	defined	a	




Relatively	small	 (<	100	subjects)	observational	 studies	have	also	 investigated	 the	
relationship	 between	 monocyte	 subsets	 and	 coronary	 artery	 plaque	 stability	 in	
patients	 with	 stable	 angina,	 unstable	 angina	 and	 those	 with	 recent	 AMI	 treated	
with	 intra-coronary	stents	(Imanishi	et	al.,	2010;	Kashiwagi	et	al.,	2010;	Liu	et	al.,	
2010).	 Collectively,	 these	 studies	 demonstrated	 that	 higher	 levels	 of	 peripheral	
CD16+	 monocytes	 positively	 correlated	 with	 plaque	 instability	 and	 stent	 failure.	
Importantly,	 there	 is	 also	 epidemiological	 evidence	 to	 suggest	 that	 CD14++	 CD16-	
CMs	may	increase	CV	risk	(Hristov	et	al.,	2010).	 In	a	study	of	700	subjects	from	a	




as	AMI	mobilises	monocytes	 (Nahrendorf	et	al.,	 2007;	Dutta	et	al.,	 2012).	 	Others	
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have	 also	 investigated	 monocyte	 subset	 kinetics	 in	 man	 and	 demonstrated	 a	
preferential	 expansion	of	 the	 IM	population	during	 the	 first	72	hours	 following	a	




humans,	 exercise	 that	 generates	 a	 catecholamine	 response	 of	 a	 similar	 order	 of	
magnitude	 to	 acute	 CV	 events	 also	 selectively	 mobilises	 CD16+	 cells	 in	 a	
catecholamine	dependent	fashion	(Birgit	Steppich	et	al.,	2000).	The	rapidity	(within	
5	 minutes)	 with	 which	 CD16+	 monocytes	 appear	 in	 the	 circulation	 suggests	
mobilisation	 from	 the	 marginal	 pool	 where	 these	 cells	 preferentially	 home	 on	
account	of	expressing	the	adhesion	molecules	CD11d	and	VLA-4	(Birgit	Steppich	et	
al.,	 2000).	 In	 healthy	 volunteers,	 intravenous	 adrenaline	 infusion	 also	 rapidly	
mobilised	 CD16+	 monocytes	 that	 had	 characteristic	 a	 CD11ahigh	 and	 CXCR1high	
expression	 allowing	 them	 to	 attach	 to	 the	 vascular	 endothelium	 and	 then	
demarginate	 under	 the	 influence	 of	 adrenaline	 agonism	 of	 surface	 β2	
adrenoreceptors	(Dimitrov,	Lange	and	Born,	2010).	
	
Overall,	data	 from	observational	studies	 lends	credibility	 to	the	notion	that	NCMs	
and	IMs	are	particularly	 important	 in	 the	pathogenesis	of	atherosclerosis	and	are	
preferentially	mobilised	 following	 acute	CV	 events	 in	 a	 catecholamine	dependent	
fashion.	 These	 studies	 are,	 however,	 limited	 by	 their	 observational	 nature,	
relatively	 small	 number	 of	 participants	 and	 a	 non-uniform	 methodological	






Macrophages	play	 a	 critical	 role	 in	 the	 aetiology	of	 atherosclerosis.	 Traditionally,	
macrophage	 subsets	 have	 been	 divided	 into	 M1	 and	 M2	 phenotypes.	 M1	
macrophages	 have	 been	 characterised	 as	 being	 ‘pro-inflammatory’	 on	 account	 of	
these	 cells	 being	 activated	 by	 a	 “classical”	 stimulus	 such	 as	 LPS	 or	 other	 TLR	
ligands	with	subsequent	production	of	pro-inflammatory	cytokines	including	IL-1β,	
TNF-α	 and	 IL-12	 (Moore,	 Sheedy	 and	 Fisher,	 2013).	M1	macrophages	 have	 been	
implicated	 in	 plaque	 evolution	 and	 destabilisation	 (Moore,	 Sheedy	 and	 Fisher,	
2013).	In	contrast,	M2	macrophages	are	thought	be	activated	“alternatively”	by	IL-
13	 and	 IL-4	 and	 deemed	 ‘anti-inflammatory’	 based	 on	 these	 cells	 secreting	 anti-
inflammatory	 cytokines	 including	 IL-10	 and	 IL-1	 receptor	 antagonist	 (Moore,	
Sheedy	 and	 Fisher,	 2013).	 M2	 macrophages	 display	 high	 endocytic	 activity	 and	
secrete	tissue	repair	 factors	 including	collagen	(Moore,	Sheedy	and	Fisher,	2013).	
The	 transcription	 factors	 NR4A1	 (NUR77)	 and	 Krüppel-like	 factor	 4	 (KLF4)	 are	
critical	 regulators	 of	macrophage	 polarisation	 and	 inhibit	M1	 polarisation	whilst	
favouring	 the	M2	phenotype	 (Liao	et	al.,	 2011;	Hamers	 et	al.,	 2012;	Hanna	 et	al.,	
2012).		
	
A	 heterogeneous	 distribution	 of	 macrophage	 populations	 has	 been	 reported	 in	
human	atherosclerotic	plaques	with	M1	macrophages	localising	to	lipid	rich	areas	
in	contrast	to	M2	macrophages	that	locate	far	from	the	lipid	core	of	the	lesion	and	
contain	 smaller	 lipid	droplets	 in	 comparison	 to	M1	 cells	 (Chinetti-Gbaguidi	et	al.,	









The	 dichotomisation	 of	 macrophages	 into	 M1	 pro-inflammatory	 and	 M2	 anti-
inflammatory	phenotypes	has,	however,	recently	been	questioned	(Moore,	Sheedy	
and	Fisher,	2013).	It	has	been	argued	that	 in	vivo,	 lesional	macrophages	are	likely	
to	 encounter	 a	 multitude	 of	 signals	 meaning	 that	 a	 phenotypic	 spectrum	 of	
macrophages	 exists	 depending	 on	 the	 prevailing	 conditions	 within	 the	
atherosclerotic	plaque.	Specifically,	the	presence	of	oxidised	lipids	(Gallardo-Soler	
et	al.,	2008)	and	other	signals	in	the	plaque	can	trigger	modulation	of	macrophages	





It	 is	 now	 increasingly	 recognised	 that	 platelets	 play	 a	 key	 role	 in	 generating	 the	
immune	responses	driving	atherosclerosis.	
	
Upon	 activation,	 platelets	 release	 the	 contents	 of	 their	 α	 granules	 including	
adenosine	 diphosphate	 (ADP)	 which	 in	 turn	 acts	 on	 platelet	 P2Y1	 and	 P2Y12	








in	 atherosclerosis	 as	 elimination	 of	 PF4	 in	 ApoE	 -/-	 mice	 dramatically	 reduced	
atherosclerotic	burden	by	73%	(Sachais	et	al.,	2007).	RANTES	(CCL5),	a	chemokine	
also	 secreted	 by	 α	 granules	 plays	 a	 key	 part	 in	 atherosclerosis	 by	 encouraging	
monocyte	 recruitment	 to	 the	 atherosclerotic	 endothelium	 (Mause	 et	 al.,	 2005).	
Activated	platelets	also	promoted	endothelial	expression	of	 ICAM-1	and	CCL2	via	




adhesion	 molecules	 on	 their	 surface	 allowing	 interactions	 between	 platelets,	
leukocytes	 and	 endothelial	 cells.	 Activated	 platelets	 release	 P-selectin	 (CD62P)	
from	 their	 α	 granules	which	 is	 expressed	 on	 the	 platelet	 plasma	membrane	 and	
facilitates	 links	 between	 thrombosis	 and	 inflammation	 (Stenberg	 et	 al.,	 1985).	 A	







Platelets	 initially	bind	 to	 leukocytes	via	PSGL1	and	 this	 interaction	 triggers	more	
firm	 interactions	 between	 leukocyte	 β2	 integrin	 CD11b/CD18	 and	 a	 number	 of	




platelets	 on	 the	 vessel	 wall	 also	 promotes	 adhesion	 of	 leukocytes	 to	 endothelial	
cells	 via	 P-selectin-PSGL1	 mediated	 interactions	 thus	 promoting	 leukocyte	
extravasation	 to	 sites	 of	 injury	 (Mine	 et	 al.,	 2001).	 Platelet	 P-selectin	 mediated	
interactions	with	leukocytes	are	critical	to	the	development	of	atherosclerosis	as	in	




platelet-aggregates	 (MPAs	and	NPAs)	has	 functional	 consequences	 for	 leukocytes	
that	 are	 important	 in	 the	 pathogenesis	 of	 atherosclerosis.	 In	monocytes,	 platelet	
binding	 via	 P-selectin-PSGL1	 increased	 expression	 and	 activity	 of	 the	 α4-β1	 and	
αM-β2	 (CD11b/CD18)	 integrins	 and	 increased	 monocyte	 adhesion	 to	 VCAM-1,	
ICAM-1	and	fibronectin	(Martins	et	al.,	2005).	Platelet	adhesion	to	monocytes	via	P-
selectin	also	modulated	cytokine	production	by	enhancing	nuclear	translocation	of	
NF-κB	with	 an	 increased	 secretion	 of	 pro-inflammatory	 cytokines	 CCL2	 (MCP-1)	
and	TNF-α	(Weyrich	et	al.,	1995).	Notably,	monocyte-platelet	 interactions	 in	vitro	
upregulated	CD16	expression	on	monocytes	shifting	the	phenotype	of	CMs	(CD14++	
CD16-)	 towards	 the	 pro-inflammatory	 IMs	 (CD14++	 CD16+)	 (Passacquale	 et	 al.,	
2011).	 In	 human	 neutrophils,	 P-selectin	 binding	 to	 PSGL-1	 induced	 activation	 of	
αM-β2	 integrins	 promoting	 the	 adhesive	 properties	 of	 these	 cells	 (Ma,	 Plow	 and	
Geng,	2004).		
	
Platelet-leukocyte	 interactions	 also	 occur	 through	 P-selectin-PSGL1	 independent	
mechanisms	 including	 triggering	 receptors	 expressed	 on	 myeloid	 cells	 (TREM)	
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of	 soluble	CD40L	 (sCD40L)	which	has	been	 shown	 to	activate	human	endothelial	
cells	 by	 increased	 production	 of	 IL-6	 and	 increased	 expression	 of	 endothelial	 P-
selectin	 and	E-selectin	 (Déchanet	et	al.,	 1997).	 These	 changes	promote	 leukocyte	
traffic	 and	 adhesion	 at	 sites	 of	 evolving	 atherosclerotic	 plaque.	 Figure	 1.6	









platelet	 aggregates.	 Platelets	 can	 be	 activated	 by	 a	 number	 of	 agonists	
including:	 adrenaline,	 thromboxane	 A2,	 thrombin,	 collagen	 and	 platelet	
activating	factor.	Upon	activation,	platelet	α	granules	degranulate	releasing	a	
number	 of	 mediators	 including:	 CD40L,	 IL-1β,	 RANTES,	 PF4,	 and	 MIP-1	 α.	
Action	 of	 these	 inflammatory	 mediators	 on	 corresponding	 monocyte	
receptors	 (CD40-CD40L,	 IL-1R-IL-1β,	 CCR5-RANTES,	 CCR3-RANTES,	 CCR1-
RANTES,	 CCR1-MIP-1α	 and	 PF4	 receptor-PF4)	 induces	 pro-inflammatory	
changes	 in	monocytes	 characterised	by	 the	production	of	MCP-1/CCL2,	 IL-6	
and	 TNF-α.	 Platelet	 membrane	 bound	 P-selectin	 interacts	 with	 PSGL1	 on	
monocytes	 to	 form	monocyte-platelet	 aggregates.	 This	 initial	 attachment	 is	
strengthened	 by	 interactions	 between	 monocyte	 expressed	 integrins	
CD11b/CD18	 and	 platelet	 glycoprotein	 1b,	 platelet	 bound	 fibrinogen	 or	
platelet	ICAM-2.	Monocyte-platelet	aggregate	formation	activates	monocytes	
and	 upregulates	 expression	 of	 monocyte	 adhesion	 molecules	 facilitating	
recruitment	 to	 atherosclerotic	 lesions.	 Also,	 monocyte	 activation	 creates	 a	
pro-inflammatory	 milieu	 by	 augmenting	 pro-inflammatory	 cytokine	
production	through	induction	of	a	number	of	pro-inflammatory	transcription	
factors	 including	 NF-κB.	 Monocyte	 activation	 also	 results	 in	 synthesis	 and	
release	 of	 platelet	 agonists	 including	 platelet	 activating	 factor	 thus	
contributing	 to	 further	 platelet	 activation	 in	 a	 vicious	 cycle.	 Abbreviations:	
CD40L,	 CD40	 ligand;	 IL-1β,	 interleukin	 1	 beta;	 RANTES,	 regulated	 on	
activation,	normal	T	cell	expressed	and	secreted;	PF4,	platelet	factor	4;	MIP-1	
α,	macrophage	 inflammatory	protein	1	alpha;	 IL-1R,	 interleukin	1	receptor;	
CCR5,	 c-c	 motif	 chemokine	 receptor	 type	 5;	 CCR3,	 c-c	 motif	 chemokine	
receptor	type	3;	CCR1,	c-c	motif	chemokine	receptor	type	1;	MCP-1,	monocyte	
chemoattractant	 protein-1;	 CCL2,	 c-c	 motif	 chemokine	 ligand	 2;	 IL-6,	
interleukin	 6;	 TNF-α,	 tumour	 necrosis	 factor	 alpha;	 PSGL1,	 P-selectin	



















enhanced	 MPA	 formation	 specifically	 in	 the	 context	 of	 T1D	 and	 T2D	 related	
angiopathy	 (Furman	 et	 al.,	 1998;	 Kaplar	 et	 al.,	 2001).	 MPA	 formation	 is	 also	
important	in	the	pathogenesis	of	acute	CV	events	with	elevated	MPA	counts	noted	
post	 AMI	 (Furman	 et	al.,	 2001;	 Sarma	 et	al.,	 2002).	 	 Circulating	MPAs	 are	 a	 very	
sensitive,	early	marker	of	AMI,	and	have	been	shown	to	be	superior	to	P-selectin	as	
a	marker	of	platelet	activation	in	vivo	(Furman	et	al.,	2001;	Michelson	et	al.,	2001).	
MPA	 formation	 in	 ACS	 may	 have	 a	 prognostic	 implication	 as	 levels	 of	 MPAs	
correlate	 with	 troponin	 elevation	 and	 are	 strongly	 related	 to	 risk	 of	 in-hospital	



















Clinical	 observational	 studies	 have	 also	 specifically	 examined	 neutrophil-platelet	
interactions.	An	early	study	of	25	patients	with	UA	compared	to	25	control	patients	
with	 stable	 angina	 reported	 a	 near	 5	 fold	 increased	 NPA	 formation	 as	 well	 as	
neutrophil	activation	demonstrated	by	increased	CD11b	expression	and	L-selectin	
shedding	 in	 the	UA	group	(Ott	et	al.,	1996)	These	data	were	supported	by	a	 later	
study	 of	 71	 patients	 with	 UA	 and	 22	 patients	 with	 stable	 CAD	 (Murasaki	 et	 al.,	
2007).	 In	 addition	 to	 a	 significantly	higher	NPA	 formation	 and	neutrophil	 CD11b	
expression,	there	was	a	higher	expression	of	platelet	P-selectin	in	patients	with	UA	
compared	to	stable	CAD	controls.		In	addition	to	UA,	excess	PNAs	(>	1	fold	increase	
compared	 to	 controls)	 have	 also	 been	 reported	 in	 23	 patients	 with	 a	 non-ST-




Overall,	 relatively	 small,	 case-control	 studies	 have	 demonstrated	 increased	 MPA	
and	NPA	 counts	 in	both	 stable	CAD	and	 following	 acute	CV	events.	However,	 the	
precise	mechanistic	 roles	 of	 leukocyte-platelet	 aggregates	 in	 the	pathophysiology	
of	 both	 stable	 and	 acute	 CV	 pathology	 have	 not	 been	 addressed	 in	 vivo.	












stages	 as	 described	 in	 Figure	 1.4.	 Progression	 of	 the	 atherosclerotic	 plaque	 from	
the	initial	fatty	streak	to	intermediate	lesions	is	also	defined	by	an	accumulation	of	
lipid	rich	largely	acellular	material	in	the	intimal	layer	(Stary	et	al.,	1994).		In	some	
advanced	 lesions,	 lipid	 pools	 enlarge	 and	 are	 invaded	 by	 plaque	 macrophages	
giving	 rise	 to	 consolidated	 necrotic	 cores	 (Bentzon	 et	 al.,	 2014).	 More	 advanced	
lesions	contain	 larger	necrotic	cores	that	completely	 lack	matrix	but	have	greater	
macrophage	 infiltration	 (Kolodgie	 et	 al.,	 2003).	 In	 the	 advanced	 atherosclerotic	
lesion,	 the	 necrotic	 core	 is	 covered	 by	 an	 overlying	 fibrous	 cap	 (Bentzon	 et	 al.,	
2014).	 The	 strength	 and	 stability	 of	 the	 fibrous	 cap	 is	 largely	 determined	 by	 the	
tensile	 strength	 of	 collagen	within	 it	 (Libby,	 2013).	 Rupturing	 of	 the	 fibrous	 cap	






in	 macrophages	 (Lusis,	 2000).	 Modification	 of	 LDL	 into	 oxLDL	 is	 critical	 to	 the	
formation	of	foam	cells	as	unmodified	LDL	particles	found	in	the	peripheral	blood	
of	healthy	volunteers	does	not	induce	foam	cell	formation	in	macrophages	in	vitro	
(Lusis,	 2000;	 Chistiakov	 et	 al.,	 2017).	 Lipid	 uptake,	 processing	 and	 efflux	 by	
macrophages	 under	 homeostatic	 conditions	 and	 dysregulation	 of	 these	
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Figure	1-7	Mechanisms	of	 foam	cell	 formation.	OxLDL	binds	LOX-1	which	 is	
expressed	 on	 endothelial	 cells.	 OxLDL	 is	 then	 trafficked	 into	 the	 arterial	
intimal	 layer,	 which	 is	 infiltrated	 by	 macrophages	 in	 atherosclerosis.	
Macrophages	internalise	oxLDL	via	CD36,	SR-A1	and	LOX-1.	Relatively	stable	
cholesterol	 esters	 upon	 entering	 macrophage	 lysosomes	 are	 converted	 to	
free	 fatty	 acids	 and	 free	 cholesterol	 under	 the	 action	 of	 LAL.	 Excess	 free	
cholesterol	then	traffics	to	the	endoplasmic	reticulum	where	under	the	action	
of	 ACAT1	 it	 is	 re-esterified	 into	 cholesterol	 esters.	Within	 the	 endoplasmic	
reticulum,	 NCEH	 directly	 opposes	 the	 action	 of	 ACAT1	 by	 degrading	
cholesterol	esters	back	 into	 fatty	acids	and	 free	cholesterol	 thus	preventing	
cholesterol	 ester	 accumulation	 in	 the	 endoplasmic	 reticulum,	 a	 number	 of	
transporters,	 including	ABCA1,	ABCG1	and	SR-B1,	efflux	free	cholesterol	out	
of	 macrophages	 in	 a	 process	 called	 reverse	 transport.	 HDL	 and	
apolipoproteins	 act	 as	 free	 cholesterol	 acceptors	 transporting	 these	
molecules	 for	 processing	 in	 the	 liver.	 Lipid	 handling	 by	 macrophages	 is	
dysregulated	 in	 atherosclerosis	 (red	 arrows).	 Under	 the	 influence	 of	
inflammatory	mediators	such	as	IFN-Υ,	scavenger	receptor	expression	on	the	
endothelium	 and	 macrophages	 is	 increased	 leading	 to	 increased	 oxLDL	
uptake.	ACAT-1	activity	 is	enhanced	through	the	actions	of	 IFN-Υ	and	TNF-α	
whilst	 there	 is	 a	 down	 regulation	 of	 NCEH	 activity.	 The	 pro-inflammatory	
cytokines	 IL-12,	 IL-18,	 IL-1β,	 IFN-Υ	 downregulate	 cholesterol	 efflux.	 An	








IFN-Υ,	 interferon	 gamma;	 TNF-α,	 tumour	 necrosis	 factor	 alpha;	 IL-12,	





Acute	 CV	 events	 such	 as	 ACS	 can	 be	 caused	 by	 two	 broad	 mechanisms:	 either	
plaque	 rupture	 or	 plaque	 erosion.	 Fibrous	 plaque	 rupture	 is	 implicated	 in	 most	
fatal	cases	of	ACS	(Libby	et	al.,	2014).	There	is	also	extensive	evidence	that	plaque	
rupture	 is	 driven	 by	 inflammation	 with	 certain	 characteristics	 of	 the	 plaque	
including:	 a	 thin	 fibrous	 cap,	 large	 necrotic	 core,	 numerous	macrophages,	 spotty	






is	modulated	 through	 effects	 of	 the	 immune	 system	on	 both	 collagen	 production	
and	degradation	 (Libby	et	al.,	2014).	 In	 the	atherosclerotic	plaque,	CD4+	T-helper	





The	 susceptibility	 of	 a	 fibrous	 cap	 to	 thinning	 and	 subsequent	 rupture	 is	 also	
dependent	 upon	 collagen	 degradation	 by	 collagenases	 (Libby,	 2013).	 The	
interaction	 of	 CD40	 with	 its	 ligand	 CD40L	 (CD154)	 is	 also	 important	 in	 the	
evolution	of	fibrous	plaques	towards	rupture	(Schönbeck,	Sukhova,	et	al.,	2000).	In	
the	atherosclerotic	plaque,	cross	talk	exists	between	the	adaptive	immune	system	




inflammatory	 cytokines	 including	 IFN-Υ	 and	 upregulates	 expression	 of	 adhesion	




evidence	 to	 suggest	 that	 emotional	 and	physical	 stimuli	 that	 induce	 activation	 of	
the	 sympathetic	 nervous	 system	 such	 as	 physical	 activity,	 anxiety,	 infections	 and	
cocaine	use	can	trigger	plaque	rupture	and	ACS	(Mittleman	and	Mostofsky,	2011).	
This	 is	 an	 important	 observation	 in	 light	 of	 hypoglycaemia	 also	 triggering	 a	
sympathetic	 response.	 Furthermore,	 sympathetic	 activation	 in	 the	 context	 of	 an	
AMI	 has	 been	 shown	 to	 aggravate	 inflammation	 in	 the	 atherosclerotic	 plaque	 in	
part	through	increased	protease	activity	(Dutta	et	al.,	2012).	
	
A	 larger	 necrotic	 core	 also	 confers	 an	 increased	 CV	 risk	 (Libby	 et	 al.,	 2014).	
Inflammation	within	the	plaque	determines	necrotic	core	formation	and	worsening	




Calcification	 within	 the	 atherosclerotic	 plaque	 is	 associated	 with	 plaque	 rupture	
and	ACS	(Camici	et	al.,	2012;	Maldonado	et	al.,	2012).	Plaque	calcification	may	have	
an	added	relevance	in	the	pathogenesis	of	ACS	in	those	with	T2D.	In	a	study	of	581	




et	 al.,	 2015).	 In	 addition,	 remodelling	 of	 coronary	 arteries	 characterised	 by	
enlargement	 is	 an	 important	 predictor	 of	 the	 future	 risk	 of	 acute	 CV	 events	
(Clarkson	et	al.,	 1994)	 and	 is	 governed	by	 inflammatory	mediators	 in	 the	plaque	
with	IL-1	signalling	being	particularly	important	(Alexander	et	al.,	2012).		
	
Thrombosis	 occurs	 when	 the	 fibrous	 cap	 ruptures	 allowing	 blood	 to	 come	 into	
direct	 contact	 with	 thrombogenic	 material	 present	 in	 the	 plaques	 core	 (Libby,	












lead	 to	AMI.	Subsequently,	pathogens	have	been	 found	 in	atherosclerotic	plaques	
including	Chlamydia	pneumoniae,	 and	cytomegalovirus	 (CMV)	 (Adam	et	al.,	 1987;	
Kuo	et	al.,	1993).	Other	seroepidemiological	studies,	however,	did	not	demonstrate	
that	previous	infection	with	a	number	of	organisms	increased	subsequent	CV	risk	
(Ridker	 et	 al.,	 1999).	 As	 debate	 has	 existed	 around	 the	 concept	 of	 a	 causative	
relationship	 between	 infectious	 pathogens	 and	 atherosclerosis,	 research	 has	




increase	 in	 atherosclerotic	 lesion	 size	 was	 demonstrated	 (Hsich	 et	 al.,	 2001;	
Ezzahiri	et	al.,	2003).	A	number	of	mechanisms	have	been	suggested	through	which	
infectious	pathogens	may	contribute	to	atherosclerosis.	These	include	the	systemic	
host	 response	 to	 infection	 that	 is	 pro-atherogenic	 including:	 production	 of	 pro-
inflammatory	 cytokines	 (chemokines	 and	 non-chemokines)	 and	 upregulation	 of	
vascular	 adhesion	 molecules	 (Epstein	 et	 al.,	 2009).	 In	 addition,	 activation	 of	
monocytes	 and	 T-cells	 and	 cross-reactivity	 with	 self-antigens	 resulting	 in	 an	
autoimmune	response	may	contribute	to	atherosclerosis	(Epstein	et	al.,	2009).	
	
Patients	 with	 diabetes	 are	 more	 prone	 to	 infections	 when	 compared	 to	 those	
without	diabetes	(Geerlings	and	Hoepelman,	1999).	The	underlying	reasons	for	this	
propensity	 to	 infection	 in	diabetes	 is	 thought	 to	be	 complex	but	 is	 in	part	due	 to	
abnormalities	 in	 both	 the	 innate	 and	 adaptive	 immune	 responses.	 A	 common	





fold	 higher	 in	 those	 with	 severe	 periodontitis	 compared	 to	 those	 without	 (P	 M	
Preshaw	et	al.,	2012).	As	 low-grade	infection	results	 in	chronic	 inflammation,	one	
explanation	for	an	increased	CV	risk	in	the	context	of	DFU	and	severe	periodontitis	
maybe	 through	 progression	 of	 atherosclerosis.	 Further,	 it	may	 be	 that	 there	 is	 a	









differing	 circumstances	 over	 the	 past	 century	 (Suffredini	 and	 Noveck,	 2014).	 In	
1976,	 a	 large	 quantity	 of	 endotoxin	 was	 extracted	 from	 E.	 coli	O:113	 for	 use	 in	
human	experimental	studies.	This	endotoxin	preparation	has	since	been	recognised	
by	the	WHO	as	a	standard	for	use	in	various	assays	(Suffredini	and	Noveck,	2014).	
Research	 over	 the	 last	 30	 years	 has	 highlighted	 the	 complexity	 of	 the	 innate	
immune	 system	as	 a	highly	 conserved	 system	of	defence	 against	 infections.	 Soon	
after	encountering	recognised	molecular	motifs	such	as	endotoxin,	 ligand	binding	
with	 microbial	 structures	 results	 in	 activation	 of	 lymphoid	 and	 myeloid	 cells	 in	
addition	 to	 humoral	 proteins.	 A	 cascade	 of	 inflammatory	 effects	 ensues	 which	
involves	 recruitment	 of	 inflammatory	 cells	 and	 proteins	 to	 the	 site	 of	 infection	
resulting	 in	 microbial	 clearance	 and	 tissue	 repair.	 Adaptive	 immune	 responses	
follow	on	from	the	initial	innate	immune	response	allowing	the	organism	to	build	a	
repertoire	 of	 defence	 against	 specific	 infectious	 agents	 if	 encountered	
prospectively.	 Following	 administration	 of	 intravenous	 endotoxin	 in	 healthy	
human	 volunteers,	 a	 constellation	 of	 inflammatory	 effects	 is	 observed	 which	 is	
dose-dependent	 and	 resembles	 the	 systemic	 inflammatory	 response	 syndrome	
seen	in	sepsis	(Suffredini,	Hochstein	and	McMahon,	1999).	Depending	on	the	dose	
of	 endotoxin,	 a	 fever	 develops	 3-5	 hours	 after	 injection	 of	 endotoxin.	 Peripheral	
blood	 leukocyte	 changes	 occur	 between	 3-5	 hours	 with	 an	 initial	 decline	 in	 the	
absolute	 number	 of	 mononuclear	 cells	 and	 a	 corresponding	 neutrophilia	
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(Suffredini,	 Hochstein	 and	 McMahon,	 1999).	 Neutrophils	 demonstrate	 an	









Suffredini,	 2001).	 Changes	 in	 DHEA	 levels	 are	 particularly	 interesting,	 as	 DHEA	
antagonises	glucocorticoid	action	and	enhances	mononuclear	cell	responses	(Fiuza	






Diabetes	 is	 common	 and	 its	 prevalence	 is	 rising	 with	 CVD	 as	 a	 leading	 cause	 of	
death	 in	 those	 with	 diabetes.	 Hypoglycaemia	 is	 commonly	 encountered	 in	 the	
management	 of	 diabetes.	 Data	 from	 recent	 large	 randomised	 trials	 suggests	 that	
hypoglycaemia	 as	 a	 consequence	 of	 intensive	 glucose	 control	 may	 be	 associated	
with	excess	CV	mortality.	Whilst	evidence	from	post-hoc	analyses	of	trials	suggests	







thrombotic	 thus	 potentially	 promoting	 increased	 CV	 risk.	 These	 studies	 have	
investigated	both	healthy	 volunteers	 and	 those	with	diabetes	but	 have,	 however,	
been	mainly	descriptive	 in	nature.	Whilst	changes	 in	pro-inflammatory	cytokines,	
endothelial	 cell	 adhesion	 molecules,	 total	 leukocyte	 kinetics	 and	 endothelial-
leukocyte	interactions	have	been	offered	as	plausible	explanations	for	increased	CV	
risk,	 in	 depth	 study	 of	 the	 various	 components	 of	 the	 inflammatory	 response	 to	





atherosclerotic	 plaque,	 yet	 there	 is	 a	 distinct	 paucity	 of	 data	 on	 these	 cells.	 In	
addition,	 interactions	 of	 monocytes	 and	 neutrophils	 with	 platelets	 to	 form	
circulating	 pro-atherogenic	 aggregates	 have	 not	 been	 comprehensively	 assessed.	
Platelet	 aggregation	 and	 activation	 in	 itself	 is	 a	 well	 recognised	 risk	 factor	 for	
macrovascular	events	especially	in	the	context	of	the	unstable	plaque	and	ACS	and	
needs	 further	 evaluation	 in	 the	 context	 of	 hypoglycaemia.	 Within	 monocyte	
subsets,	the	CD16+	NCMs	and	IMs	have	been	shown	in	human	observational	studies	
to	 be	 prospectively	 linked	with	 future	 CV	 risk.	 There	 is	 little	 data	 examining	 the	
effects	of	hypoglycaemia	on	monocyte	subset	kinetics	and	activation.	Furthermore,	
most	 human	 experimental	 studies	 have	 concentrated	 on	 the	 acute	 inflammatory	
effects	 of	 hypoglycaemia.	 Data	 from	 clinical	 trials,	 however,	 indicate	 that	
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hypoglycaemia	 predicts	 CV	mortality	 downstream	 from	 the	 event	 (Duckworth	 et	
al.,	 2009;	Bonds	et	al.,	 2010).	 Lastly,	 there	 is	 a	 dearth	 of	 experimental	 data	 from	
murine	 models	 combining	 hypoglycaemia	 and	 atherosclerosis.	 As	 ethical	










a) Develop	 a	 novel	 experimental	 model	 to	 explore	 the	 effects	 of	 acute	
hypoglycaemia	 on	 innate	 immune	 responses	 and	 platelet	 biology	 in	
healthy	human	volunteers	
b) Develop	 a	 robust	 murine	 model	 of	 recurrent	 hypoglycaemia	 and	
atherosclerosis	
c) Explore	 the	 consequences	of	hypoglycaemia	on	plaque	biology	 in	 the	
murine	model	
	
To	 probe	 how	hypoglycaemia	may	modulate	monocyte	 function	 in	 the	 human	 in	
vivo,	 I	 chose	 to	 combine	 a	 classical	 hypoglycaemic	 stimulus	with	 a	 subsequent	 in	
vivo	 systemic	 stimulus	of	 the	 innate	 immune	 system.	To	achieve	 this,	 I	 combined	
hyperinsulinaemic-hypoglycaemic,	 hyperinsulinaemic-euglycaemic	 and	 sham-
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saline	 (normoglycaemic)	 clamps	 with	 low-dose	 intravenous	 endotoxin	 challenge	
48	hours	later	in	healthy	volunteers.		This	model	allowed	me	to	probe	the	durable	
effects	of	hypoglycaemia	on	the	innate	immune	system.	In	addition,	endotoxaemia	



































The	 effects	 of	 hypoglycaemia	 on	 monocyte	 biology	 have	 received	 very	 little	
attention	 in	 humans.	 I	 aimed	 to	 examine	 the	 extent	 to	 which	 hypoglycaemia	
modulates	 innate	 immune	 function	 principally	 employing	 multi-colour	 flow	
cytometric	 analysis	 to	 enumerate	 monocyte	 subsets	 and	 platelet-leukocyte	
aggregates	 as	 well	 as	 studying	 established	 monocyte	 activation	 markers.	 All	







before	 seeking	 to	 use	 these	 in	 people	 with	 diabetes.	 In	 addition,	 as	 I	 was	
establishing	 a	novel	model,	 it	was	 important	 to	 study	 inflammatory	 responses	 in	
healthy	humans	so	that	these	could	be	used	as	a	direct	comparator	for	those	with	






This	 study	 received	 favourable	 approval	 from	 the	 local	 ethics	 committee	 (REC	
14/YH/1264)	 and	 all	 participants	 provided	 written	 informed	 consent.	 All	
experiments	were	 conducted	 in	 accordance	with	 the	 principles	 enshrined	 in	 the	
Declaration	 of	 Helsinki.	 I	 investigated	 the	 inflammatory	 consequences	 of	
hypoglycaemia	 using	 the	 hyperinsulinaemic	 hypoglycaemic	 clamp.	 The	 latter	 is	 a	
well	established	technique	for	the	experimental	study	of	hypoglycaemia	(DeFronzo,	




hypoglycaemia	 as	 a	 consequence.	 However,	 pharmacological	 hyperinsulinaemia	
necessary	 for	 precise	 glucose	 control	 during	 clamps	 may	 introduce	 artefact	 by	
suppression	of	inflammation	(Chaudhuri	et	al.,	2004;	Dandona	et	al.,	2010).	
	
The	main	ethical	 issue	with	clamp	studies	 is	 the	potential	of	 cardiac	arrhythmias	
during	 hypoglycaemia.	 The	 occurrence	 of	 arrhythmias	 with	 hypoglycaemia	
however,	is	exceedingly	rare	and	generally	is	reported	at	severe	hypoglycaemia	(<	
2mmol/l	 glucose)	 whilst	 I	 aimed	 to	 achieve	 a	 nadir	 of	 2.5	 mmol/l	 glucose	 in	 a	
controlled	 fashion.	 In	 addition,	 my	 group	 had	 previously	 performed	 over	 500	
hyperinsulinaemic	 clamps	 in	 our	 unit	 on	 healthy	 volunteers	 and	 patients	 with	
diabetes,	 including	those	with	T2D,	and	had	reported	no	serious	adverse	events.	I	
performed	 ECG	 monitoring	 throughout	 the	 hyperinsulinaemic	 clamp	 along	 with	






Over	 the	past	20	years,	 approximately	 a	 thousand	healthy	volunteers	have	 taken	




joint	 aches,	 muscle	 aches,	 and	 occasionally	 chills.	 The	 degree	 of	 fever	 varies	
somewhat	 among	 people,	 but	 on	 average,	 oral	 temperature	 will	 rise	 to	 38°C.	
Previous	 experience	 within	 our	 group	 of	 using	 2	 ng/kg	 intravenous	 endotoxin	
indicated	 various	 side	 effects	 may	 occur	 (M.	 R.	 Thomas	 et	 al.,	 2015).	 The	 peak	
temperature	rise	occurred	at	1-2	hours	following	endotoxin	and	then	temperature	
returned	 to	 normal	 by	 the	 end	 of	 the	 study	 day.	 Rarely	 participants	 experienced	
nausea	 and	 vomiting.	 I	 administered	 a	 much	 lower	 endotoxin	 dose	 (0.3	 ng/kg)	
hence	the	above	effects	were	not	observed	in	this	study.	This	was	in	keeping	with	


















(hyperinsulinaemic-hypoglycaemia	 (2.5	 mmol/l)	 /euglycaemia	 (6	 mmol/l)	 and	
sham-saline	 controls)	 conducted	 in	 a	 random	 group	 order	 at	 the	 NIHR	 Sheffield	
Clinical	 Research	 Facility,	 Northern	 General	 Hospital,	 Sheffield,	 United	 Kingdom	
between	January	2015	and	April	2016.	The	sham-saline	control	arm	controlled	for	
direct	immunological	actions	of	insulin.	Clamp	visits	and	endotoxin	challenge	were	
separated	 by	 48	 hours	 to	 minimise	 potential	 carryover	 effects,	 principally	 the	





to	 3	 experimental	 groups	 (8	 subjects/group	 in	 total):	 group	 1	 =	 experimental	
hypoglycaemia	and	endotoxin	challenge,	group	2	=	experimental	euglycaemia	and	










Figure	 2-1	 Overview	 of	 study	 visits.	 Interested	 volunteers	 underwent	 a	
formal	 screening	 visit	 to	 establish	 eligibility	 as	 per	 the	 study	 inclusion	 and	
















Table	 2.1	 Physical,	 biochemical	 and	 inflammatory	 parameters	 that	 were	
assessed	 over	 the	 course	 of	 experiments.	 Measurements	 for	 sham-saline	
control	 group	 (group	 3)	 were	 identical	 to	 the	 hypoglycaemia	 and	
euglycaemia	groups.	Abbreviations:	FBC,	full	blood	count;	LFT,	liver	function	
test;	 UE,	 urea	 and	 electrolytes;	 HR,	 heart	 rate;	 BP,	 blood	 pressure;	 GLU,	
glucose;	 EU,	 euglycaemia;	 HYPO,	 hypoglycaemia;	 hsCRP,	 high-sensitivity	 c	
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HR,BP,ECG	 	 	 	 	 	 	 	 	 	 	 	 	 	 	


























	 	 	 	 	 	 	 	 	 	 	
	
	 	 	
Cytokines	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Platelet	studies	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
hsCRP	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
HbA1c,lipids,FBC,	
LFT	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
Cortisol	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Growth	hormone	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Catecholamines	 	 	 	 	 	 	 	 	 	 	 	 	 	 	






of	 Sheffield.	 Emails	 advertising	 the	 study	 were	 sent	 using	 a	 broad	 University	 of	
Sheffield	 email	 distribution	 list.	 I	 recruited	 healthy	 individuals	 without	 diabetes	
and	 with	 no	 history	 of	 CVD	 between	 the	 ages	 of	 18-65.	 Specific	 inclusion	 and	























































Screening	 included	 collection	 of	 demographic	 information,	 full	 history	 (including	
enquiry	into	symptoms	of	diabetes	and	CVD),	and	a	thorough	clinical	examination	
including	measurement	 of	 resting	 heart	 rate,	 blood	 pressure	 and	 tympanic	 body	
temperature.		A	drug	history	was	obtained	including	specific	enquiry	into	allergies,	
over	 the	 count	 medication	 and	 recreational	 drug	 use.	 Blood	 was	 drawn	 for	 full	
blood	count,	urea	and	electrolytes,	random	glucose,	lipid	profile,	liver	function	test	
and	 HbA1c.	 A	 baseline	 12	 lead	 ECG	 was	 performed.	 I	 allowed	 for	 a	 13%	 (1/8)	














3. An	intravenous	cannula	was	 inserted	into	the	antecubital	 fossa	of	 the	non-
dominant	arm.		
4. A	 second	 retrograde	 cannula	 was	 inserted	 following	 application	 of	 local	
anaesthetic	cream	(EMLA,	Astra	Zeneca,	UK)	to	the	dorsal	hand	vein	of	the	




allowing	 determination	 of	 the	 arterialised	 blood	 glucose	 values.	 A	 slow	
infusion	of	0.9%	sodium	chloride	was	used	to	keep	this	cannula	patent.	
5. A	 third	 cannula	 was	 inserted	 in	 the	 contralateral	 antecubital	 fossa	 for	
biochemical	 and	 thrombosis	 measurements.	 	 Measurements	 for	 urea	 and	
electrolytes,	 hormones	 (including	 cortisol,	 growth	 hormone	 and	
catecholamines),	 thrombosis	 and	 inflammatory	 markers	 were	 taken	 at	
baseline	and	60	minutes.	
6. Test	 period:	 Baseline	 glucose	 was	 assessed	 by	 capillary	 blood	 glucose	
testing.	 For	 the	 hyperinsulinaemic	 clamp	 procedure,	 a	 primed	 continuous	








7. A	 20%	 dextrose	 (Baxter,	 Baxter	 Healthcare	 Ltd,	 Norfolk,	 UK)	 infusion	
administered	via	an	infusion	pump	(Alaris	®	GP	plus,	Cardinal	Health,	1180	
Rolle,	 Switzerland)	 was	 adjusted	 according	 to	 arterialised	 blood	 glucose	
concentrations	measured	every	5	minutes	using	a	bedside	glucose	analyser	
(Yellow	 Spring	 Instruments,	 Ohio,	 USA).	 Blood	 glucose	 was	 titrated	 from	
baseline	 to	 a	 target	 of	 6	 mmol/l	 over	 30	 minutes.	 Blood	 glucose	 was	
maintained	at	the	target	level	for	60	minutes.	The	time	when	target	glucose	
of	 6	 mmol/l	 is	 reached	 is	 designated	 time	 0.	 Volunteers	 were	 blinded	 to	
glucose	levels.		
8. Heart	 rate,	 blood	 pressure	 and	 high	 resolution	 ECG	 monitoring	 were	
performed.	
9. Recovery:	 At	 the	 end	 of	 the	 60	 minute	 test	 period,	 the	 clamp	 insulin	
infusion	was	switched	off.	 	A	20%	dextrose	 infusion	was	continued	for	the	
next	 20	 minutes	 to	 maintain	 a	 blood	 glucose	 level	 of	 at	 least	 6	 mmol/l.	
Glucose	 was	 monitored	 every	 5	 minutes	 for	 the	 first	 10	 minutes	 during	


















1. Volunteers	 returned	 48	 hours	 following	 the	 clamp	 visit.	 Volunteers	were	





dominant	 arm.	 An	 additional	 intravenous	 cannula	 was	 inserted	 into	 the	
contralateral	 antecubital	 fossa	 for	 blood	 sampling	 throughout	 the	 study	
visit	and	kept	patent	using	a	slow	infusion	of	0.9%	sodium	chloride.	
5. Escherichia	 coli	O:113	 LPS	 (obtained	 from	Dr	 Anthony	 Suffredini,	 Clinical	
Centre	 Reference	 Endotoxin	 National	 Institutes	 of	 Health,	 Bethesda,	
Maryland,	USA)	was	used.		Endotoxin	powder	was	reconstituted	in	1	ml	of	
sterile	0.9%	sodium	chloride	to	form	a	solution	at	a	concentration	of	1000	






30	minute	 intervals	 for	360	minutes	post	endotoxin	 injection	 (designated	
time	0).	
7. A	 continuous	 intravenous	 infusion	 of	 125	 ml/hr	 of	 0.9%	 NaCl	 was	
administered	 for	 240	minutes	 following	 endotoxin	 challenge	 through	 the	
cannula	used	for	endotoxin	injection	to	avoid	hypotension.	
8. Blood	was	taken	 for	urea	and	electrolytes,	glucose,	hormones,	 thrombosis	
and	inflammatory	markers	at	baseline	(0)	and	at	120,	240	and	360	minutes	








continued	 for	 at	 least	 20	 minutes	 until	 euglycaemia	 was	 reached.	 Volunteers	
received	a	standardised	meal	and	had	blood	glucose	monitored	for	at	least	1	hour	
after	 the	 end	 of	 clamps	 to	 ensure	 blood	 glucose	 in	 the	 euglycaemic	 range.	 All	
participants	were	advised	to	be	wary	of	increased	risk	of	hypoglycaemia	in	the	next	
48	 hours,	 although	 the	 risk	 was	 deemed	 to	 be	 small	 in	 healthy	 volunteers.	
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the	 same	 pre-visit	 preparation	 as	 those	 allocated	 to	 the	 euglycaemia	 and	
hypoglycaemia	 groups.	 The	 experimental	 protocol	 including	 intravenous	
cannulation	 and	 blood	 sampling	 for	 the	 sham	 clamp	 visits	 was	 identical	 to	 the	
euglycaemia	 and	 hypoglycaemia	 arms	 except	 no	 glucose	 manipulation	 occurred	





























Blood	 (5	 ml)	 was	 collected	 into	 a	 serum	 separator	 tube	 (SST)	 (BD	 Vacutainer®	
SSTTM	II	Advance)	and	samples	were	allowed	 to	clot	 for	30	minutes.	The	samples	
were	centrifuged	and	the	serum	frozen	at	-20oC	until	measured	using	a	commercial	
immunoradiometric	 assay	 (Cobas	 system,	 Roche	 Diagnostics,	 Burgess	 Hill,	 West	
Sussex,	 UK).	 This	 assay	 was	 performed	 in	 Sheffield	 Teaching	 Hospitals	 (STH)	


























to	 centrifugation	 at	 3000g	 for	 10	 minutes	 at	 room	 temperature.	 The	 resulting	
plasma	 was	 stored	 at	 -80oC.	 Samples	 were	 sent	 for	 batch	 analysis	 at	 the	 Royal	
Devon	and	Exeter	NHS	 trust	 laboratories	using	 a	dedicated	 immunoassay	 (Cobas	
insulin	 electrochemiluminescence	 immunoassay,	 Roche	 Diagnostics,	 Burgess	 Hill,	
West	 Sussex,	 UK).	 	 Briefly,	 this	 assay	 employed	 a	mouse	monoclonal	 anti-insulin	











Blood	 (5	ml)	 was	 collected	 into	 EDTA	 tubes	 (BD	 VacutainerTM	 K3E)	 and	 plasma	
obtained	by	centrifugation	at	3000g	for	25	minutes	at	room	temperature.	Aliquots	
of	plasma	were	 stored	at	 -80oC	 for	 analysis	by	 cytometric	bead	array	 in	 the	 core	
flow	cytometry	facility	at	the	University	of	Sheffield.		Analysis	using	cytokine	bead	
array	was	employed	as	it	allowed	multiple	analytes	to	be	assayed	at	the	same	time	
using	 fewer	 dilutions	 and	 small	 sample	 sizes.	 Cross-reactivity	 between	 analytes	
was	 avoided	 by	 strictly	 adhering	 to	 the	 cytokine	 combination	 specified	 by	 the	








25	 μL	 of	 the	 sample	 or	 standard	 was	 added	 and	 mixed.	 The	 tubes	 were	 then	
incubated	 in	 the	 dark	 for	 1	 hour	 at	 room	 temperature.	 Following	 this,	 25	 μL	 of	
detection	master	mix	was	added	to	each	tube	and	the	tubes	incubated	in	the	dark	at	
room	temperature	for	2	hours.	Wash	buffer	(500	μL)	was	added	to	each	tube	using	
repeat	 pipetting	 and	 the	 samples	 centrifuged	 at	 200g	 for	 5	 minutes.	 The	
supernatant	 was	 then	 aspirated	 and	 the	 pellet	 resuspended	 in	 200	 μL	 of	 wash	
buffer	prior	to	transferring	samples	to	a	96	well	plate	which	was	run	on	an	Attune	
flow	 cytometer	 (Thermo	 Fisher	 Scientific,	 Altrincham,	 Greater	 Manchester,	 UK)		
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with	 data	 analysed	 using	 the	 instruments	 software.	 Standard	 curves	 for	 each	











dihydrate	 (3.13% w/v) with	 care	 to	 avoid	 agitation	 and	 thus	 activation.	 Citrate	
anticoagulated	whole	blood	(480μl)	was	added	to	four	plastic	round	base	tubes	to	
neatly	 fit	 into	 a	heat	 block	 at	 37	 ˚C.	A	 stirrer	bar	was	 added	 to	one	 tube	but	not	
others	 to	 promote	 agitation	 and	 thus	 formation	 of	 MPAs	 acting	 as	 a	 positive	
control.	Blood	was	incubated	in	the	heat	block	for	10	minutes	at	37	˚C.	At	the	end	of	
incubation,	 100	 μl	 of	 blood	 was	 taken	 from	 each	 tube	 and	 pipetted	 into	
corresponding	 pre-labelled	 plastic	 tubes	 on	 a	 rack	 containing	 2	 ml	 of	 1	 in	 10	
fluorescence-activates	cell	sorting	(FACS)	lyse	solution	(BD,	Oxford,	UK)	(diluted	in	
sterile	water)	and	 left	undisturbed	 for	10	minutes.	Addition	of	blood	 to	 the	FACS	
lysis	solution	resulted	in	lysis	of	erythrocytes.	Following	FACS	lysis,	samples	were	
centrifuged	 at	 300g	 for	 5	 minutes.	 Once	 the	 supernatant	 had	 been	 carefully	
removed	 using	 a	 transfer	 pipette	 in	 200	 μl	 aliquots,	 the	 resultant	 pellet	 was	
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resuspended	 in	 50	 μl	 phosphate	 buffered	 saline	 (PBS)	 and	 10%	 bovine	 serum	
albumin.	The	resulting	suspension	was	stained	with	target	antibody	cocktails	and	
isotype	 cocktails.	 Staining	with	 antibodies	was	 performed	 using	 FITC-conjugated	
CD16	 (302006,	 BioLegend,	 London,	 UK,	 diluted	 1	 in	 10	 in	 PBS),	 APC-conjugated	
CD14	(325608,	BioLegend,	London,	UK,	diluted	1	in	10	in	PBS)	and	PE-conjugated	
CD42a	(558819,	BD	Biosciences,	Oxford,	UK	diluted	1	in	3	in	PBS).	Isotype	staining	
was	 performed	 using	 FITC	 Mouse	 IgG1,	 κ	 isotype	 Ctrl	 Antibody	 (400108,	
BioLegend,	London,	UK,),	APC	Mouse	 IgG1,	κ	 isotype	Ctrl	 (FC)	Antibody	(400122,	







and	 side	 scatter	 morphology	 and	 positively	 selected	 using	 CD14	 expression.	
Neutrophils	were	 gated	 using	 forward	 and	 side	 scatter	morphology	 and	 through	
exclusion	 of	 monocytes.	 Monocyte-platelet	 aggregation	 was	 determined	 by	
measuring	monocyte	median	 fluorescence	 of	 the	 platelet	 specific	marker	 CD42a.	








the	core	 flow	cytometry	 facility	at	 the	University	of	Sheffield	using	the	LSRII	 flow	
cytometer	 (BD	 Biosciences,	 New	 Jersey,	 USA).	 FITC-conjugated	 CD16	 (302006,	
BioLegend,	London,	UK,)	and	APC-conjugated	CD14	 (325608,	BioLegend,	London,	
UK,)	were	used	as	monocyte	phenotyping	markers.	PE-conjugated	CD66c	(551478,	
BD	Biosciences,	Oxford,	UK)	was	used	 as	 a	 neutrophil	 exclusion	marker.	 PE-Cy7-
conjugated	 CD11b	 (301322,	 BioLegend,	 London,	 UK)	 and	 (PerCP)-eFluor®	 710-
conjugated	 CX3CR1	 (46-6099-42,	 eBioscience,	 Thermo	 Fisher	 Scientific,	
Manchester,	UK)	were	used	as	monocyte	activation	markers.	Table	2.2	summarises	


















	Table	2.2	 Summary	of	human	 cell	markers	 against	which	 target	 antibodies	
are	 directed,	 conjugated	 flourochromes	 used	 and	 combination	 of	 lasers	
employed	 in	 the	 LSRII	 flow	 cytometer.	 Abbreviations:	 FSC,	 forward	 scatter;	
SSC,	 side	 scatter;	 FITC,	 fluorescein	 isothiocyanate;	 PE,	 phycoerythrin;	 APC,	
allophycocyanin;	 PECy7,	 phycoerythrin-Cy7;	 (PerCP)-eFluor®710,	 peridinin	
chlorophyll	protein.	
	
Traditional	 isotype	 controls	 for	 the	antibodies	used	were	as	 follows:	FITC	Mouse	
IgG1,	κ	isotype	Ctrl	Antibody	(400108,	BioLegend,	London,	UK,),	APC	Mouse	IgG1,	κ	
isotype	 Ctrl	 (FC)	 Antibody	 (400122,	 BioLegend,	 London,	 UK),	 Mouse	 IgG1	 κ		
isotype	 Control	 PE	 (555749,	 BD	Biosciences,	 Oxford,	 UK),	 PE/Cy7	Mouse	 IgG1,	 κ	
isotype	Ctrl	Antibody	(400126,	BioLegend,	London,	UK)	and	Rat	 IgG2b	κ	 isotype	
Control	 PerCP-eFluor®	 710	 (46-4031-82,	 eBioscience,	 Thermo	 Fisher	 Scientific,	
Manchester,	 UK).	 In	 addition	 to	 isotype	 controls,	 staining	 using	 a	 fluorescence	
minus	 one	 (FMO)	 strategy	was	 employed	 for	 all	 subjects	 at	 baseline	 before	 each	
clamp	 visit.	 	 In	 an	 FMO	 control	 strategy,	 cells	 are	 stained	 with	 all	 but	 one	

















tubes	 (tube	 2	 and	 tube	 3)	 were	 stained	 in	 duplicate	 with	 all	 antibodies	




visit	 (visit	 2).	 Seven	 separate	 1.5	 ml	 Eppendorf	 tubes	 were	 prepared.	 One	
tube	was	designated	unstained	and	acted	as	a	negative	control.	An	additional	
tube	 of	 whole	 blood	 was	 stained	 with	 all	 antibodies	 in	 the	 panel	
(CD14/CD16/CD66c/CD11b/CX3CR1).	The	remaining	five	tubes	were	stained	





Staining	 FITC	 PE	 APC	 PE-Cy7	 PErCP	710	
Unstained	 -	 -	 -	 -	 -	
CD	16	
FITC	
-	 +2.5	µL	 +2.5	µL	 +2.5	µL	 +2.5	µL	
CD	66c	PE	 +2.5	µL	 -	 +2.5	µL	 +2.5	µL	 +2.5	µL	
CD14	APC	 +2.5	µL	 +2.5	µL	 -	 +2.5	µL	 +2.5	µL	
CD	11b	
PE-Cy7	
+2.5	µL	 +2.5	µL	 +2.5	µL	 -	 +2.5	µL	
CX3CR1	
PErCP	710	





isotype	 controls	 (1	 in	 2	 dilution	 from	 neat).	 The	 tube	 was	 gently	 tapped	 to	






were	 briefly	 vortexed	 to	 lyse	 erythrocytes.	 FACS	 lysed	 samples	were	 centrifuged	
using	a	micro-centrifuge	at	2000	rpm	for	4	minutes.	The	resulting	supernatant	was	
carefully	 removed	 in	 500	μl	 aliquots	 in	 order	 not	 to	 disturb	 the	white	 blood	 cell	
pellet	 and	 the	 latter	 was	 resuspended	 in	 450	 μl	 of	 PBS.	 100	 μl	 of	 1%	 w/v	
formaldehyde	 was	 added	 to	 each	 sample.	 To	 allow	 enumeration	 of	 the	 absolute	
number	 of	 monocyte	 subsets	 per	 μl	 of	 blood,	 CountBrightTM	 beads	 (15	 μl,	 Life	
Technologies,	 USA)	 were	 added.	 Samples	 were	 immediately	 processed	 using	 the	
LSRII	flow	cytometer.	Flow	cytometry	was	performed	for	all	subjects	on	the	day	of	
sampling.	 Compensation	 was	 performed	 using	 positive	 and	 negative	 anti-mouse	
and	 anti-rat	 compensation	 beads	 (Molecular	 Probes,	 Life	 Technologies,	 USA).	
Monocytes	were	gated	using	morphology	on	forward	and	side	scatter	and	through	













A B C D 




FSC	 and	 SSC	 axes.	 B)	 CountBrightTM	 are	 dissected	 out	 based	 on	 intense	
fluorescence	and	granulocytes	 are	 separated	based	on	positivity	 for	CD66c.	
Beads	 (C)	 and	 granulocytes	 (D)	 plotted	 on	 FSC	 and	 SSC	 respectively.	 E)	 All	
CD66c	negative	events	are	plotted	on	FSC	and	SSC	and	monocytes	are	gated	
around	based	on	their	FSC	and	SSC	profile.	F)	All	cells	 in	 the	monocyte	gate	
are	plotted	on	CD14	APC	 (x-axis)	 vs.	 CD16	FITC	 (y-axis).	 Cells	 that	 are	dual	
negative	for	CD14	and	CD16	are	designated	non-monocytes	and	gated	out.	G)	
Monocyte	 subsets	 are	 identified	 based	 on	 their	 CD14	 (x-axis)	 and	 CD16	 (y-
axis)	 profiles.	 H)	 Monocytes	 are	 dissected	 out	 into	 classical	 monocytes	
CD14++CD16-,	 intermediate	 monocytes	 CD14++	 CD16+	 and	 non-classical	







Diagnostica	 GmBH,	 Munich,	 Germany)	 and	 precautions	 taken	 to	 avoid	 agitation.	
Platelet	 aggregation	was	measured	 using	 impedance	 aggregometry	 (Multiplate®,	
Verum	Diagnostica	GmBH,	Munich,	Germany).	Aliquots	of	300	μl	saline	and	300μl	








90%	 power	 to	 a	 significance	 of	 5%	 to	 detect	 a	 50%	 relative	 difference	 in	
mobilisation	 of	 monocytes	 between	 hypoglycaemia	 and	 controls.	 Eight	 subjects	
were	 recruited	 per	 group	 to	 allow	 for	 a	 13%	 drop	 out	 rate.	 Mean	 baseline	
measurements	 of	 glucose	 were	 compared	 between	 groups	 using	 analysis	 of	
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variance	 (ANOVA).	Mean	measurements	 of	 glucose,	 insulin,	 and	 adrenaline	 at	 60	
minutes	 post	 clamp	 were	 compared	 adjusting	 for	 clamp	 baseline	 measurement,	
using	analysis	of	covariance	(ANCOVA).	In	the	event	of	unequal	variance	between	
groups,	 a	 log	 transform	was	 applied	 and	 the	 analysis	 repeated.	 Longitudinal	 and	
















in	 a	 robust	 animal	model.	 The	 aim	of	 these	 experiments	was	 therefore	 to	 firstly,	
establish	a	robust	murine	model	of	experimental	hypoglycaemia	in	pre-established	










Animal	 experiments	 were	 carried	 out	 under	 the	 project	 licence	 PPL	 70/7992	
(previously	40/3307)	held	by	Professor	Sheila	Francis,	University	of	 Sheffield.	 	A	







identified	 by	 ear	 clips	 and	 a	 corresponding	 unique	 identification	 number.	 All	
animals	were	housed	at	the	University	of	Sheffield	animal	research	facility	based	at	
the	Royal	Hallamshire	Hospital	in	a	controlled	environment	at	22°C	with	constant	
air	 pressure	 and	 12	 hour	 cycle	 of	 alternating	 light/darkness.	 Mice	 were	 specific	
pathogen	free	and	housed	in	open	top	cages.	The	maximum	number	of	mice	housed	























	A	 rodent	model	of	 recurrent	 insulin	 induced	hypoglycaemia	had	been	developed	
by	 our	 collaborators	 (McNeilly	 et	 al.,	 2017).	 However,	 a	 model	 of	 combined	
experimental	hypoglycaemia	and	atherosclerosis	in	ApoE	-/-	mice	fed	Western	diet	
was	 hitherto	 untested.	 Thus,	 in	 order	 to	 achieve	 experimental	 hypoglycaemia,	
optimisation	of	 experimental	 conditions	was	undertaken	 in	both	 fed	and	non-fed	
animals	with	 an	 insulin	 dose	 finding	 exercise	 and	 variation	 of	 fasting	 conditions.		
Experimental	 conditions	 employed	 in	 the	 definitive	 experiment	 are	 described	
below.		Methodological	details	of	optimisation	experiments	that	differ	are	included	




insulin,	 ApoE	 -/-	 mice	 were	 familiarised	 with	 the	 experimental	 laboratory	 by	




of	 the	 Bp-2000	 blood	 pressure	 analysis	 system	 (Visitech	 Systems	 Inc,	 Apex,	 NC)	
during	 hypoglycaemia	 or	 sham	 saline	 injection.	 In	 order	 to	 acclimatise	 mice	 to	
these	 conditions	 they	 were	 trained	 on	 this	 platform	 at	 the	 same	 time	 of	 day	 as	
planned	experiments	on	a	weekly	basis	(60	minutes/week)	for	7	weeks	during	the	





Mice	 were	 placed	 on	 the	 heated	 Bp-2000	 blood	 pressure	 analysis	 platform,	 the	
lateral	 tail	 vein	 was	 identified	 and	 a	 non-terminal	 lateral	 tail	 vein	 incision	 was	
made	 using	 a	 sterile	 surgical	 blade	 (Swann	 Morton	 Ltd,	 Sheffield,	 UK).	
Approximately	 5	 μL	 of	 blood	 was	 encouraged	 to	 form	 a	 micro	 droplet	 by	
application	 of	 gentle	 pressure	 at	 both	 ends	 of	 the	 small	 cut	 and	 blood	 glucose	
values	 were	 determined	 using	 a	 FreeStyle	 Optium	 Neo	 blood	 glucose	 meter	
(Abbott,	 Lake	 Bluff,	 Illinois,	 USA).	 The	 FreeStyle	 Optium	 Neo	 satisfies	 the	
International	 Organisation	 for	 Standardisation	 (ISO)	 2013	 blood	 glucose	 meter	
accuracy	 standards	 (ISO:	 15197:2013)	 and	was	 calibrated	 to	 high	 and	 low	 sugar	
values	 using	 manufacturer	 provided	 control	 solutions	 at	 the	 start	 of	 each	
experiment.	A	baseline	blood	glucose	was	measured	and	hypoglycaemia	induced	by	
an	 intraperitoneal	 (i.p.)	 injection	 of	 2.5-3.7	 mU/g	 Actrapid	 insulin	 (Human	
Actrapid,	Novo	Nordisk	Pharmaceuticals	Ltd,	Crawley,	West	Sussex,	UK).	Actrapid	





120	 minutes	 by	 gently	 massaging	 the	 tail	 veins	 snip	 site.	 Animals	 were	 closely	
monitored	 for	adverse	signs	of	hypoglycaemia	and	 in	 this	scenario	rescued	by	an	
i.p.	of	1	ml	20%	Dextrose	(Baxter,	Baxter	Healthcare	Ltd,	Norfolk	UK)	and	placed	in	
an	incubator	at	33°C.	In	the	event	that	hypoglycaemia	was	irrecoverable,	mice	were	
euthanised	 using	 a	 Schedule	 1	method.	 At	 the	 end	 of	 the	 experiment,	mice	were	
returned	to	their	cages	and	fed	a	mash	chow	diet.	
	













Following	 feeding,	mice	 in	each	group	underwent	either	hypoglycaemia	or	 sham-
saline	 injection	 on	 an	 alternate	 day	 basis	 for	 4	 consecutive	 weeks.	 Thus,	 each	







Figure	 2-3	 Schematic	 representation	 of	 the	 experimental	 protocol	 used	 to	
induce	 recurrent	 hypoglycaemia	 vs.	 sham-saline	 injection.	 ApoE	 -/-	mice	 fed	
Western	 diet	 for	 7	 weeks	 were	 allocated	 to	 either	 receive	 hypoglycaemia	
(group	 1)	 or	 a	 sham-saline	 (group	 2).	 Group	 1	 mice	 underwent	
hypoglycaemia	on	Mondays	and	Wednesdays.	Group	2	mice	received	a	saline	
control	injection	on	Tuesdays	and	Thursdays.	The	experiment	was	conducted	







At	 the	 end	 of	 the	 study,	 mice	 were	 weighed	 and	 sacrificed	 by	 an	 overdose	 of	








Blood	was	 collected	 via	 cardiac	 puncture	 once	 the	 pedal	 reflex	was	 lost.	 A	 1	ml	
heparinised	 syringe	 (1:100	 in	 blood)	 was	 inserted	 using	 a	 left	 lateral	 approach	
through	 the	 intercostal	 spaces	 in	 the	upper	part	of	 the	 thoracic	 cavity	aiming	 for	
the	 left	ventricle	 in	order	 to	obtain	a	single,	good	quality	sample	of	mouse	blood.	
Care	was	 taken	 to	obtain	 the	maximum	volume	of	blood	at	 first	 attempt	 so	as	 to	
minimise	potential	damage	and	contusions	to	cardiovascular	tissue	that	was	to	be	
excised.	 In	 order	 to	 isolate	 plasma,	 whole	 blood	was	 centrifuged	 at	 3000g	 for	 5	
minutes	 in	 a	 microcentrifuge	 (Beckman	 Coulter,	 High	 Wycombe,	 UK).	 Isolated	




small	 incision	made	 in	 the	 abdominal	 aorta	 to	 allow	 extravasation	 of	 blood.	 The	
thoracic	 cavity	 was	 then	 exposed	 by	 performing	 a	 median	 sternotomy.	 The	 left	
ventricle	was	identified	and	injected	with	1	ml	of	PBS	followed	by	1	ml	of	10%	v/v	





Following	perfusion	 fixation,	CV	 tissue	was	excised.	Firstly,	 the	 thoracic	cage	was	
removed	 to	 allow	 direct	 visualisation	 of	 the	 heart,	 great	 vessels	 and	 lungs.	 Next,	
using	careful	blunt	dissection,	 the	 thymus,	 thyroid,	 trachea	and	oesophagus	were	




abdominal	 aorta.	 Starting	 at	 just	 above	 the	 diaphragm,	 the	 thoracic	 aorta	 was	
identified	 and	 carefully	 separated	 from	 the	 inferior	 vena	 cava	 and	 connective	
tissue.	Working	in	a	cephalic	direction,	fat	was	dissected	from	the	aorta	and	small	
branching	vessels	removed	using	blunt	dissection	only.	Upon	arriving	at	the	aortic	








The	 left	common	carotid	and	 left	 subclavian	arteries	were	 then	cut	and	 the	aorta	
mobilised	by	excising	 it	at	 its	origin	at	 the	heart.	 	The	descending	aorta	was	then	
excised	 at	 just	 above	 the	 diaphragm.	 The	whole	 aorta	was	 transferred	 to	 a	 Petri	
dish	 and	 kept	 moist	 with	 PBS.	 Under	 microscopic	 guidance,	 blunt	 forceps	 were	
used	to	separate	the	aorta	from	closely	adhering	adventitial	fat	with	utmost	care	to	
avoid	 damaging	 the	 vessel.	 Aortae	 were	 then	 cut	 using	 sprung	 vannas	 (curved	
pointed	 tip)	 scissors.	The	 inside	 curvature	was	 cut	along	 its	 entire	 length	and	on	
the	 outside	 curvature	 the	 cutting	 edge	 ended	 at	 the	 top	 of	 the	 descending	 aorta.	
This	 allowed	 the	 entire	 inside	 surface	 of	 the	 vessels	 to	 be	 exposed.	 The	 vessels	
were	 stored	 in	 4%	 w/v	 paraformaldehyde	 (PFA;	 VWR	 International	 Ltd,	 BDH	




All	 tissue	 was	 stored	 at	 4°C	 in	 either	 10%	 v/v	 buffered	 formalin	 or	 %	 w/v	
























Brachiocephalic	 arteries	 were	 removed	 from	 PBS,	 straightened	 and	 gently	
sandwiched	 between	 two	 sheets	 of	 Whatman	 grade	 1	 filter	 paper	 (Whatman	
International,	UK).	The	samples	with	the	filter	papers	were	placed	inside	a	plastic	





higher	 concentrations	 of	 alcohol	 (50%,	 70%,	 90%	 and	 100%	 v/v	 ethanol)	 for	 1	
hour	 per	 concentration	 of	 alcohol.	 There	 was	 also	 a	 change	 of	 ethanol	 after	
submersion	 in	 100%	 ethanol.	 Tissue	 was	 then	 placed	 in	 a	 1:1	mixture	 of	 100%	
ethanol	and	xylene	(Thermo	Fisher	Scientific,	UK)	for	1	hour.	Following	this,	tissue	
was	placed	in	xylene	over	two	x	1	hour	steps	with	a	change	of	liquid	after	the	first	
xylene	 step.	 Tissue	 was	 then	 stored	 in	 molten	 wax	 in	 60°C	 overnight.	 This	
temperature	was	chosen	to	ensure	 infiltration	of	wax	 into	 tissues.	Briefly,	molten	
wax	should	be	held	at	1-2°C	above	its	melting	point	and	as	the	melting	point	was	






artery	 for	 sectioning.	 Following	 the	 dehydration	 protocol,	 histological	 cassettes	





temperature	 for	3	hours.	Once	 the	wax	had	 set,	 the	wax	block	was	 trimmed	 to	 a	
small	cuboidal	shape	containing	the	artery.	Secondly,	this	piece	of	wax	was	rotated	







Wax	blocks	were	pressed	out	of	mould	and	placed	on	 ice	 for	at	 least	60	minutes	
prior	to	sectioning	using	a	Leica	RM2135	microtome	(Leica	Microsystems,	Wetzlar,	
Germany).	Cut	vessel	sections	were	floated	out	on	a	water	bath	at	34-35°C	as	this	
aided	 in	 flattening	 the	 extremely	 thin	 slices	 of	 tissue.	 Polysine	glass	 slides	 (VWR	
International	Ltd,	UK)	were	gently	submerged	just	below	floating	sections	of	tissue	
in	the	water	bath	and	then	pulled	out	to	seamlessly	collect	sections	of	tissue.	Tissue	


















Sigma-Aldrich,	UK).	Oil	 red	O	powder	 (Sigma-Aldrich,	UK)	was	 then	added	 to	 the	
solution	until	saturation.	The	saturated	solution	was	filtered	using	Whatman	grade	
1	filter	paper	(Whatman	International,	UK)	and	the	final	stain	diluted	to	60%	v/v	
using	 distilled	 water.	 Individual	 vessels	 were	 then	 stained	 in	 1.5	 ml	 Eppendorf	
tubes	by	initially	rinsing	aortae	in	distilled	water	followed	by	60%	v/v	isopropanol	
for	2	minutes.	Following	this	step,	vessels	were	immersed	in	oil	red	O	stain	for	15	
minutes	 prior	 to	 being	 rinsed	 with	 60%	 v/v	 isopropanol	 for	 2	 minutes.	 Finally,	
aortae	were	immersed	in	distilled	water	prior	to	being	mounted	en	face.	In	order	to	
perform	this,	molten	wax	was	poured	onto	15	cm	Petri	dishes	and	allowed	to	set	at	
room	 temperature	 reasonably	 firm	 yet	 malleable	 consistency.	 Individual	 vessels	
were	 then	placed	on	 the	wax	and	opened	gently	with	blunt	 forceps	 to	 reveal	 the	
inner	surface	with	the	lumen	facing	up.	Once	in	position,	0.2	mm	diameter	micro-
needles	 (Fine	 Science	 Tools,	 Heidelberg,	 Germany)	 were	 used	 to	 pin	 the	 aortae	














rinsed	 in	 tap	 water.	 Tissue	 sections	 then	 underwent	 oxidation	 with	 0.25%	 w/v	
aqueous	 potassium	 permanganate	 for	 3	 minutes.	 Following	 this,	 sections	 were	
bleached	with	 1%	w/v	 oxalic	 acid	 for	 3	minutes	 prior	 to	 being	 rinsed	 in	 water.	
Nuclei	 were	 then	 stained	 with	 Carazzi’s	 haematoxylin	 for	 2	 minutes	 and	
differentiated	with	 1%	 v/v	 hydrochloric	 acid	 in	 70%	 v/v	 ethanol	 for	 5	 seconds.	
Tissue	sections	were	then	exposed	to	hot	running	tap	water	for	5	minutes.		
	
Slides	with	 sections	were	 then	 stained	with	 alcian	 blue	 (1%	w/v	 in	 3%	aqueous	
acetic	acid,	pH	2.5)	for	5	minutes	and	the	stain	rinsed	in	water	and	then	95%	v/v	
ethanol	before	staining	with	Miller’s	elastin	 for	30	minutes.	Following	 this,	 tissue	
was	differentiated	 in	95%	v/v	ethanol	and	rinsed	 in	water	prior	 to	being	stained	
with	 Curtis’	 modified	 Van	 Gieson	 reagent	 (10	 ml	 1%	 w/v	 Ponceau	 S	 in	 90	 ml	











Brachiocephalic	 artery	 sections	 were	 stained	 for	 MAC-3	 which	 is	 an	 established	
macrophage	marker.	 Slides	 containing	 sections	were	de-waxed	 in	 xylene	prior	 to	
rehydration	in	graded	alcohols	to	water.	Treatment	with	hydrogen	peroxide	(30%	
v/v;	 Sigma-Aldrich,	 UK)	 blocked	 endogenous	 peroxidases	 and	 incubation	 in	 1%	
Marvel	buffer	(commercially	available	0.1%	w/v	milk	buffer)	in	PBS	for	30	minutes	
blocked	 non-specific	 antibody	 binding.	 Antigen	 retrieval	 was	 performed	 if	
necessary	prior	 to	blocking	with	milk	buffer.	Slides	were	 incubated	with	rat	anti-




200	 in	 PBS)	 for	 30	 minutes	 at	 room	 temperature.	 In	 order	 to	 amplify	 positive	
staining,	this	step	was	followed	by	incubation	of	sections	with	avidin-biotinylated	




(Sigma-Aldrich,	 UK)	 until	 colour	 development	 was	 witnessed	 when	 the	 reaction	
was	 stopped	 by	 rinsing	 slides	 first	 in	 distilled	water	 and	 then	 PBS.	 Lastly,	 slides	











Stained	 sections	 images	 were	 acquired	 by	 using	 a	 camera	 connected	 to	 a	 light	
microscope	 for	 brachiocephalic	 arteries.	 A	 camera	 connected	 to	 a	 dissecting	
microscope	was	used	for	en	face	aortae.	Atherosclerotic	lesion	area	was	calculated	
by	 analysis	 of	 captured	 images	 using	 the	 NIS-elements	 image	 analysis	 software	
(Nikon,	 Kingston-upon-Thames,	 UK).	 To	 eliminate	 any	 potential	 bias,	








area	 of	 each	 aorta	 was	 manually	 traced	 by	 closely	 following	 the	 vessel	 outline.	
Using	 the	 software	 threshold	 function	 that	 incorporated	 hue,	 saturation	 and	
intensity	 filters,	 areas	 positively	 staining	 for	 oil	 red	 O	 were	 identified.	 Total	
atherosclerotic	 lesion	 area	 was	 calculated	 and	 expressed	 as	 a	 percentage	 of	 the	
total	 surface	 area	 of	 each	 vessel.	 Lesion	 area	was	 assessed	 in	whole	 aortae,	 and	








and	 an	 image	 of	 a	 ruler	was	 used	 to	 calibrate	 the	 software.	 B)	 Image	 of	 an	
aorta	 with	 positive	 areas	 stained	 in	 red.	 C)	 The	 total	 surface	 area	 of	 each	
vessel	was	calculated	by	manually	tracing	the	vessel	as	shown	in	red.	D)	The	
NIS-elements	 software	 was	 used	 to	 select	 areas	 of	 positive	 staining	
highlighted	 in	 red	 by	 using	 the	 threshold	 function	 and	 applying	 hue,	








Brachiocephalic	 artery	 sections	 were	 captured	 at	 x100	 magnification.	 Eight	
sections	taken	from	a	200	μm	section	of	the	brachiocephalic	artery	containing	the	































quantified	 by	 manually	 tracing	 the	 EEL	 for	 each	 vessel	 in	 the	 NIS-elements	
software.	 Atherosclerotic	 lesion	 area	was	 quantified	 by	manually	 tracing	 around	
the	 lesion.	Total	atherosclerotic	 lesion	area	was	expressed	as	a	percentage	of	 the	


















Figure	 2-6	 Measurement	 of	 atherosclerotic	 plaque	 lesion	 area	 in	 a	
brachiocephalic	 artery.	 A)	 MVG	 stained	 brachiocephalic	 artery,	 scale	 bar	 =	
100	 μm.	 B)	 The	 EEL	 was	 used	 to	 measured	 the	 vessel	 CSA	 and	 manually	
traced	 as	 shown	 in	 red	 using	 the	 NIS-elements	 software.	 C)	 The	
atherosclerotic	plaque	was	manually	 traced	 in	green	using	 the	 software.	D)	
Total	plaque	area	(green)	was	calculated	by	the	software	and	expressed	as	a	
percentage	 of	 the	 calculated	 and	 equation	 corrected	 total	 vessel	 CSA	 (red).	

















Figure	 2-7	 Quantification	 of	 positive	 immunohistochemical	 staining	 for	
macrophages.	 A)	MAC-3	 staining	 in	 a	 brachiocephalic	 artery,	 positive	 areas	















Adrenaline	 was	 measured	 at	 0	 minutes	 and	 60	 minutes	 following	 i.p.	 insulin	
injection	on	the	7th	episode	of	hypoglycaemia	or	sham-saline	injection	(week	4).	In	
unrestrained	 mice,	 whole	 blood	 (40	 μl)	 obtained	 from	 the	 tail	 vein	 cut	 was	




Germany)	 by	 Dr	 Alison	McNeilly	 at	 the	 University	 of	 Dundee.	 During	 this	 assay,	
adrenaline	 was	 extracted	 from	 the	 plasma	 (10μl	 per	 sample)	 using	 a	 cis-diol-
specific	 affinity	 gel,	 acylated	 and	 converted	 enzymatically.	 In	 this	 competitive	
enzyme-linked	 immunosorbent	assay	(ELISA),	 the	antigen	was	bound	to	 the	solid	
phase	of	the	microtiter	plate.	The	derivatised	standards,	controls	and	samples	and	
the	solid	phase	bound	analytes	compete	 for	a	 fixed	number	of	antiserum	binding	
sites.	 After	 the	 system	 is	 in	 equilibrium,	 free	 antigen	 and	 free	 antigen-antiserum	
complexes	 are	 removed	 by	 washing.	 The	 antibody	 bound	 to	 the	 solid	 phase	 is	
detected	 by	 an	 anti-rabbit	 IgG-peroxidase	 conjugate	 using	 3,3’,5,5’	
tetramethylbenzidine	(TMB)	as	a	substrate.	The	reaction	 is	monitored	at	450	nm.	








obtain	 serum	 at	 STH	 laboratories.	 Total	 cholesterol,	 HDL	 and	 triglycerides	 were	








0.05	 was	 deemed	 statistically	 significant.	 Analyses	 were	 performed	 using	 Graph	









Chapter	 3-	 Effects	 of	 hypoglycaemia	 and	 low	 dose	
endotoxaemia	on	inflammatory	responses	in	humans	
This	chapter	takes	the	form	of	a	published	paper	upon	which	I	am	first	author.	I	
was	 the	primary	 contributor	 to	 this	manuscript	 and	my	 contribution	 included:	
experimental	 design	 (with	 guidance	 from	 supervisory	 team),	 performing	 all	
experimental	 work	 (with	 some	 technical	 assistance)	 and	 data	 analysis,	










	 	 	 	 	













Iatrogenic	 hypoglycaemia	 remains	 a	 major	 barrier	 to	 effective	 treatment	 of	
insulin-treated	diabetes	(Cryer,	2008).	The	ACCORD	trial	showed	that	intensive	
glucose	 control,	 during	 which	 patients	 were	 exposed	 to	 significantly	 more	
hypoglycaemia	(Gerstein	et	al.,	2008),	was	associated	with	excess	CV	mortality.	
Despite	 the	 evidence	 confirming	 an	 association	 between	 hypoglycaemia	 and	
mortality,	cause	and	effect	has	not	been	established.	Trial	evidence	suggests	that	
the	 relationship	 is,	 at	 least	 in	 part,	 explained	 by	 ‘confounding’,	 i.e.	 that	
hypoglycaemia	 identifies	 individuals	 with	 comorbidities	 who	 are	 both	
vulnerable	to	hypoglycaemia	and	more	likely	to	die	for	other	reasons	(Zoungas	
et	al.,	 2010).	Nevertheless,	 a	 recent	 large	meta-analysis	 (Goto	 et	al.,	 2013)	 has	
suggested	 that	 comorbidities	 alone	 are	 unlikely	 to	 explain	 this	 relationship.	




Hypoglycaemia	 has	 pro-inflammatory	 consequences,	 including	 increases	 in	




et	 al.,	 2010).	 In	 addition,	 hypoglycaemia	 has	 been	 shown	 to	 increase	 pro-
inflammatory	 cytokines	 (Dotson	 et	 al.,	 2008;	 Razavi	 Nematollahi	 et	 al.,	 2009;	
Gogitidze	Joy	et	al.,	2010)	and	promote	rises	in	the	levels	of	pro-atherogenic	cell	
adhesion	 molecules	 (Gogitidze	 Joy	 et	 al.,	 2010).	 Repeated	 episodes	 of	
hypoglycaemia	 have	 also	 been	 reported	 to	 impair	 nitric	 oxide-mediated	
vasodilation	(Joy	et	al.,	2015).	
	
Monocytes	 are	 phagocytes	 that	 are	 central	 to	 the	 aetiology	 of	 atherosclerosis	
(Oude	Nijhuis	 et	 al.	 2007)	 and	 play	 a	 role	 in	 precipitating	 acute	 CV	 events	 by	
promoting	plaque	destabilisation	and	rupture	(Newby	et	al.,	2009).	The	extent	to	
which	 monocytosis	 and	 monocyte	 activation	 is	 modified	 by	 hypoglycaemia	
remains	uncertain.	Recent	studies	have	also	determined	that	monocytes	can	be	
classified	into	3	distinct	subsets,	termed	classical	monocytes	(CM:	CD14++	CD16-,	
‘Mon1’),	 intermediate	monocytes	 (IM:	CD14++	CD16+,	 ‘Mon2’),	 and	non-classical	
monocytes	(NCM:	CD14+	CD16++,	 ‘Mon3’)	(Ziegler-Heitbrock	et	al.,	2010;	Weber	
et	 al.,	 2016).	 A	 number	 of	 observational	 studies	 indicate	 that	 IMs	 may	 be	
particularly	pro-atherogenic.	Elevated	levels	of	IMs	are	associated	with	adverse	
CV	outcomes	 (Rogacev	et	al.,	 2011,	 2012;	Tapp	et	al.,	 2012;	 Zhou	et	al.,	 2016),	
independently	 predict	 future	 CV	 events	 (Rogacev	 et	 al.,	 2012),	 and	 have	 been	
associated	with	coronary	plaque	vulnerability	in	patients	with	angina	(Kashiwagi	






(Dutta	 et	 al.,	 2012).	 In	 humans,	 CD16+	 monocytes	 selectively	 mobilise,	 in	 a	
catecholamine-dependent	 fashion,	 following	 exercise	 (Birgit	 Steppich	 et	 al.,	
2000).	 As	 epinephrine	 (adrenaline)	 is	 the	 key	 counter-regulatory	 hormone	
produced	 in	 response	 to	 hypoglycaemia,	 I	 hypothesised	 that	 hypoglycaemia	
would	also	exert	significant	effects	on	monocytes.	I	further	hypothesised	that	we	
would	see	additional	synergistic	changes	in	monocyte	and	platelet	activation,	as	
revealed	 by	 formation	 of	 monocyte-platelet	 aggregates,	 which	 are	 increased	
after	AMI	(Furman	et	al.,	2001;	Tapp	et	al.,	2012)	To	probe	how	hypoglycaemia	
may	 modulate	 monocyte	 function	 in	 the	 human	 in	 vivo,	 I	 chose	 to	 combine	 a	
classical	hypoglycaemic	stimulus	with	a	subsequent	in	vivo	systemic	stimulus	of	





















Table	 3.1	 Comparison	 of	 participant	 characteristics	 at	 baseline.	 Data	 are	
mean	±	SD	or	median	(interquartile	range).	p	values	indicate	comparisons	
between	 study	 groups	 via	 parametric	 or	 nonparametric	 testing.	
Abbreviations:	BMI,	body	mass	index;	WBC,	white	blood	cells.	
	
Parameter	 Hypoglycaemia	 Euglycaemia	 Sham-saline	 p	
Total	n=24	 8	 8	 8	 N/A	
Sex	(M/F)	 4/4	 4/4	 4/4	 N/A	
Age	(years)	 21	(19-22)	 21	(20-23)	 21.5	(21-26)	 0.299	
BMI	
(kg/m2)	

























































































Assessed for eligibility 





screening blood results 
(n=8) 
Dose finding exercise 
for low dose IV 
endotoxin (n=2) as per 
protocol not included in 
final analysis      




















Coryzal illness n=2 






































and	 euglycaemia	 clamps,	 respectively.	 Glucose	 values	 at	 the	 end	 of	 the	 sham-
saline	 clamp	 were	 4.64	 ±	 0.09	 mmol/l.	 A	 counter-regulatory	 response	 to	
hypoglycaemia	 was	 evident	 with	 epinephrine	 (adrenaline)	 levels	 during	
hypoglycaemia	 (1.87	 ±	 0.25	 nmol/l)	 being	 significantly	 higher	 (p	 <	 0.001)	
compared	 to	 euglycaemia	 (0.07	 ±	 0.01	 nmol/l)	 and	 sham-saline	 (0.10	 ±	 0.04	
nmol/l)	 (Figure	 3.1	 B).	 Free	 insulin	 levels	 at	 the	 end	 of	 clamp	 were	 similar	
between	hypoglycaemia	(968.5	±	149.1	pmol/l)	and	euglycaemia	groups	(1025.4	
±	81.4	pmol/l,	p	=	0.996)	but	significantly	higher	(p	<	0.001)	 then	 those	 in	 the	
sham-saline	(31.3	±	6.3	pmol/l)	group	(Figure	3.1	C).	Serum	cortisol	and	growth	










Figure	 3-1	 Glucose,	 insulin	 and	 counter-regulatory	 hormones	 in	 clamp	
studies.	Arterialised	whole	blood	glucose	values	during	hyperinsulinaemic	
hypoglycaemic,	 euglycaemic	 and	 sham-saline	 clamps	 (a),	 epinephrine	
(adrenaline)	 (b),	 free	 insulin	 (c),	 cortisol	 (d)	and	growth	hormone	values	
(e)	 after	 60	 minutes	 of	 hypoglycaemia,	 euglycaemia	 or	 sham-saline	
injection.	 Data	 are	 mean	 (SEM),	 *p<0.05,	 **p<0.01,	 ***p<0.001,	 ns-non-
significant,	 p-values	 are	 provided	 for	 comparison	 between	 study	 groups.	
Black	 circles	 (and	 dashed	 line	 3.1	 A)-hypoglycaemia	 group;	 open	 circles-










I	 determined	 if	 hypoglycaemia	 results	 in	 changes	 in	 circulating	 leukocytes.	
Hypoglycaemia	 significantly	 increased	 the	 total	 number	 of	WBCs	 compared	 to	
controls	 (Figure	 3.2	 A).	 There	was	 an	 increase	 across	 all	 classes	 of	 leukocytes	





I	 sought	 to	 determine	 if	 hypoglycaemia	 exerted	 specific	 effects	 on	 monocyte	
subsets	 associated	 with	 cardiac	 pathology.	 Hypoglycaemia	 increased	 the	
absolute	 number	 of	 all	 three	 circulating	 monocyte	 subsets	 compared	 to	
euglycaemia	 and	 sham-saline	 (Fig.	 3.3	 B-D).	 The	 number	 of	 circulating	 NCMs	
after	 60	minutes	 of	 hypoglycaemia	 compared	 to	 baseline	 (17.6	 ±	 2.9	 cells/μl)	
increased	twofold.	IM	numbers	after	60	minutes	of	hypoglycaemia	compared	to	
baseline	 (23.2	 ±	 4.5	 cells/μl)	 increased	 by	 a	 factor	 of	 1.81	 and	 CMs	 after	 60	
minutes	 of	 hypoglycaemia	 compared	 to	 baseline	 (442.4	 ±	 55.3	 cells/μl)	








Figure	 3-2	 Peripheral	 total	 white	 blood	 cell,	 neutrophil	 and	 lymphocyte	
kinetics	 in	 experimental	 hypoglycaemia	 and	 controls.	 Number	 of	
circulating	 total	 WBCs	 (a),	 neutrophils	 (b)	 and	 lymphocytes	 (c)	 after	 60	
minutes	of	hypoglycaemia,	euglycaemia	or	sham-saline	injection.	Data	are	
mean	 (SEM),	 **p<0.01,	 ***p<0.001,	 p-values	 are	provided	 for	 comparison	
between	 study	 groups.	 Black	 circles-hypoglycaemia	 group;	 open	 circles-





Figure	 3-3	 Total	 monocyte	 count	 and	 monocyte	 subset	 kinetics	 in	
experimental	hypoglycaemia	and	controls.	Absolute	circulating	numbers	of	
total	monocytes	(a)	and	monocyte	subsets	comprising	of	NCMs	(b),	IMs	(c)	
and	 CMs	 (d)	 after	 60	 minutes	 of	 hypoglycaemia,	 euglycaemia	 or	 sham-
saline	 injection.	 Data	 are	 mean	 (SEM),	 *p<0.05,	 **p<0.01,	 ***p<0.001,	 p-
values	 are	provided	 for	 comparison	between	 study	 groups.	Black	 circles-
hypoglycaemia	 group;	 open	 circles-euglycaemia	 group;	 black	 triangles-





















to	 leukocyte	 mobilisation	 and	 inflammation	 in	 the	 vasculature	 (Totani	 and	
Evangelista,	 2010).	 I	 therefore	 studied	 platelet	 number	 and	 function	 and	 their	
interaction	 with	 leukocytes.	 Total	 platelet	 count	 increased	 in	 hypoglycaemia	
compared	to	euglycaemia	and	sham-saline	controls	(Figure	3.4	A).	ADP-induced	
platelet	 aggregation	 increased	 following	 60	 minutes	 of	 hypoglycaemia	 versus	
euglycaemia	 (p	 =	 0.014)	 and	 there	 was	 numerically,	 but	 not	 statistically	
significantly,	 higher	 platelet	 aggregation	 detected	 in	 the	 hypoglycaemia	 group	
compared	to	sham-saline	group	(p	=	0.064)	(Figure	3.4	B).	The	total	number	of	
MPAs	 increased	 following	 60	 minutes	 of	 hypoglycaemia	 compared	 to	
euglycaemia	 (Figure	 3.4	 C).	Whilst	 total	MPAs	were	 not	 significantly	 higher	 in	
hypoglycaemia	compared	to	sham-saline	controls	at	60	minutes	(Figure	3.4	C),	I	
observed	 specific	 increases	 in	 non-classical	monocyte	 (NCM)	 and	 intermediate	










aggregation	 to	 ADP	 6.45	 μM	 (b),	 total	 MPA	 formation	 (c)	 and	 MPA	
formation	within	monocyte	 subsets;	NCM-MPAs	 (d),	 IM-MPAs	 (e)	and	CM-
MPAs	 (f)	 after	 60	minutes	 of	 hypoglycaemia,	 euglycaemia	 or	 sham-saline	
injection.	 Data	 are	 mean	 (SEM),	 *p<0.05,	 **p<0.01,	 ns-non-significant,	 p-
values	 are	provided	 for	 comparison	between	 study	 groups.	Black	 circles-
hypoglycaemia	 group;	 open	 circles-euglycaemia	 group;	 black	 triangles-
sham-saline	 group.	 MPA,	 monocyte-platelet	 aggregates;	 NCM-MPA,	 non-






To	 further	 explore	 the	 activation	 state	 of	 monocytes	 after	 hypoglycaemia,	 I	
studied	 expression	 levels	 of	 chemokine	 receptor	 CX3C	 chemokine	 receptor	 1	







of	 hypoglycaemia,	 euglycaemia	 or	 sham-saline	 injection.	 Data	 are	
geometric	mean	(SEM),	ns-non-significant,	solid	horizontal	lines	represent	







To	 determine	 if	 prior	 hypoglycaemia	 affected	 the	 subsequent	 response	 to	 a	
classical	immune	activator,	and	thus	to	reveal	if	hypoglycaemia	had	any	longer-
lasting	effects	on	the	innate	immune	system,	I	next	proceeded	to	a	low-dose	(0.3	
ng/kg)	 intravenous	 endotoxin	 challenge	 48	 hours	 after	 the	 hypoglycaemic	
challenge	in	all	subjects.	Consistent	with	the	low-dose	model	employed,	no	fever	






were	 not	 significantly	 different	 between	 study	 groups	 6	 hours	 following	
endotoxin	 administration	 (Figure	 3.6	 A).	 In	 the	 hypoglycaemia	 group,	
epinephrine	 levels	 were	 0.15	 ±	 0.04	 nmol/l	 versus	 0.06	 ±	 0.01	 nmol/l	 in	
euglycaemia	group	and	0.09	±	0.01	nmol/l	in	sham-saline	group.	There	were	also	
no	differences	detected	between	groups	in	serum	cortisol	and	growth	hormone	
levels	 following	 endotoxin	 administration	 (Figure	 3.6	 B&C).	 However,	 a	 rise	
versus	 baseline	 in	 the	 stress	 hormone	 cortisol	 was	 evident	 whereby	 serum	












Figure	 3-6	 Changes	 in	 epinephrine	 (adrenaline),	 cortisol	 and	 growth	
hormone	response	post	endotoxin	challenge.	Epinephrine	(a),	cortisol	(b)	
and	growth	hormone	(c)	responses	2,	4	and	6	hours	following	low	dose	(0.3	





groups.	 Dashed	 line	 in	 (a)	 illustrates	 the	 mean	 epinephrine	 response	 in	






I	 observed	 that	 antecedent	 hypoglycaemia	 modulated	 the	 subsequent	 WBC	
response	 to	endotoxin.	Total	number	of	WBCs	 increased	significantly	 following	
endotoxin	 in	 all	 the	 study	 groups	 (Figure	 3.7	 A).	 The	 peak	 WBC	 response	
occurred	 at	 4	 hours	 post	 endotoxin	 and	 this	 was	 significantly	 higher	 in	 the	
hypoglycaemia	 group	 at	 10.96	 ±	 0.97x109/l	 vs.	 8.21	 ±	 0.85x109/l	 in	 the	
euglycaemia	 group	 (p	 =	 0.012)	 (Figure	 3.7	 A).	 Total	WBC	 count	 4	 hours	 post	
endotoxin	 in	 the	 sham-saline	 group	 was	 10.65	 ±	 0.64x109/l	 and	 this	 was	
significantly	higher	compared	to	euglycaemia	(p	=	0.033),	but	not	hypoglycaemia	
(p	 =	 0.974).	 The	 rise	 in	 WBCs	 was	 mainly	 a	 consequence	 of	 an	 increase	 in	
neutrophil	 count	 (Figure	 3.7	 B).	 The	 lymphocyte	 count	 decreased	 following	
endotoxin	 (Figure	 3.7	 C)	 and	 the	 monocyte	 count	 initially	 decreased	 prior	 to	
recovery	 6	 hours	 post	 endotoxin	 (Figure	 3.8	 A).	 There	was	 a	 trend	 towards	 a	
higher	total	monocyte	count	in	the	hypoglycaemia	group	4	hours	post	endotoxin	
compared	 to	 euglycaemia	 but	 this	 comparison	 did	 not	 reach	 statistical	
significance	 (p	 =	 0.085).	 The	 absolute	 number	 of	 circulating	monocyte	 subsets	
did	 not	 differ	 significantly	 between	 study	 groups	 (Fig.	 3.8	 C-D).	 NCM	 and	 IM	
numbers	 decreased	 significantly	 following	 endotoxin	 compared	 to	 baseline	
values	 in	 all	 groups	 (p	 <	 0.001)	 (Figure	 3.8	 B&C).	 Compared	 to	 baseline,	 CM	











Figure	 3-7	 Peripheral	 total	 white	 blood	 cell,	 neutrophil	 and	 lymphocyte	
kinetics	 post	 endotoxin	 challenge.	 Number	 of	 circulating	 total	WBCs	 (a),	
neutrophils	 (b)	 and	 lymphocytes	 (c)	 2,	 4	 and	6	hours	 following	 low	dose	
(0.3	 ng/kg)	 intravenous	 endotoxin	 challenge	 in	 participants	 that	
underwent	hypoglycaemia,	 euglycaemia	or	a	 sham-saline	 clamp	48	hours	
earlier.	 Data	 are	 mean	 (SEM),	 *p<0.05,	 ns-non-significant,	 p-values	 are	
provided	for	comparison	between	study	groups,	solid	horizontal	line	in	(c)	
represents	 significance	 for	 comparison	 between	 study	 groups.	 Black	










clamp	 48	 hours	 earlier.	 Data	 are	 mean	 (SEM),	 ***p<0.001,	 ns-non-
significant,	p-value	on	dashed	 line	 in	 (b)	 represents	 change	 in	number	of	
NCMs	at	2,	4	and	6	hours	compared	to	baseline	in	all	study	groups.	p-value	
on	dashed	line	in	(c)	represents	change	in	number	of	IM	at	2,	4	and	6	hours	
compared	 to	 baseline	 in	 all	 study	 groups.	 P-value	 on	 dashed	 lines	 in	 (d)	
represent	change	in	number	of	CMs	at	2	and	6	hours	compared	to	baseline	
in	 all	 study	 groups.	 Solid	 horizontal	 lines	 represent	 significance	 for	
comparison	 between	 study	 groups.	 Black	 circles-hypoglycaemia	 group;	
open	 circles-euglycaemia	 group;	 black	 triangles-sham-saline	 group.	 NCM,	















of	 cell	 surface	 marker	 CX3CR1	 expression.	 Endotoxin	 administration	 caused	 a	
significant	decline	in	expression	of	this	marker	across	all	study	groups	compared	
to	baseline	(p	<	0.001)	(Figure	3.9	A).	This	was	accompanied	by	an	 increase	 in	












Figure	 3-9	 Expression	 of	 CX3CR1	 on	 monocytes	 and	 plasma	 levels	 of	
CX3CL1	post	 endotoxin	 challenge.	 CX3CR1	expression	on	 total	monocytes	
(a)	and	monocyte	subsets	comprising	of	NCMs	(b),	IMs	(c)	and	CMs	(d)	2,	4	
and	 6	 hours	 following	 low	 dose	 (0.3	 ng/kg)	 intravenous	 endotoxin	
challenge	in	participants	that	underwent	hypoglycaemia,	euglycaemia	or	a	
sham-saline	clamp	48	hours	earlier.	CX3CL1	values	determined	 in	plasma	
are	 shown	 in	 (e).	 Data	 are	 geometric	 mean	 (SEM),	 ***p<0.001,	 ns-non-
significant,	 p-values	 on	 dashed	 line	 in	 (a)	 and	 (e)	 represent	 changes	 in	
CX3CR1	on	all	monocytes	and	plasma	CX3CL1	expression	respectively	at	2,	4	
and	6	hours	compared	to	baseline	in	all	study	groups.	Solid	horizontal	lines	
represent	 significance	 for	 comparison	between	 study	 groups.	Black	bars-
hypoglycaemia	group	(n=8);	white	bars-euglycaemia	group	(n=8);	striped	








positive	monocytes	 post	 endotoxin	 challenge.	 CD11b	 expression	 on	 total	
monocytes	 (a)	 and	 percentage	 (%)	 of	 monocytes	 that	 positively	 express	
CD11b	 (b)	 2,	 4	 and	 6	 hours	 following	 low	 dose	 (0.3	 ng/kg)	 intravenous	
endotoxin	 challenge	 in	 participants	 that	 underwent	 hypoglycaemia,	
euglycaemia	or	a	sham-saline	clamp	48	hours	earlier.	Data	are	geometric	
mean	 (SEM)	 in	 (a)	 and	mean	 (SEM)	 in	 (b),	 **p<0.01,	 ***p<0.001,	 ns-non-
significant,	dashed	 lines	 in	(a)	represents	change	 in	CD11b	expression	on	
all	monocytes	at	4	and	6	hours	compared	to	baseline	in	all	study	groups.	P-
value	 in	 (b)	 is	 for	 comparison	 of	 CD11b	 percentage	 expression	 between	
hypoglycaemia	 and	 euglycaemia.	 Solid	 horizontal	 line	 in	 (a)	 represents	








Episodes	 of	 hypoglycaemia	 may	 increase	 both	 the	 rate	 of	 progression	 of	
atherosclerosis	 and	 increase	 the	 risk	 of	 thrombosis	 of	 the	 unstable	 plaque.	 I	
aimed	 to	 investigate	 the	 effect	 of	 acute	 experimental	 hypoglycaemia	 and	
subsequent	 low-dose	endotoxaemia	on	aspects	of	 the	 innate	 immune	 response	
(total	 leukocytes,	 leukocyte	 subsets	 and	 specifically	 monocyte	 subsets),	
thrombosis	 (platelet	 aggregation)	 and	 cross-talk	 between	 inflammation	 and	
thrombosis	 (monocyte-platelet	 aggregates).	 My	 main	 findings	 were:	 (1)	
hypoglycaemia	 increased	the	number	of	all	 three	circulating	monocyte	 subsets,	
in	 association	 with	 a	 stress	 response	 characterised	 by	 increased	 plasma	
epinephrine	 levels;	 (2)	 hypoglycaemia	 increased	 platelet	 reactivity,	 promoted	
formation	 of	 MPAs	 and	 promoted	 aggregate	 formation	 between	 pro-
inflammatory	monocytes	and	platelets;	 (3)	 leukocyte	mobilisation	 to	 the	stress	
response	 of	 low-dose	 endotoxin	 was	 independent	 of	 epinephrine,	 and	
antecedent	 hypoglycaemia	 resulted	 in	 a	 significantly	 higher	 inflammatory	
leukocyte	response	to	low-dose	endotoxin	administered	48	hours	later.	
	
As	 shown	 previously	 (Razavi	 Nematollahi	 et	 al.,	 2009;	 Ratter	 et	 al.,	 2017),	 	 I	
confirm	that	hypoglycaemia	results	in	leukocytosis.	In	addition,	I	present,	for	the	
first	 time,	 the	 effect	 of	 hypoglycaemia	 on	 monocyte	 subset	 kinetics	 and	








et	 al.	 also	 recently	 determined	 that	 hypoglycaemia	 might	 modify	 selective	
monocyte	mobilisation	 (Ratter	 et	 al.,	 2017).	 However,	 they	 did	 not	 phenotype	
monocyte	subsets	but	rather	measured	total	levels	of	CD16	on	peripheral	blood	
mononuclear	cells	isolated	from	both	healthy	participants	and	those	with	T1D	in	
experimental	 hypoglycaemia	 settings.	 Our	 data	 identify	 specific	 changes	 in	
monocyte	subsets	that	have	been	previously	 linked	to	monocyte	activation	and	
atherogenesis.	 As	 observational	 data	 support	 the	 notion	 of	 CD16+	 monocytes	
being	pro-atherogenic	 (Kashiwagi	et	al.,	2010;	Rogacev	et	al.,	2012;	Tapp	et	al.,	
2012;	Zhou	et	al.,	2016),	and	adrenergic	modulation	of	monocytes	induces	pro-




suggested	an	 increase	 in	platelet	reactivity;	however,	 this	was	 in	the	context	of	
significant	hypoglycaemic	stimulus	as	part	of	an	insulin	stress	test	(Hutton	et	al.,	
1979).	 An	 older	 investigation	 into	 the	 effect	 of	 hypoglycaemia	 on	 monocyte-
platelet	 interactions	 in	 T1D	 and	 healthy	 controls	 has	 also	 suggested	 a	 trend	
towards	increased	MPA	formation,	but	these	data	were	not	conclusive	with	little	
difference	 between	 euglycaemic	 and	 hypoglycaemic	 conditions	 (Wright	 et	 al.,	
2010).	 My	 study	 also	 recapitulates	 and	 extends	 previous	 findings	 that	
hypoglycaemia	 is	 prothrombotic,	 as	 evidenced	 by	 an	 increased	 platelet	 count	
and	 increased	 platelet	 reactivity	 to	 ADP	 (Trovati	 et	 al.,	 1986).	 I	 have	 now	




demonstrating	 MPA	 formation	 within	 monocyte	 subsets	 in	 experimental	
hypoglycaemia.	 MPA	 formation	 is	 a	 highly	 sensitive	marker	 of	 both	monocyte	
and	 platelet	 activation	 (Michelson	 et	 al.,	 2001;	 Wrigley	 et	 al.,	 2013).	 MPA	
formation	promotes	monocyte	release	of	 the	pro-inflammatory	cytokines;	TNF-
α,	 C-X-C	motif	 chemokine	 ligand	 8	 (CXCL8)	 and	 C-C	motif	 chemokine	 ligand	 2	
(CCL2)	 (Neumann	 et	al.,	 1997;	 Bournazos	 et	al.,	 2008)	 and	 increases	 adhesive	
properties	 of	 monocytes	 (Martins	 et	 al.,	 2006),	 thereby	 representing	 a	 bridge	
between	 inflammation	 and	 thrombosis,	 that	may	 serve	 to	 increase	 CV	 risk.	 In	
acute	 coronary	 syndromes,	MPA	 formation	 correlates	with	 troponin	 elevation,	
risk	 of	 in-hospital	 cardiac	 events	 including	 death	 and	 risk	 of	 future	 cardiac	
events	(Zhang	et	al.,	2007;	Tapp	et	al.,	2012).	I	have	also	shown	that	NCMs	and	
IMs	 aggregate	 more	 readily	 with	 platelets	 in	 response	 to	 hypoglycaemia	
compared	 to	 CMs.	 A	 similar	 observation	 of	 proportionally	 higher	 IM-MPA	 and	
NCM-MPA	 formation	 has	 been	 reported	 in	 patients	 following	 an	 ST-elevation	
myocardial	 infarction	 (STEMI)	with	higher	 IM-MPAs	 in	particular	being	a	poor	
prognostic	 indicator	 at	 6	weeks	 following	 STEMI	 (Tapp	et	al.,	 2012).	 Thus,	my	
data	 suggest	 that	 hypoglycaemia	 not	 only	 increased	 circulating	 numbers	 of	
CD16+	monocytes,	 but	 also	promoted	 increased	 interaction	between	 these	pro-
inflammatory	monocyte	subsets	and	platelets.		
	
In	 a	 first	 model	 of	 its	 type,	 I	 wished	 to	 determine	 whether	 antecedent	
hypoglycaemia	modulated	responses	to	low-dose	endotoxin.	I	chose	a	low-dose	
endotoxin	model	firstly	because	I	felt	it	the	safest	way	to	combine	the	clamp	and	





foot	 ulceration	 and	 periodontitis	 which	 might	 further	 increase	 the	 risk	 of	 CV	
mortality	 (Brownrigg	 et	 al.,	 2012;	 P.	 M.	 Preshaw	 et	 al.,	 2012).	 In	my	model,	 I	
observed	in	all	groups	that	monocytes	were	activated	even	in	response	to	 low-
dose	 endotoxin,	 as	 indicated	 by	 upregulation	 of	 systemic	 levels	 of	 the	 CX3CR1	
ligand	 CX3CL1,	 and	 the	 upregulation	 of	 the	 adhesion	 molecule	 CD11b	 on	 the	
monocytes	 themselves.	 Interestingly,	 compared	 to	 euglycaemia,	 hypoglycaemia	
resulted	 in	greater	 leukocyte	mobilisation	 in	response	 to	 low-dose	 intravenous	
endotoxaemia	 48	 hours	 later.	 Furthermore,	 I	 noted	 a	 non-significant	 trend	
towards	a	higher	total	monocyte	count	in	the	hypoglycaemia	group	4	hours	post	
endotoxin	 compared	 to	 euglycaemia.	 The	 percentage	 of	 monocytes	 that	 were	
CD11b	 positive	 was	 also	 higher	 in	 hypoglycaemia	 group	 compared	 to	
euglycaemia	group	at	2	hours	post	 endotoxin.	Levels	of	 leukocyte	mobilisation	
were	similar	between	groups	who	received	prior	sham-saline	or	hypoglycaemia.	





differential	 leukocyte	 mobilisation	 to	 endotoxin	 are	 unlikely	 to	 be	 due	 to	
differences	between	groups	in	epinephrine,	cortisol	and	growth	hormone	levels	
post	endotoxin,	as	 these	were	not	significantly	different.	My	observation	 that	a	









immune	 cell	 kinetics	 and	 activation	 status	 in	 response	 to	 experimental	
hypoglycaemia	 and	 endotoxin	 challenge	 in	 vivo.	 The	 separation	 of	 clamp	 and	
endotoxin	 studies	 by	 48	hours	 allowed	me	 to	 probe	 the	 longitudinal	 effects	 of	




One	 limitation	 was	 my	 decision	 to	 study	 a	 relatively	 small	 number	 of	 young	
healthy	participants.	This	limits	the	applicability	of	my	findings	to	older	patients	
with	 diabetes,	 established	 CV	 risk	 factors	 and	 atherosclerosis.	 For	 ethical	 and	
safety	 reasons,	 I	 decided	 to	 examine	my	 novel	 experimental	model	 initially	 in	
healthy	participants.	I	also	specifically	adopted	a	low-dose	endotoxin	model	with	
future	 translatability	 in	 older,	 higher-risk	 participants	 in	mind.	 Future	 studies	
should	 therefore	 confirm	my	 findings	 in	 those	with	 diabetes.	 In	 addition,	 it	 is	
worth	 noting	 that	 I	 studied	 cell	 numbers,	 phenotypic	 changes	 and	 activation	
status	 in	 circulating	 immune	 cells	 and	 this	 may	 not	 necessarily	 reflect	 the	
functional	capacity	of	these	cells	in	an	atherosclerotic	plaque.	An	animal	model	of	






induced	 prothrombotic	 changes	 by	 increasing	 platelet	 reactivity.	 In	 addition,	
hypoglycaemia	 amplified	 interactions	 between	 platelets	 and	 monocytes	 by	
promoting	 MPA	 formation	 with	 enhanced	 aggregation	 of	 pro-inflammatory	































al.,	 2008;	 Duckworth	 et	 al.,	 2009).	 Further,	 there	 is	 accumulating	 evidence	
associating	hypoglycaemia	with	all-cause	mortality	and	an	increased	incidence	of	
CV	events	(Khunti	et	al.,	2015)	which	cannot	be	explained	by	confounding	factors	
alone	 (Goto	 et	 al.,	 2013).	 Moreover,	 analyses	 from	 clinical	 trials	 show	 that	
potentially	 deleterious	 effects	 of	 hypoglycaemia	 may	 persist	 for	 weeks	
downstream	from	the	episodes	(Duckworth	et	al.,	2009;	Pieber	et	al.,	2018).		
	










CV	 events	 are	 limited	 as	 they	 studied	 relatively	 small	 number	 of	 young	












to	 explore	 causality.	 Animal	 experimentation	 in	 non-obese	 diabetic	 Goto-
Kakizaki	rats	had	suggested	that	repetitive	hypoglycaemia	resulted	in	increased	
sympathetic	 activity	 with	 resulting	 induction	 of	 monocyte	 adhesion	 to	
endothelial	cells	in	the	aorta	(Jin	et	al.,	2011)	and	augmented	intimal	thickening	






ease	 of	 breeding,	 low	 cost	 of	 maintenance	 and	 reliable	 development	 of	
atherosclerosis	 over	 short	 periods	 of	 time	 (Getz	 and	 Reardon,	 2012).	 ApoE	 is	
essential	 for	 catabolism	of	 triglyceride	 rich	 lipoproteins	 (Schaefer	et	al.,	 1986).		
In	humans,	a	familial	form	of	ApoE	deficiency	results	in	defective	binding	to	the	




premature	 atherosclerosis	 and	 CV	 events	 (Schaefer	 et	al.,	 1986).	 ApoE	-/-	mice	
develop	 plaques	 which	 are	morphologically	 similar	 to	 those	 found	 in	 humans	
and	 thus	 have	 a	 fibrous	 cap	 containing	 smooth	 muscle	 cells	 supported	 by	 a	
connective	 tissue	 matrix	 that	 encapsulates	 a	 necrotic	 core	 containing	 foamy	
macrophages	 (Piedrahita	 et	 al.,	 1992;	 Nakashima	 et	 al.,	 1994).	 ApoE	 -/-	 mice	
spontaneously	develop	advanced	atherosclerotic	lesions	by	20	weeks	of	age	even	
when	 fed	 a	 chow	 diet	 (Nakashima	 et	 al.,	 1994).	 Feeding	 these	 pre-disposed	




In	 this	 chapter	 I	 describe	 the	 development	 of	 a	 novel	 murine	 model	 of	
hypoglycaemia	on	the	background	of	pre-established	atherosclerosis.	Data	from	
clinical	studies	suggest	that	an	episode	of	severe	hypoglycaemia	confers	durable	
effects.	 Furthermore,	 patients	 rarely	 suffer	 just	 one	 episode	 of	 severe	
hypoglycaemia	in	clinical	practice.	The	aim	of	these	experiments,	therefore,	was	
to	 develop	 a	 robust	 model	 of	 recurrent	 hypoglycaemia	 of	 significant	 depth	 to	



















ApoE	 -/-	mice:	 JAX	 B6.129P2-ApoE	 tm1Unc/J	were	 purchased	 from	 Charles	 River	





Crawley,	 West	 Sussex,	 UK)	 would	 be	 a	 safe	 starting	 point	 for	 mice	 with	 a	
C57BL/6J	background.	Animals	were	fasted	for	3	hours	prior	to	i.p.	 injection	of	
insulin	 and	 tail	 vein	 blood	 glucose	 was	 obtained	 at	 baseline	 and	 regularly	
thereafter	 for	at	 least	90	minutes,	 later	extended	to	135	minutes	and	 then	150	
minutes.	Following	initial	experiments	in	a	male	mouse,	the	dose	of	insulin	was	
sequentially	increased	in	subsequent	animals	giving	a	dose	range	of	0.75	mU/g,	











Massachusetts,	 USA)	 aged	 approximately	 at	 6-7	 weeks.	 Following	 1	 week	 of	
acclimatisation,	 mice	 were	 fed	 5g/day/animal	 of	 Western	 diet	 (ABdiets,	
Woerden,	 The	Netherlands)	 for	 6	weeks	 and	 hence	were	 aged	 between	 12-14	
weeks	when	hypoglycaemia	was	induced.	Anticipating	higher	insulin	resistance	
given	a	higher	total	body	weight	and	based	on	experience	from	non-fed	animals,	
an	 initial	 insulin	 dose	 of	 1.5	mU/g	was	 selected.	Mice	were	 fasted	 for	 3	 hours	
prior	to	i.p.	insulin.	To	promote	animal	welfare,	the	dose	of	insulin	was	increased	







Massachusetts,	USA)	 aged	9-10	weeks	 and	 following	1	week	of	 acclimatisation	











either	hypoglycaemia	or	 sham-saline	 injection	on	 an	 alternate	day	basis.	 Thus,	
each	 animal	underwent	4	 episodes	of	 insulin	 induced	hypoglycaemia	or	 sham-




Figure	 4-1	 Experimental	 design	 used	 to	 develop	 a	 protocol	 for	 recurrent	
hypoglycaemia	vs.	sham-saline	injection.	ApoE	-/-	mice	fed	Western	diet	for	
7	weeks	were	allocated	 to	 either	 a	 receive	hypoglycaemia	 (group	1)	or	 a	
sham-saline	 (group	 2).	 Group	 1	 mice	 underwent	 hypoglycaemia	 on	
Mondays	and	Wednesdays.	Group	2	mice	received	a	saline	control	injection	




All	 animals	 were	 fasted	 for	 3	 hours	 before	 i.p.	 insulin.	 Due	 to	 heterogeneity	
between	mice	 in	 the	dose-response	relationship	of	 i.p.	 insulin	 injection	and	tail	
vein	blood	glucose	values,	an	insulin	dose	of	1.3	mU/g	was	selected	as	a	starting	
point	 for	 safe	 induction	 of	 hypoglycaemia	 in	 Western	 diet	 fed	 mice.	 A	 final	































handled	 identically	 but	 instead	 of	 insulin	 received	 a	 fixed	 volume	 (200	 μl)	
injection	of	0.9%	v/v	sodium	chloride.	
	








Baseline	 data	 from	 this	 first	 experiment	 indicated	 that	 chow	 fed	 ApoE	 -/-	mice	
(JAX	B6.129P2-ApoE	tm1Unc/J)	had	a	mean	body	weight	at	age	12-13	weeks	of	age	
of	21.4	grams	(Table	4.1).	












the	 fasting	period	 to	2	hours,	 an	extension	of	blood	glucose	monitoring	 to	135	




minutes	 following	 i.p.	 insulin	and	survived	 the	protocol	 (Figure	4.2	B).	 	Mice	3	
and	4	were	females	and	received	0.85mU/g	and	1mU/g	i.p.	insulin	respectively.	





female	 ApoE	 -/-	mice	 on	 a	 chow	 diet	 (n=4).	 A&B)	 Glucose	 profile	 in	male	
mice.	Mouse	1	did	not	survive	the	protocol.	C)	Glucose	profile	 in	a	 female	
mouse	with	a	dose	escalation	to	0.85	mU/g.	D)	Failure	to	achieve	a	glucose	

























Insulin dose 0.75 mU/g




















Insulin dose 0.85 mU/g





















Insulin dose 0.75 mU/g





























mice	 in	 4.3.1,	 I	 next	 conducted	 experiments	 on	 Western	 diet	 fed	 mice	 to:	 a)	
establish	 an	 insulin	 dose	 range	 in	 fed	 mice	 and	 b)	 test	 the	 severity	 and	
survivability	of	hypoglycaemia	 in	 fed	animals.	Given	the	variability	observed	 in	
glucose	 response	 to	 insulin	 in	 female	 mice,	 I	 decided	 to	 take	 experiments	
forward	in	male	mice.	
	









blood	 glucose	 was	 1.2	 mmol/l	 at	 120	 minutes	 (Figure	 4.3).	 This	 mouse	 was	
sacrificed	using	an	overdose	of	sodium	pentobarbital	as	per	schedule	1.	In	light	
of	this,	the	remaining	three	mice	had	a	reduced	dose	of	insulin	at	1.3	mU/g	and	
had	mash	 chow	diet	made	 available	 in	 the	 cage	 once	 the	 hypoglycaemia	 nadir	
had	been	 reached.	The	 three	 remaining	 animals	 survived	 the	 experiment.	 Two	
out	of	three	mice	were	administered	150	μl	i.p.	injection	of	20%	dextrose	to	aid	























extended	 period,	 b)	 demonstrate	 biochemical	 validity	 of	 the	 model	 by	
measurement	of	plasma	adrenaline	and	serum	lipids	c),	explore	atherosclerotic	
disease	 burden	 at	 one	 anatomical	 site	 in	 fed	 mice	 in	 order	 to	 compare	































defective	 counter-regulatory	 responses	 to	 recurrent	 insulin	 induced	
hypoglycaemia	 (McNeilly	 et	 al.,	 2017)	 an	 insulin	 dose	 range	 provided	 the	









0.6	 grams	 in	 the	hypoglycaemia	 group	vs.	 32.1	±	0.6	 grams	 in	 the	 sham-saline	













Figure	4-4	Body	weight	 in	Western	diet	 fed	male	ApoE	 -/-	mice.	A)	Mice	 in	
the	 hypoglycaemia	 (n=8)	 and	 sham-saline	 group	 (n=8)	 steadily	 gained	
weight	through	the	feeding	period	with	no	significant	difference	at	the	end	











































































































Serum	 lipids	 were	 biochemically	 analysed	 for	 mice	 in	 the	 hypoglycaemia	 and	
sham-saline	 group	 at	 sacrifice.	 All	 lipid	 parameters	 were	 elevated	 in	 mice	 on	















Total	cholesterol	 29.8	±	1.3	 27.3	±	3.2	 0.534	
HDL	cholesterol	 7.9	±	1.1	 5.9	±	0.8	 0.178	
LDL	cholesterol	 21.2	±	1.5	 20.5	±	2.6	 0.854	







Baseline	 fasting	 blood	 glucose	 values	 were	 10.4	 ±	 0.3	 mmol/l	 in	 the	
hypoglycaemia	group	vs.	 10.3	 	 ±	0.3	mmol/l	 in	 sham-saline	group	 (p	=	0.981).	
Blood	 glucose	 values	 fell	 steadily	 following	 i.p.	 insulin	 in	 the	 hypoglycaemia	
group	to	reach	a	nadir	of	relative	hypoglycaemia	at	6.6		±	0.4	mmol/l	compared	
to	 11.8	 	 ±	 0.5	mmol/l	 in	 sham-saline	 group	 at	 60	minutes	 (p	 <	 0.001)	 (Figure	
4.5).	 Following	 recovery	 from	 relative	 hypoglycaemia,	 blood	 glucose	 values	
steadily	rose	to	14.7	±	0.5	mmol/l	vs.	12.5	±	0.4	at	120	minutes	(hypoglycaemia	




corresponding	 with	 the	 relative	 hypoglycaemia	 nadir.	 Mice	 displayed	 reduced	
levels	 of	 activity	 and	 demonstrated	 diminished	 interest	 in	 their	 surroundings	
with	 a	 return	 to	 normal	 behaviour	 following	 resolution	 of	 hypoglycaemia	 thus	






























Figure	 4-5	 Cumulative	 blood	 glucose	 profiles	 following	 i.p.	 insulin	 (dose	
range	 1.3-2.2	 mU/g)	 (n=8)	 vs.	 control	 mice	 (n=8)	 that	 received	 a	 sham-
saline	 injection	 (200	 μl)	 in	 a	model	 of	 recurrent	 relative	 hypoglycaemia	
lasting	 3	weeks	 in	Western	 diet	 fed	 ApoE	 -/-	mice.	 The	 glucose	 nadir	was	
consistently	 reached	 at	 60	 minutes	 in	 the	 hypoglycaemia	 group.	 Blood	















































plasma	 adrenaline	 levels	 rose	 to	 4.92	 ±	 1.22	 nmol/l	 following	 60	 minutes	 of	





in	 Western	 diet	 fed	 ApoE	 -/-	mice.	 Data	 are	 mean	 ±	 SEM,	 ***p<0.001,	60	
minutes	 data	 in	 the	 hypoglycaemia	 group	 are	 for	 n=6	 mice	 due	 to	














































aortae	 following	 4	 episodes	 of	 insulin	 induced	 relative	 hypoglycaemia	
(n=7)	compared	to	sham-saline	injection	(n=8)	in	Western	diet	fed	ApoE	-/-	
mice.	A)	Representative	 images	demonstrate	atherosclerotic	burden	from	










































Data	 obtained	 from	 study	 of	 humans	 suggest	 that	 hypoglycaemia	 is	 associated	
with	increased	CV	risk	(Khunti	et	al.,	2015).	In	this	chapter,	I	have	described	the	
development	 of	 a	 novel	 murine	 model	 of	 combined	 recurrent	 relative	
hypoglycaemia	 (relative	 to	high	 tail	 blood	 glucose	 values	 at	 baseline)	 and	pre-
established	 atherosclerosis	 to	 enable	 studies	 into	 the	 effects	 of	 hypoglycaemia	
on	the	atherosclerotic	plaque.	
	
Preliminary	 experiments	 were	 conducted	 in	 chow	 fed	 mice	 to	 establish	 a	
protocol	 for	 insulin	 induced	hypoglycaemia	and	to	explore	differences	between	
male	and	female	C57BL/6J	ApoE	-/-	mice	in	their	response	to	hypoglycaemia.	One	
interesting	 finding	 from	 these	 experiments	was	 that	whilst	 the	 two	male	mice	
had	 a	 similar	 blood	 glucose	 profile	 in	 response	 to	 i.p.	 insulin,	 the	 response	
between	 the	 two	 female	mice	 was	 inconsistent.	 Despite	 similar	 body	 weights,	
handling	and	a	dose	escalation	of	insulin,	there	was	an	initial	sharp	decline	in	the	
blood	 glucose	profile	 for	 female	mouse	4	 at	 15	minutes	 post	 i.p.	 insulin	 to	 6.9	
mmol/l	 prior	 to	 a	 sharp	 rise	 in	 blood	 glucose	 to	 9.4	 mmol/l	 at	 45	 minutes	
implying	 stronger	 counter-regulation	 compared	 to	 other	 animals.	 This	
experiment	 was	 limited,	 however,	 as	 counter-regulatory	 hormones	 were	 not	
measured	in	these	mice.	
	
It	 was	 important	 to	 study	 female	 mice	 as	 previous	 work	 has	 shown	 that	
atherosclerotic	 lesions	 are	 larger	 and	more	 advanced	 in	 young	 female	 ApoE	-/-	
mice	compared	to	male	mice	(Caligiuri	et	al.,	1999).	This	makes	female	ApoE	-/-	
mice	 appealing	 to	 study	 when	 setting	 up	 a	 model	 of	 atherosclerosis.	 This	
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important	 sex	 difference	 in	 atherosclerotic	 lesion	 development	 has	 also	
previously	 been	 noted	 in	 other	 C57BL/6	 mouse	 models	 of	 atherosclerosis	
(Paigen	et	al.,	1987)	and	is	thought	to	be	mediated,	at	least	in	part,	by	oestrogen	







in	 human	 females	 was	 also	 demonstrated	 in	 two	 studies	 (Davis	 et	 al.,	 1993;	
Fanelli	 et	 al.,	 1994).	 It	 was	 therefore,	 of	 additional	 relevance	 to	 study	 female	
mice	 in	 order	 to	 develop	 a	 murine	 model	 of	 hypoglycaemia	 that	 mirrors	 the	
human	condition	as	closely	as	possible.		
	
My	 preliminary	 data	 demonstrating	 a	 heterogeneity	 between	male	 and	 female	
mice	 in	 their	 response	 to	 insulin	 induced	 hypoglycaemia	 are	 in	 keeping	 with	
previous	data	that	showed	a	gender	difference	in	the	response	to	insulin	in	mice	
(Karlsson,	 Scheurink	 and	 Ahrén,	 2002).	 It	 is	 known	 that	 female	 mice	 have	 a	
larger	 α	 cell	mass	 and	 stronger	 glucagon	 response	 to	 hypoglycaemia,	whereas	
the	sympathetic	response	to	hypoglycaemia	is	stronger	in	male	mice	(Karlsson,	
Scheurink	 and	 Ahrén,	 2002).	 Thus,	 taken	 together,	 initial	 experiments	
highlighted	 potential	 inter-species	 differences	 between	 man	 and	 mouse	 in	
gender	 responses	 to	 hypoglycaemia.	 On	 balance,	 and	 in	 light	 of	 preliminary	
findings,	 female	 mice	 were	 not	 used	 in	 the	 final	 optimised	 model	 in	 order	 to	
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minimise	 the	 introduction	 of	 confounding	 factors	 that	 would	 potentially	
preclude	 reliable	 induction	 of	 recurrent	 hypoglycaemia	 on	 a	 consistent	
atherosclerotic	plaque	burden.	
	
Male	 ApoE	 -/-	mice	 fed	 high	 fat	 Western	 diet	 had,	 as	 expected,	 a	 higher	 body	
weight	compared	to	chow	fed	mice.	As	Western	diet	feeding	is	known	to	induce	
insulin	 resistance	 in	 male	 ApoE	 -/-	mice	 (Schierwagen	 et	 al.,	 2015;	 Han	 et	 al.,	
2017),	 a	 dose	 increment	 of	 i.p.	 insulin	 was	 performed	 compared	 to	 chow	 fed	
mice.	 One	mouse	was	 lost	 to	 an	 apparent	 hypoglycaemia-related	 death	with	 a	
suggestion	 of	 pre-terminal	 hypoglycaemic	 seizure.	 The	 loss	 of	 this	 animal	
highlighted	 ApoE	 -/-	 mice	 vulnerability	 to	 hypoglycaemia	 prompting	 a	 dose	
reduction	of	insulin.	This	finding	is	consistent	with	previous	work	demonstrating	
Western	diet	 fed	ApoE	 -/-	mice	of	a	C57BL/6J	strain	are	particularly	susceptible	
to	 insulin	 induced	hypoglycaemia	displaying	a	deeper	and	 longer	 lasting	 fall	 in	




i.p.	 insulin	 and	 a	 dose	 range	 of	 insulin	 (1.3-2.2	 mU/g)	 derived	 from	 this	
experiment	that	was	comparable	to	insulin	doses	(0.75-2	mU/g)	used	in	ApoE	-/-	
and	 other	 murine	 models	 of	 hypoglycaemia	 (Havel	 et	 al.,	 1993;	 Karlsson,	
Scheurink	and	Ahrén,	2002;	Li	et	al.,	2011).		
	
Data	 generated	 during	 the	 development	 of	 a	 model	 of	 recurrent	 relative	
hypoglycaemia	 in	 male	 ApoE	 -/-	 mice	 demonstrated	 a	 final	 body	 weight	
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consistent	 with	 published	 data	 from	 ApoE	 -/-	 mice	 fed	 Western	 diet	 for	 an	
equivalent	 period	 (Schierwagen	 et	 al.,	 2015).	 My	 finding	 of	 non-significant	
difference	 in	 the	body	weights	between	hypoglycaemia	and	control	mice	at	 the	
end	of	 the	 feeding	period	and	during	experimental	weeks	was	notable	 for	 two	
reasons.	 Firstly,	 it	 demonstrated	 comparable	 diet	 consumption	 between	 the	






al.,	 2003;	 Sell	 and	 Eckel,	 2010;	 Osborn	 and	 Olefsky,	 2012)	 and	 low-grade	
inflammation	is	critical	to	the	aetiology	of	atherosclerosis	(Ross,	1999).		
	
In	 line	 with	 previous	 observations	 (Nakashima	 et	 al.,	 1994),	 Western	 diet	
induced	hyperlipidaemia	in	ApoE	-/-		mice.	Biochemical	analyses	of	serum	lipids,	
however,	 revealed	 no	 significant	 difference	 between	 groups	 at	 sacrifice.	 Thus,	
the	 effects	 of	 dyslipidaemia	 on	 potential	 between	 group	 differences	 in	
atherosclerosis	were	controlled	for	in	this	model.		
	
In	 my	 study,	 blood	 glucose	 profile	 data	 revealed	 lower	 mean	 fasting	 blood	
glucose	 values	 than	 obtained	 in	 an	 older	 study	 (Li	 et	 al.,	 2011).	 The	 latter	
investigated	hyperglycaemia	in	female	ApoE	-/-	C57BL/6J	mice	fed	a	Western	diet	
for	 12	 weeks.	 The	 authors	 performed	 insulin	 tolerance	 tests	 thereby	 yielding	












mice	 fed	 Western	 diet	 for	 6	 weeks	 and	 a	 lower	 body	 weight.	 However,	 one	
animal	 had	 irrecoverable	 hypoglycaemia	 and	 two	 out	 of	 three	 animals	 needed	







proof	 of	 hypoglycaemia	 and	 augmented	 observed	 physical	 findings	 of	 altered	
mouse	behaviour	suggestive	of	neuroglycopenia	in	hypoglycaemic	mice.	Further,	
as	 adrenaline	 levels	 were	measured	 after	 the	 third	 episode	 of	 hypoglycaemia,	
elevated	 levels	 suggested	 that	 the	 counter-regulatory	 response	 was	 still	
preserved	 despite	 recurrent	 relative	 hypoglycaemia	 in	 my	 model.	 Data	 in	
humans	 (Heller	 and	 Cryer,	 1991)	 and	 rodents	 (McNeilly	 et	 al.,	 2017)	




hypoglycaemia	 may	 aggravate	 atherosclerosis	 at	 least	 in	 part	 through	
sympathetic	mediated	activation	of	inflammatory	pathways	(Dutta	et	al.,	2012),	I	
wanted	 to	 avoid	 significant	 diminution	 of	 the	 sympathetic	 response	 to	
hypoglycaemia	in	my	model.	Further,	clinical	trials	of	intensive	glycaemic	control	
demonstrating	 an	 association	 between	 hypoglycaemia	 and	 CV	 risk	 were	
conducted	 in	 patients	 with	 T2D	 in	 whom	 the	 hypoglycaemia	 burden	 is	
significantly	 lower	than	in	those	with	T1D	(Donnelly	et	al.,	2005)	and	defective	




Rebound	 hyperglycaemia	 as	 a	 consequence	 of	 hypoglycaemia	 recovery	 was	
noted	 at	 120	minutes	 in	 the	 hypoglycaemia	 group	 of	mice	with	 blood	 glucose	
values	 being	 higher	 than	 fasting	 levels	 and	 significantly	 higher	 compared	 to	
controls.	 This	 limited	 my	 model	 as	 it	 was	 designed	 to	 study	 the	 effects	 of	
hypoglycaemia	 on	 atherosclerosis.	 Evidence	 from	 healthy	 humans	 and	 those	
with	T1D	suggests	that	hyperglycaemia	after	recovery	from	hypoglycaemia	can	
worsen	 endothelial	 dysfunction,	 increase	 oxidative	 stress	 and	 promote	
inflammation	(Ceriello	et	al.,	2012).	Further,	data	from	ApoE	-/-	mice	fed	maltose	
twice	 weekly	 with	 resultant	 repetitive	 postprandial	 hyperglycaemia	
demonstrated	 an	 increased	 adherence	 of	 macrophages	 to	 the	 vascular	
endothelium	and	an	increase	in	atherosclerotic	lesion	size	compared	to	controls	
(Mita	 et	 al.,	 2007).	 Collectively,	 therefore,	 fluctuations	 in	 blood	 glucose	 can	
influence	 inflammation	 and	 progression	 of	 atherosclerosis.	 Thus,	 as	 part	 of	
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not	 reveal	 a	 significant	 difference	 between	 hypoglycaemia	 and	 sham-saline.	
Total	 atherosclerotic	 lesion	 burden	 was,	 however,	 in	 line	 with	 published	 data	
from	 studies	 conducted	 locally	 using	 an	 identical	 strain	 of	 mice	 (West	 et	 al.,	
2014).	 A	 trend	 towards	 a	 lower	 total	 atherosclerotic	 burden	 in	 the	
hypoglycaemia	 group	 of	mice	 that	 received	 i.p.	 insulin	 compared	 to	 the	 sham-
saline	 group	 is	 of	 interest	 and	 could	 have	 been	 further	 explored	 by	 in-depth	
analysis	 of	 more	 robust	 histological	 endpoints	 as	 well	 as	 measurement	 of		
differences	in	plasma	cytokines	between	the	two	groups.	Insulin	has	been	shown	
to	 have	 a	 number	 of	 anti-inflammatory	 effects.	 Insulin	 via	 activation	 of	
phosphatidylinositol	kinase	(PI3K)	and	AkT	kinase,	 induces	NO	synthase	which	






infusion	 has	 been	 shown	 to	 significantly	 suppress	 TLRs	 1,2,4,7	 and	 9	 mRNA	
expression	in	mononuclear	cells	(Ghanim	et	al.,	2008).	TLRs	are	important	in	the	
pathophysiology	 of	 atherosclerosis	 as	 they	 induce	 inflammation	 through	
activation	of	a	number	of	pro-inflammatory	transcription	factors.	In	addition,	to	
dampening	 inflammatory	 indices,	 insulin	 has	 been	 shown	 to	 exert	 anti-
atherosclerotic	 effects.	 In	 the	 DCCT	 study,	 intensive	 insulin	 therapy	




in	 the	 DCCT	 group	 that	 had	 received	 intensive	 insulin	 therapy	 (Nathan	 et	 al.,	
2003).	Also,	in	experimental	animals,	ApoE-/-	mice	that	received	oral	insulin	had	
significantly	attenuated	atherosclerotic	plaque	progression	through	reduction	in	
serum	 and	macrophage	 oxidative	 stress	 (Shamir	 et	al.,	 2003).	 Conversely,	 in	 a	
mouse	 model	 where	 insulin	 signalling	 was	 disrupted	 through	 lack	 of	 insulin	
receptor	 substrate	 2,	 the	 vasculature	 was	 more	 susceptible	 to	 atherosclerosis	
(Kubota	 et	 al.,	 2003).	 In	 light	 of	 these	 data,	 a	 trend	 towards	 a	 lower	
atherosclerotic	 burden	 in	 mice	 subjected	 to	 recurrent	 insulin	 induced	




on	 endotoxin	 mediated	 inflammation.	 However,	 in	 humans	 a	 sufficient	




decided	 to	 extend	 the	 experiment	 duration	 to	 double	 the	 hypoglycaemic	
stimulus	 to	 a	 total	 of	 8	 episodes.	 To	 facilitate	 more	 readily	 a	 lower	
hypoglycaemic	 stimulus,	 I	 also	 elected	 to	 fast	 animals	 overnight	 to	 deplete	







One	 limitation	 is	 that	 I	did	not	specifically	 induce	diabetes	 in	my	mice	 through	
the	 use	 of	 streptozotocin	 for	 example	 and	 then	 insulin	 treat	 them	 to	 emulate	
more	 closely	 the	 T2D	 population	 studied	 in	 various	 clinical	 trials.	 It	 is	
conceivable	that	in	my	model,	in	atherosusceptible	animals,	high	fat	Western	diet	
for	 7	 weeks	 induced	 abnormal	 glucose	 tolerance,	 if	 not	 frank	 T2D,	 which	 has	
been	 observed	 in	 ApoE-/-	mice	 fed	Western	 diet	 for	 12	weeks	 (Li	 et	al.,	 2011).	
However,	 ethical	 constraints	 meant	 that	 I	 could	 not	 take	 more	 than	 10%	 of	
overall	 blood	 volume	 (approximately	 100	 μl)	 on	 any	 experimental	 day	 and	
therefore	 could	 not	 perform	oral	 glucose	 tolerance	 tests	 or	measure	HbA1c	 to	
confirm	this.	Furthermore,	in	aiming	to	test	the	effects	of	hypoglycaemia	on	the	
vasculature,	 induction	 of	 diabetes	 and	 then	 insulin	 treatment	 in	mice	 prior	 to	
superimposed	 recurrent	 relative	 hypoglycaemia	 would	 have	 added	 potential	
confounding	of	glucose	variability	between	mice	and	groups	which	would	have	
been	 difficult	 to	 control.	 Experiments	 would	 also	 be	 strengthened	 by	
measurement	 of	 insulin	 in	 all	 mice	 in	 addition	 to	 inflammatory	 cytokines,	
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additional	 counter-regulatory	 hormones	 including	 glucagon	 and	 circulating	
leukocytes	 including	 monocytes.	 Limits	 to	 blood	 letting	 in	 mice,	 however,	
precluded	this.	
	
In	 conclusion,	 over	 a	 number	 of	 optimisation	 steps,	 I	 successfully	 developed	 a	
novel	 murine	 model	 of	 recurrent	 relative	 hypoglycaemia	 and	 pre-established	




Chapter	 5-	 Consequences	 of	 recurrent	 hypoglycaemia	 on	




There	 is	 a	 growing	body	 of	 evidence	 linking	hypoglycaemia	with	 increased	CV	






have	 also	 suggested	 that	 confounding	 due	 to	 comorbidities	 may	 explain	 the	
relationship	between	hypoglycaemia	and	mortality	(Heller	et	al.,	2017;	Pieber	et	
al.,	 2018).	 Evidence	 for	 a	 causal	 relationship	 between	 hypoglycaemia	 and	 CV	
events	is	supported	by	systematic	reviews	that	have	included	a	large	number	of	
participants	 from	 observational	 studies	 and	 performed	 statistical	 analyses	 to	
account	for	confounding	from	comorbidities	(Goto	et	al.,	2013;	Yeh	et	al.,	2016).	
Further,	recent	human	experimental	medicine	studies	in	both	healthy	volunteers	
and	 those	 with	 diabetes	 have	 offered	 mechanisms	 that	 explain	 a	 relationship	






causal	 relationship	 between	 hypoglycaemia	 and	 CV	 events.	 Atherosclerotic	
lesion	 burden	 and	 plaque	 rupture	 is	 responsible	 for	 acute	 CV	 events	 and	 I	
therefore	 hypothesised	 that	 recurrent	 hypoglycaemia	 increases	 total	 plaque	
burden	 and	 causes	 inflammatory	 changes	 within	 the	 plaque	 that	 increase	 the	
risk	of	plaque	rupture.	In	order	to	test	this	hypothesis,	I	first	developed	a	mouse	
model	 of	 recurrent	 relative	 hypoglycaemia	 and	 atherosclerosis	 as	 described	 in	
chapter	 4.	 In	 this	 chapter,	 I	 describe	 experiments	 using	 my	 model	 to	 explore	








sham-saline	 injection	 (n=10).	 Each	 animal	 underwent	 8	 episodes	 of	 insulin	
induced	 hypoglycaemia	 or	 sham-saline	 injection	 over	 4	 consecutive	 weeks.		













One	 mouse	 was	 lost	 to	 irrecoverable	 hypoglycaemia	 on	 day	 1	 and	 week	 1	 of	
experiments.	Another	mouse	from	the	sham-saline	group	was	lost	to	a	laceration	
sustained	 from	 tail	 vein	 injury	within	 the	 first	week	 of	 experiments.	 Data	was	











groups	 displayed	 a	 positive	weight	 trajectory	 during	 feeding.	 The	 pre-sacrifice	




























Total	cholesterol	 28.8	±	2.3	 28.5	±	1.7	 0.928	
HDL	cholesterol	 8.0	±	0.5	 7.7	±	0.2	 0.560	
LDL	cholesterol	 19.9	±	2.0	 19.9	±	1.5	 0.988	






















Fasting	 blood	 glucose	 values	 were	 12.0	 ±	 0.18	 mmol/l	 in	 the	 hypoglycaemia	
group	vs.	12.0	±	0.2	mmol/l	in	the	sham-saline	group	(p	=	0.985).		Following	i.p.	
insulin,	blood	glucose	values	 fell	 to	a	 relative	hypoglycaemia	nadir	of	6.1	±	0.3	
mmol/l	 compared	 to	 13.4	 ±	 0.3	mmol/l	 in	 the	 sham-saline	 group	 (p	 <	 0.001)	







(n=9)	over	 a	4	weeks	 experiment	 in	Western	diet	 fed	ApoE	 -/-	mice.	Data	






















































































plaque	area	between	hypoglycaemia	and	 sham-saline	 groups.	Total	 lesion	area		
presented	as	a	percentage	of	 the	total	aortic	surface	area	 in	the	hypoglycaemia	
group	 was	 10.8	 ±	 0.9%	 vs.	 8.2	 ±	 0.8%	 in	 the	 sham-saline	 group	 (p	 =	 0.062)	
(Figure	 5.3	 A).	 In	 order	 to	 assess	 regional	 differences	 in	 atheroma	 formation,	
lesion	analysis	was	performed	in	aortic	arch	and	descending	aorta.	There	were	
no	significant	differences	between	groups	at	these	sites.	Aortic	arch	lesion	area	
in	 the	 hypoglycaemia	 group	 was	 22.4	 ±	 2.8%	 vs.	 19.3	 ±	 1.8%	 in	 sham-saline	
controls	 (p	=	0.380)(Figure	5.3	B).	Descending	aortic	analyses	showed	a	 lesion	





















































































































































plaque	 formation	 in	 hypoglycaemia	 and	 sham-saline	 groups.	 B)	 Plaque	
area	 expressed	 as	 a	 percentage	 of	 the	 total	 vessel	 CSA	 in	 hypoglycaemia	



































a	percentage	of	positive	 staining	over	 total	brachiocephalic	 lesion	area	did	not	





Figure	 5-5	 Macrophage	 staining	 positive	 for	 MAC-3	 in	 cross	 sections	 of	
brachiocephalic	arteries.	A)	Representative	images	demonstrating	positive	
immunohistochemical	staining	 in	hypoglycaemia	and	sham-saline	groups.	






































moderate	 relative	 hypoglycaemia	 and	 aggravation	 of	 pre-established	
atherosclerosis	 in	 a	 combined	 murine	 model.	 My	 main	 findings	 are	 that	
compared	 to	 sham-saline	 controls:	 (1)	 hypoglycaemia	 resulted	 in	 a	 trend	
towards	 increased	 atherosclerotic	 lesion	 burden	 in	 oil	 red	 O	 stained	 whole	




Whilst	 completing	my	 studies,	 Nakajima	 et	 al.	 published	 data	 using	 their	 own	
combined	model	 of	 recurrent	 hypoglycaemia	 in	ApoE	 -/-	mice	 (Nakajima	 et	al.,	
2015).	The	latter	studied	the	effects	of	repetitive	hyperglycaemia,	hypoglycaemia	
and	control	conditions	on	the	progression	of	atherosclerosis	in	multiple	groups	
of	 ApoE	 -/-	mice	 on	 a	 C57BL/6J	 background.	 The	 authors	 found	 that	 recurrent	
hypoglycaemia,	 hyperglycaemia	 or	 their	 combination	 did	 not	 increase	 total	
atherosclerotic	lesion	burden	quantified	by	oil	red	O	staining	at	the	aortic	sinus	
and	whole	aortae	(Nakajima	et	al.,	2015).	These	findings	are	broadly	in	keeping	
with	 my	 own	 data	 that	 overall,	 repetitive	 relative	 hypoglycaemia	 had	 no	
statistically	 significant	 impact	 on	 atherosclerosis.	 Methodologically,	 my	 model	
differed	 from	 the	 Nakajima	 study.	 Nakajima	 and	 colleagues	 studied	 a	 larger	
number	of	mice	 (n=22	vs.	n=10)	over	a	 longer	period	 (15	weeks	vs.	4	weeks),	
used	 far	 higher	 doses	 of	 insulin	 (8	 IU/kg	 vs.	 2.5-3.7	 IU/kg)	 and	 fed	 animals	 a	




mouse	 survivability	 in	 their	 model	 with	 a	 loss	 of	 20%	 of	 animals	 in	 the	
hypoglycaemia	group.	The	authors	do	not	mention	 rescue	glucose	 therapy	and	
infrequently	 measured	 blood	 glucose	 suggesting	 that	 a	 significant	 number	 of	
animals	were	lost	to	severe	hypoglycaemia.	Further,	as	a	high	dose	of	i.p.	insulin	
was	 given	 once	 a	 week	 over	 15	 weeks,	 it	 is	 plausible	 that	 mice	 became	
increasingly	 vulnerable	 on	 account	 of	 developing	 defective	 counter-regulation.	
Surprisingly,	 however,	 the	 authors	 did	 not	 measure	 counter-regulatory	
hormones	to	assess	this.	Overall,	it	is	likely	that	in	the	Nakajima	model,	chronic	
hyperinsulinaemia	 resulted	 in	 reduced	 atherogenesis,	 thus	 opposing	 any	 pro-




was	 not	 sufficient	 to	 overcome	 known	 anti-inflammatory	 and	 anti-atherogenic	
effects	 of	 insulin	 as	 previously	 described.	 This	 is	 supported	 by	 an	 increase	 in	




episodes	appears	 to	have	also	 reversed	 the	 trend	where	 I	previously	observed	
higher	 atheroma	 formation	 at	 the	 aorta	 in	 the	 sham-saline	 groups	 vs.	
hypoglycaemia	 (Figure	 4.8,	 chapter	 4).	 	 In	 both	 experiments,	 identical	ApoE	 -/-
mice	were	fed	Western	diet	for	7	weeks	and	had	comparable	body	weights,	lipid	
profile	 and	 hypoglycaemic	 nadirs.	 Thus,	 it	 may	 be	 that	 to	 assess	 more	
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episodes	 of	 the	 same	 severity	 reduced	 the	peak	 adrenaline	 response	 to	 3.87	±	
1.01	nmol/l	as	described	in	this	chapter	compared	to	4.92	±	1.22	nmol/l	in	mice	
described	 in	 chapter	 4.	 Overall,	 the	 magnitude	 of	 effect	 of	 recurrent	 relative	
hypoglycaemia	vs.	sham-saline	injection	on	atherosclerotic	lesion	burden	at	the	




Whilst	 total	 lesion	area	appeared	to	 increase	at	 the	aorta	 in	the	hypoglycaemia	
group,	there	was	no	difference	or	suggestion	of	a	trend	in	atherosclerotic	lesion	
burden	 between	 groups	 in	 MVG	 stained	 cross	 sections	 of	 brachiocephalic	
arteries.	 Whilst	 little	 is	 known	 about	 the	 effects	 of	 hypoglycaemia	 on	
atherosclerosis	at	regional	sites	in	the	vasculature,	there	are	data	to	suggest	that	




the	 effect	 of	 hypoglycaemia	 on	 atheroma	 formation.	 Initially,	 however,	 future	
work	 needs	 to	 investigate	 the	 effects	 of	 recurrent	 hypoglycaemia	 on	 lesion	
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consistent	with	 clinical	 experience,	 trial	 data	 and	 human	 experimental	 studies	
that	have	studied	the	relationship	between	hypoglycaemia	and	CV	risk.	In	clinical	
practice,	 hypoglycaemia	 is	 relatively	 commonly	 encountered,	 yet	 CV	mortality	
following	a	few	episodes	is,	thankfully,	rare.	Further,	clinical	studies	suggest	that	
hypoglycaemia	may	serve	 to	 increase	CV	risk	 longitudinally	over	many	months	
(Duckworth	et	al.,	2009;	Pieber	et	al.,	2018).	Also,	as	I	show	in	chapter	3	(Iqbal	et	
al.,	2019),	hypoglycaemia	induces	relatively	transient	pro-inflammatory	and	pro-
atherothrombotic	 changes	 that	 are	 likely	 consequent	 upon	 sympatho-adrenal	
activation,	 whilst	 the	 innate	 immune	 system	may	 be	 primed	 to	 respond	more	
robustly	in	a	durable	fashion.	It	then	follows	that	the	catecholamine	response	to	
episodes	 of	 acute	 relative	 hypoglycaemia	 in	 ApoE	 -/-	mice	may	 have	mobilised	
monocytes	 and	 thus	 transiently	 increased	monocyte/macrophage	 traffic	 to	 the	
plaque	with	a	decline	back	to	baseline	levels	in	between	repeated	episodes.	Thus,	
this	 relatively	 brief	 experiment	 may	 not	 have	 captured	 an	 increase	 in	 plaque	
macrophage	numbers	that	may	occur	insidiously	over	several	weeks	to	months	
and	cumulatively	increase	the	risk	of	plaque	instability	and	AMI	as	clinical	data	
suggests.	 This	 hypothesis	 could	 be	 tested	 in	 further	 work	 by	 prolonging	 the	
duration	 of	 experiments	 or	 looking	 at	 immediate	 acute	monocyte	 recruitment	
after	 episodes	 of	 hypoglycaemia.	 Since	 it	 has	 also	 been	 shown	 that	 in	 ApoE	 -/-	
mice	 extramedullary	 haematopoiesis	 plays	 a	 role	 in	 chronic	
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monocyte/macrophage	 accumulation	 in	 plaques	weeks	 after	 events	 associated	
with	 significant	 systemic	 stress	 and	 sympatho-adrenal	 activation	 (Dutta	 et	 al.,	
2012),	current	experiments	would	have	been	strengthened	by	harvesting	mouse	
spleens	 for	 flow	 cytometric	 analyses	 of	 progenitor	 cells.	 In	 addition,	 as	
extramedullary	haematopoiesis	generates	pro-inflammatory	Ly-6chigh	monocytes	




assess	 for	molecular	signals	of	activation	 for	example	 through	quantification	of	




hypoglycaemia	 and	 aggravation	 of	 atherosclerosis,	 I	 was	 able	 to	 quantify	 the	
extent	 and	 inflammatory	 burden	 of	 the	 atherosclerotic	 plaque	 in	 my	 murine	
model.	Whilst	there	was	a	suggestion	of	accelerated	atherosclerosis	at	the	aorta	
in	the	hypoglycaemia	group,	one	 limitation	was	the	 lack	of	statistical	power.	 In	
addition,	due	 to	 time	constraints,	 lesion	burden	was	only	assessed	at	 two	sites	
and	the	aortic	sinus	not	studied.	Also,	smooth	muscle	and	collagen	content	and	
markers	 of	 plaque	 vulnerability	 including	 neovascularisation,	 buried	 cap	







The	early	 termination	of	 the	ACCORD	trial	 (Gerstein	et	al.,	2008)	on	account	of	
increased	mortality	in	the	intensive	glycaemic	treatment	arm	provoked	interest	
and	 fuelled	 debate	 in	 understanding	 a	 potential	 relationship	 between	
hypoglycaemia	 and	 adverse	 CV	 events.	 There	 was	 existing	 data	 from	 human	
studies	 that	 demonstrated	 hypoglycaemia	 exerted	 pro-inflammatory,	 pro-
atherothrombotic	 and	arrhythmogenic	 effects.	These	 studies,	however,	 ignored	
the	 effects	 of	 hypoglycaemia	 on	 monocyte	 mobilisation,	 activation	 and	
monocyte-platelet	interactions	all	of	which	are	important	in	the	pathophysiology	
of	acute	CV	events.	Further,	longer	lasting	effects	of	hypoglycaemia	on	the	innate	
immune	 system	 that	 could	 serve	 to	 increase	 CV	 risk	 had	 not	 been	 performed.	
Another	 issue	 was	 that	 cause	 and	 effect	 had	 not	 been	 demonstrated	 between	
hypoglycaemia	and	CV	risk	with	ethical	 limitations	preventing	experimentation	
in	 humans	 that	 would	 yield	 these	 data.	 This	 has	 led	 some	 to	 argue	 that	
hypoglycaemia	 is	 simply	 a	 risk	marker	 for	 susceptibility	 to	 adverse	 outcomes,	
including	 CV	 events,	 as	 it	 is	 more	 frequently	 encountered	 in	 those	 with	
underlying	severe	comorbid	illnesses.	
	
With	 existing	 deficiencies	 in	 the	 literature	 in	 mind,	 in	 this	 thesis	 I	 set	 out	 to	
investigate	mechanisms	through	which	hypoglycaemia	could	increase	CV	risk.		I	
developed	 a	 novel	 human	 experimental	model	 of	 combined	 hyperinsulinaemic	
hypoglycaemic,	euglycaemic	and	sham-saline	clamps	with	low	dose	intravenous	








In	 this	 chapter	 I	 will	 describe	 the	 key	 findings	 from	 both	 human	 and	murine	






moderate	 hypoglycaemia	 lasting	 60	 minutes	 in	 healthy	 volunteers:	 mobilised	
monocytes	 with	 preferential	 mobilisation	 of	 CD16+	 pro-inflammatory	 subsets,	
increased	 platelet	 reactivity,	 encouraged	 formation	 of	 MPAs	 between	 pro-
inflammatory	 monocytes	 and	 platelets	 and	 resulted	 in	 a	 significantly	 higher	
leukocyte	response	to	low	dose	endotoxin	challenge	48	hours	later.	
	
I	 showed	 for	 the	 first	 time	 that	 hypoglycaemia	 mobilises	 pro-inflammatory	
subsets	 of	 monocytes.	 This	 adds	 to	 the	 existing	 paradigm	 that	 an	 acute	
leukocytosis	 ensues	 following	 hypoglycaemia	 and	 is	 likely	 consequent	 upon	
sympatho-adrenal	 activation.	 I	 postulate	 that	 the	 catecholamine	 response	 to	
hypoglycaemia	 mobilises	 CD16+	monocytes	 from	 the	 marginal	 pool	 and	 these	
cells	were	preferentially	mobilised	on	account	of	either	richer	β2	adrenoreceptor	
expression	 or	 by	 being	 particularly	 sensitive	 to	 modulation	 through	




in	 response	 to	 the	 adrenergic	 stress	 of	 acute	 exercise	 but	 fails	 to	 inhibit	 CM	
mobilisation	 (Graff	 et	 al.,	 2018).	 Also,	 quantifying	 expression	 of	 β2	
adrenoreceptors	 on	 the	 three	 different	 monocyte	 subsets	 under	 steady	 state	
conditions	 and	 following	 adrenergic	 stress	 would	 provide	 data	 to	 test	 my	





in	 CD16	 expression	 on	 peripheral	 blood	 mononuclear	 cells	 following	
hypoglycaemia	which	is	complementary	with	my	own	findings,	but	they	did	not	
phenotype	 and	 enumerate	 distinct	 monocyte	 subsets.	 The	 authors	 also	
demonstrated	 that	pro-inflammatory	 leukocyte	mobilisation	was	diminished	 in	
those	 with	 T1D	 and	 impaired	 awareness	 of	 hypoglycaemia	 highlighting	 that	
counter-regulatory	 hormones	 modulate	 these	 changes.	 The	 same	 group	 have	
also	 in	 a	 subsequent	 publication	 demonstrated	 that	 hypoglycaemia	 mobilises	
NCM	 in	 those	 with	 T1D	 (Ratter	 et	 al.,	 2018).	 These	 data,	 have	 therefore,	
reproduced	 and	 confirmed	 my	 original	 finding	 in	 healthy	 volunteers	 in	 those	
with	T1D.	
	
A	 consistent	 picture	 is	 now	 therefore	 emerging	 that	 hypoglycaemia	 mobilises	
pro-inflammatory	 monocyte	 subsets	 and	 that	 this	 may	 increase	 CV	 risk.	
However,	 it	 is	 well	 known	 that	 the	 adrenergic	 stress	 of	 exercise	 also	




increase	 following	 hypoglycaemia	 including:	 platelet	 activation,	 endothelial	
dysfunction,	 pro-inflammatory	 cytokines	 and	 selectin	 release	 are	 also	 elevated	
following	 acute	 strenuous	 exercise	 in	 those	 without	 diabetes	 (Cwikiel	 et	 al.,	
2018).	 The	 beneficial	 cardioprotective	 and	 anti-atherogenic	 effects	 of	 exercise	
are	however,	well	established.	 In	understanding	 this	paradox	 it	 is	 important	 to	
revisit	 clinical	 trial	 data	 that	 suggest	 that	 in	 those	 with	 low	 atherosclerotic	
burden,	 intensive	 glycaemic	 control	 had	 potentially	 favourable	 effects	 in	
comparison	 to	 those	 that	 had	 a	 high	 CV	 disease	 burden	 where	 intensive	
glycaemic	control	was	deleterious	(Reaven	et	al.,	2009).	It	is	therefore	plausible	
that	pro-inflammatory	monocyte	mobilisation	and	activation	in	those	with	little	
or	 no	 CAD	 serves	 as	 a	 normal	 physiological	 response	 to	 adrenergic	 stress	 in	





I	 found	 that	 platelets	 are	 activated	 following	 hypoglycaemia	 and	 that	 they	
interact	 more	 readily	 with	 monocytes	 to	 form	 MPAs.	 Further,	 I	 showed	 that	









1997;	Martins	 et	 al.,	 2006).	 Preferential	 formation	 of	 CD16+	monocyte	 specific	
MPA	following	hypoglycaemia	is	a	novel	and	important	finding	given	these	have	
shown	to	be	elevated	post	STEMI	(Zhou	et	al.,	2016).	My	observation	is	at	least	in	
part	 due	 to	 a	 higher	 NCM	 and	 IM	 counts	 that	 were	 observed	 following	
hypoglycaemia,	 but	 also	 likely	 highlights	 the	 higher	 inflammatory	 potential	 of	
these	 subsets	 expressed	 as	 increased	 interaction	 with	 platelets	 under	
hypoglycaemic	 conditions.	 MPA	 formation	 following	 hypoglycaemia	 also	
demonstrates	 that	 both	 inflammatory	 and	 thrombotic	 pathways	 are	 activated	
creating	 a	 pro-atherogenic	 ensemble.	 Given	 that	 P2Y12	 antagonism	 using	
clopidogrel	and	ticagrelor	significantly	reduces	MPA	formation	(M.	R.	Thomas	et	
al.,	 2015)	 these	 complexes	 maybe	 an	 important	 future	 target	 in	 mitigating	
hypoglycaemia	 associated	 CV	 risk.	 As	 a	 first	 step	 however,	 future	 studies	 of	




resulted	 in	greater	 leukocyte	mobilisation	 in	response	 to	 low	dose	 intravenous	
endotoxin	 challenge	 2	 days	 later.	 Hypoglycaemia	 thus	 appeared	 to	 prime	 the	
innate	 immune	 system	 and	 exerted	 durable	 effects.	 This	 finding	 is	 clinically	








in	 fact	 very	 similar	 between	 sham-saline	 controls	 that	 received	 no	 insulin	 and	
the	hyperinsulinaemic-hypoglycaemia	group.	Importantly,	insulin	exposure	was	
matched	 between	 hypoglycaemia	 and	 euglycaemia	 groups.	 There	 are	 two	
important	conclusions	that	can	be	drawn	from	this	finding.		First,	consistent	with	
known	 anti-inflammatory	 effects	 of	 insulin	 that	 I	 have	 previously	 described	
(chapters	 1,	 2,	 3	 and	 discussion	 chapter	 4)	 hyperinsulinaemic-euglycaemia	
suppressed	 leukocyte	 mobilisation	 upon	 classical	 stimulation	 of	 the	 innate	
immune	 system	with	 endotoxin	 challenge	 48	 hours	 later.	 Hypoglycaemia	was,	
however,	 able	 to	 abolish	 these	 anti-inflammatory	 effects	 and	 resulted	 in	 a	
leukocyte	 response	 on	 endotoxin	 challenge	 that	was	 comparable	 to	 those	 that	
had	no	prior	insulin	exposure	(sham-saline	group).	Secondly,	counter-regulatory	
hormones	 did	 not	 differ	 significantly	 between	 groups	 following	 endotoxin	
challenge	 and	 thus	 differences	 in	 leukocyte	 mobilisation	 were	 independent	 of	
this.	 This	 raises	 important	 questions	 as	 to	 how	 a	 single	 episode	 of	 moderate	
hypoglycaemia	modulates	the	immune	system	to	respond	more	robustly	2	days	
later.	 It	 is	 known	 that	 tissue	 exposure	 to	 chronic	hyperglycaemia	 can	 result	 in	
epigenetic	modifications	which	result	 in	persistent	vascular	complications	even	
if	 current	 glucose	 control	 is	 optimised	 (Keating	 et	 al.,	 2018).	 Thus,	
hypoglycaemia	may	 exert	 a	 variety	 of	 short-term	 effects	 on	 bone	marrow	 cell	
production	 rates,	 intracellular	 signalling	 and	 sensitivity	 to	 or	 resistance	 to	
endotoxin	 signalling,	 and	 potential	 long-term	 changes	 in	 cellular	 function	







cohort	was	 not	 representative	 of	 those	 studied	 in	 trials	 of	 intensive	 glycaemic	
control	and	also	limits	the	applicability	of	my	findings	to	older	people	with	T1D	
or	 T2D	 and	 atherosclerosis.	 I	 was	 cognisant	 of	 this	 when	 designing	 my	
experiments,	however,	 I	wanted	to	safely	establish	my	hitherto	untested	model	
of	combined	hypoglycaemia	and	endotoxin	challenge	in	healthy	volunteers	first.	I	
also	 chose	 the	 lowest	 possible	 dose	 of	 intravenous	 endotoxin	 that	would	 yield	
sufficient	stimulation	of	the	innate	immune	system.	This	allows	me	to	seamlessly	
test	my	model	in	older	and	more	vulnerable	people	with	diabetes	in	the	future.	
Arguably,	 having	 three	 independent	 parallel	 groups	 is	 also	 a	 limitation	 in	 my	
study	 design	 as	 considerable	 heterogeneity	 can	 exist	 between	 individuals.	 A	
more	 robust	 model	 would	 involve	 each	 subject	 undergoing	 three	 separate	
clamps	 studies	 (hypoglycaemia,	 euglycaemia	 and	 sham-saline)	 followed	 by	 an	
endotoxin	challenge	2	days	later	on	each	occasion	with	in-built	washout	periods	
of	at	least	2	weeks.	Using	this	approach,	each	subject	would	thus	act	as	their	own	
control	 minimising	 the	 effects	 of	 inter-individual	 variability.	 I	 deemed	 this	
design,	 however,	 to	 be	 neither	 practical	 given	 time	 constraints	 nor	 ethically	
acceptable	given	the	high	experimental	burden	for	each	subject.	
	
In	 addition	 to	 signalling	 via	 β2	 adrenoreceptors,	 adrenaline	 also	 promotes	
monocyte	demargination	 from	 the	vascular	endothelium,	mostly	 likely	 through	
modulating	CD11a	and	CX3CR1	mediated	adhesion	to	the	vessel	wall	(Dimitrov,	
Lange	 and	 Born,	 2010).	 I	 quantified	 CX3CR1	 and	 CD11b	 expressions	 on	









2017).	 Further,	 I	 would	 have	 wished	 to	 probe	 deeper	 the	 effects	 of	
hypoglycaemia	 on	 the	 inflammatory	 potential	 of	 monocytes.	 This	 could	 have	
been	 explored	 by	 monocyte	 purification	 following	 clamp	 and	 endotoxin	
challenge	 and	 study	 of	 MMP,	 IL-1β,	 and	 IL-1ra	 protein	 expression	 and	 IL-1β	
processing	 using	 qPCR	 and	 Western	 blotting.	 Finally,	 fate-mapping	 of	 human	
monocyte	subsets	in	my	model	by	using	in	vivo	deuterium	labelling	for	example	







in	 ApoE	 -/-	 mice	 fed	 a	 high	 fat	 Western	 diet.	 Whilst	 developing	 my	 model,	 I	
elected	 to	 study	 male	 mice	 given	 observed	 sex	 differences	 in	 the	 glucose	
response	to	insulin.	I	then	established	a	safe	insulin	dose	range	in	Western	diet	





serum	lipids	between	groups.	 Importantly,	 I	also	proved	biochemically	 that	my	
hypoglycaemic	stimulus	was	sufficient	to	induce	a	catecholamine	response	in	my	
chosen	 strain.	 I	 noted	 rebound	 hyperglycaemia	 following	 recovery	 from	
hypoglycaemia	 in	 mice.	 I	 recognised	 this	 as	 a	 potential	 confounder	 given		
glycaemic	 flux	 	 from	 hypoglycaemia	 to	 hyperglycaemia	 in	 humans	 has	 been	
shown	to	worsen	endothelial	dysfunction	and	activate	thrombosis	(Ceriello	et	al.,	
2012).	In	a	further	refinement,	I	avoided	this	when	definitively	testing	my	model	
(chapter	 5).	 Exploratory	 assessment	 of	 atherosclerotic	 burden	 at	 the	 aorta	
during	 model	 development	 demonstrated	 no	 difference	 in	 atherosclerosis	
between	 groups	 and	 a	 higher	 lesion	 burden	was	 noted	 in	 the	 control	 group.	 I	
reasoned	 that	observed	results	may	have	been	a	consequence	of	 the	burden	of	
hypoglycaemia	 not	 being	 sufficient	 to	 counter	 anti-atherogenic	 effects	 of	
hyperinsulinaemia.	 In	 further	 development,	 I	 therefore	 elected	 to	 double	 the	
hypoglycaemic	exposure	from	4	to	8	episodes	as	described	in	chapter	5.	To	my	
knowledge,	 I	 was	 able	 to	 develop	 for	 the	 first	 time	 a	 model	 of	 recurrent	
hypoglycaemia	 with	 established	 atherosclerotic	 plaque	 formation	 and	 a	 high	
level	of	animal	survivability.	One	strength	of	my	model	is	that	it	 is	amenable	to	
modifications	 including	 increasing	 or	 decreasing	 the	 burden	 and	 severity	 of	
hypoglycaemia	and	atherosclerotic	lesion	burden.	This	model	can	be	developed	
further	 and	 serve	 as	 a	 foundation	 for	 work	 exploring	 causality	 between	
hypoglycaemia	and	atherosclerosis.	
	
In	 the	 second	phase	of	 animal	 experiments	 (chapter	5),	 I	 employed	my	mouse	





resulted	 in	a	 trend	 towards	higher	atherosclerotic	burden	at	 the	aorta,	but	did	





to	 enable	 me	 to	 draw	 any	 definitive	 conclusions.	 A	 published	 study	 has	 also	
reported	no	effect	of	recurrent	hypoglycaemia	on	plaque	burden	in	ApoE	-/-mice	
(Nakajima	et	al.,	2015).	As	discussed	in	chapter	5,	however,	the	high	insulin	dose,	





controls.	 It	 is	 tempting	 to	 hypothesise	 that	 hypoglycaemia	 may	 preferentially	
promote	 atheroma	 formation	 at	 some	 sites	 over	 others	 on	 account	 of	 local	
factors	 consequent	 upon	 haemodynamic	 and	 flow	 patterns	 in	 vascular	 beds.		
However,	prior	to	exploring	potential	regional	variation,	it	is	imperative	to	first	
explore	the	effects	of	hypoglycaemia	on	lesion	burden	at	the	aortic	sinus	which	I	








be	 out	 of	 keeping	 with	 clinical	 data	 in	 humans.	 I	 postulate	 that	 the	 effects	 of	
hypoglycaemia	in	modulating	the	inflammatory	phenotype	of	the	plaque	may	not	
have	been	captured	over	the	relatively	short	course	of	my	experiments	and	that	
cumulative	 exposure	 to	 repeated	 episodes	 of	 hypoglycaemia	 over	 a	 longer	
period	would	 definitively	 test	 this.	 Overall,	whilst	 suggesting	 emerging	 trends,	





One	major	 limitation	 of	 my	 animal	 model	 was	 the	 lack	 of	 sufficient	 power	 to	
enable	 me	 to	 test	 my	 hypothesis	 more	 robustly.	 Whilst	 statistical	 power	
appeared	to	just	fall	short	of	significance	for	some	data,	having	had	more	animals	
in	each	group	would	have	certainly	strengthened	the	study.	The	primary	reason	




time	 point.	 I	 wanted	 to	 ensure	 mice	 were	 exposed	 to	 repeated	 episodes	 of	
hypoglycaemia	 over	 a	 number	 of	 weeks	 but	 also	 had	 to	 balance	 this	 with	 the	
severity	 of	 protocol	 allowed	 on	 the	 licence	 and	 ethical	 limits	 to	 the	 frequency	
and	volume	of	blood	sampling.	This	alongside	side	practical,	monetary	and	time	






A	more	 fundamental	 limitation	of	animal	experimentation	 is	 its	applicability	 to	
humans	given	known	differences	in	biology	between	man	and	mouse.	Even	with	
best	efforts	to	mimic	human	disease,	data	yielded	from	animal	experimentation	
is	 open	 to	 question	 in	 its	 applicability	 to	 humans.	 There	 are	 also	 inherent	
differences	in	atherosclerosis	and	CV	physiology	between	these	species.	ApoE	-/-	
mice	 unlike	 humans	 for	 example	 rarely	 develop	 plaques	 within	 the	 coronary	
arteries	 (Nakashima	 et	 al.,	 1994).	 In	 addition,	 elevated	 heart	 rate	 and	 diurnal	
heart	 rate	 variation	 are	 both	 associated	with	 atherosclerotic	 plaque	 formation	
(Bassiouny	et	al.,	2002)	and	 in	a	C57BL/6	mouse	the	average	heart	rate	 is	550	
beats	per	minute	compared	 to	70	 in	an	average	human	(Tiemann	et	al.,	2003).	
Despite	 the	 challenges	 of	 recapitulating	 human	 disease	 in	 animal	 models	 and	














fat	 from	 the	 outer	 vessel	 wall	 of	 all	 specimens	 as	 described	 in	 chapter	 2,	
invariably	some	tissue	may	have	adhered	to	the	vessels.	As	I	quantified	atheroma	
in	all	vessels	relative	to	the	total	vessel	area,	residual	fat	on	certain	vessels	could	
have	 influenced	 results.	 Thus,	 this	 method	 of	 lesion	 assessment	 is	 somewhat	
crude.	Being	aware	of	this,	and	also	of	the	potential	for	introduction	of	bias,	I	had	
my	histological	data	for	oil	red	O	stained	aortae	analysed	by	a	colleague	blinded	






the	 field	 through	 parallel	 human	 and	 animal	 experimentation	 which	 I	 will	
discuss	below.	Some	of	the	described	work	is	along	themes	that	are	going	to	be	
explored	 in	 the	 Innovate	 Medicine	 Initiative	 (IMI)	 funded	 ‘Hypoglycaemia	
redefining	 solutions	 for	 better	 lives’	 (Hypo-RESOLVE)	 project	 (https://hypo-




I	 and	 other	 have	 demonstrated	 that	 acute	 hypoglycaemia	 can	 mobilise	 pro-
inflammatory	 leukocyte	 subsets	 in	 healthy	 volunteers	 and	 those	 with	 T1D	
(Ratter	et	al.,	2017,	2018;	 Iqbal	et	al.,	2019).	 I	also	showed	that	hypoglycaemia	
activates	 the	 immune	 system	 for	 at	 least	 2	 days	 where	 the	 acute	 adrenergic	
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stress	 from	 the	 initial	 episode	 in	not	 implicated	 (chapter	3)(Iqbal	et	al.,	 2019).	
Whilst	 circulating	 cell	 kinetics	 have	 been	 studied,	 deeper	 effects	 of	
hypoglycaemia	on	the	pro-inflammatory	and	thus	pro-atherosclerotic	properties	




in	 the	 absence	 of	 established	 CVD	 or	 significant	 CV	 risk	 factors.	 By	 employing	
hyperinsulinaemic	 hypoglycaemic	 (2.5	 mmol/l)	 and	 euglycaemic	 clamps	 (6.0	
mmol/l),	one	could	first	enumerate	and	phenotype	monocytes,	T	cells,	NK,	NKT	
and	monocyte	subset	specific	MPAs	 in	 this	cohort	 to	confirm	or	refute	 findings	
existing	 findings.	 To	 explore	 the	 impact	 of	 hypoglycaemia	 on	 inflammatory	
potential,	 it	will	 then	be	 important	 to	 isolate	monocytes	 immediately	 following	
clamp	 and	 7	 and	 30	 days	 later	 to	 probe	 longitudinal	 effects.	 One	 could	 then	
examine	the	impact	of	hypoglycaemia	on	monocytes	by	assessing	ex	vivo	the	pro-
inflammatory	 cytokine	 response	 (TNF-α,	 IL-1β,	 IL-1ra,	 sCX3CL1	 and	 CCL2)	 to	
LPS	stimulation.	Further,	it	will	be	important	to	prepare	isolated	monocytes	for	
RNA	 sequencing	 of	 pro-inflammatory	 genes	 (IL-1β,	 MMP)	 and	 epigenetic	
analysis	 (DNA	 methylation	 and	 histone	 acetylation).	 In	 addition	 to	 focus	 on	
monocytes,	 another	 interesting	 angle	would	 be	 to	 examine	 both	 the	 short	 and	
medium	 term	 effects	 of	 hypoglycaemia	 on	 circulating	 progenitor	 cells	 that	
contribute	to	plaque	structure.	Circulating	haematopoietic	stem	cells	for	example	





If	 one	 of	 the	mechanisms	 through	which	 hypoglycaemia	 does	 indeed	 promote	
atherosclerosis	 is	 the	 cumulative	 and	 chronic	 traffic	 of	 pro-inflammatory	
monocytes	 to	 the	 atherosclerotic	 plaque,	 then	 what	 potential	 therapeutic	
strategies	can	be	employed	to	mitigate	this?	In	translating	this	body	of	work	for	
future	 patient	 benefit,	 two	 potential	 therapeutic	 strategies	 could	 be	 explored.	
First,	 pro-inflammatory	 NCMs	 and	 IMs	 have	 a	 unique	 CX3CR1high	 CCR2low	
chemokine	receptor	profile.	CCR2	plays	an	integral	role	in	monocyte	egress	from	
the	 bone	 marrow,	 recruitment	 to	 atherosclerotic	 lesions	 (Zernecke,	
Shagdarsuren	and	Weber,	2008)	and	CCR2	gene	deletion	in	a	double	knock-out	
mouse	 model	 has	 delayed	 atherosclerotic	 lesion	 progression	 (Boring	 et	 al.,	
1998).	 Thus,	 modulating	 the	 CCL2-CCR2	 axis	 maybe	 an	 appealing	 target	 in	
potentially	 reducing	 hypoglycaemia	 associated	 CV	 risk.	 An	 oral	 antagonist	 to	
CCR2	has	been	tested	in	human	patients	with	rheumatoid	arthritis	(Vergunst	et	
al.,	 2008).	Whilst	 the	 results	 were	 disappointing	 in	 rheumatoid	 disease,	 there	
maybe	 merit	 in	 exploring	 this	 avenue	 in	 those	 with	 diabetes,	 CVD	 and	 a	
propensity	 to	 recurrent	 hypoglycaemia.	 As	 diabetes	 is	 a	 chronic	 condition	 and	





As	 pro-inflammatory	 leukocyte	 subsets	 are	 likely	mobilised	 via	 the	 adrenergic	
stress	associated	with	hypoglycaemia,	beta	blockade	could	inhibit	this	effect.	As	
demargination	of	CD16+	cells	is	primarily	mediated	through	β2	adrenoreceptors	
(Graff	 et	 al.,	 2018)	 a	 non-specific	 beta	 blocker	 such	 as	 nadolol	 or	 propranolol	
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would	 need	 to	 be	 used.	 Also	 as	 an	 additional	 potential	 mechanism	 linking	
hypoglycaemia	 and	 CV	 risk	 is	 related	 to	 haemodynamic	 changes	 and	
tachyarrhythmias	 as	 described	 in	 chapter	 1,	 combined	 β1	 and	 β2	 blockade	
would	potentially	 target	 two	distinct	 risk	 factors.	 Indeed,	 combined	β1	 and	β2	
blockade	has	been	shown	to	reduce	 lethal	cardiac	arrhythmias	 in	rats	(Reno	et	
al.,	2013),	although	the	hypoglycaemic	stimulus	in	this	study	was	extreme	(<	1.0	
mmol/l)	 and	 not	 commonly	 encountered	 in	 humans.	 It	 seems	 somewhat	
counterintuitive,	however,	 to	consider	at	 least	combined	beta	blockers	 in	those	
already	 at	 risk	 of	 hypoglycaemia	 as	 these	 agents	 are	 known	 to	 impair	
glycogenesis,	 gluconeogenesis	 and	 lipolysis	 thus	 prolong	 and	 enhance	
hypoglycaemia	 (Mills	 and	 Horn,	 1985).	 The	 answer	 could	 lie	 in	 the	 use	 of	
selective	blockade	of	β1	adrenoreceptors	by	using	agents	such	as	bisoprolol	for	










In	 order	 to	 examine	 the	 relationship	 between	 hypoglycaemia	 and	 CV	 events	 a	
more	 complete	 and	 robust	 animal	 model	 is	 required.	 Building	 on	 my	 model,	





by	 using	 standard	 insulin	 release	 implant	 (Linplant)	 mice	 could	 be	 insulin	




of	 CV	 function	 including	 telemetry	 and	 endothelial	 function	 assessed	 by	 flow	
mediated	dilatation	as	previously	described	(Wang	et	al.,	2015).	Flow	cytometric	
assays	 to	phenotype	murine	monocyte	 subsets	 and	 circulating	progenitor	 cells	
during	 hypoglycaemia	 and	 over	 longitudinal	 time	 points	 would	 compliment	
future	human	experiments	as	described.	In	order	to	assess	inflammation	further,	
mice	would	 be	 splenectomised	 at	 sacrifice	 to	 study	 immune	 cells	 focussing	 on	
HSCs	 (Dutta	 et	 al.,	 2012;	 Robbins	 et	 al.,	 2012).	 Assessment	 of	 atherosclerotic	
lesion	burden	would	also	demand	assessment	at	three	anatomical	sites	including	
the	 aorta,	 brachiocephalic	 artery	 and	 aortic	 sinus.	 To	 further	 characterise	 the	
inflammatory	signal	of	the	plaque	following	hypoglycaemia,	one	option	could	be	
to	 isolate	 plaque	 macrophages	 using	 laser	 capture	 micro-dissection	 and	
extracting	 RNA	 (Feig	 and	 Fisher,	 2013)	 for	 micro-array	 analysis	 	 to	 assess	
expression	 of	 genes	 that	 maybe	 differentially	 expressed	 following	 recurrent	
hypoglycaemia	 compared	 to	 controls.	 Additionally,	 epigenetic	 analysis	 of	 CV	








Hypoglycaemia	 remains	 a	major	 barrier	 to	 intensive	 treatment	with	 insulin	 in	
those	 with	 diabetes.	 A	 significant	 body	 of	 data	 now	 exists	 to	 support	 a	
relationship	 between	 hypoglycaemia	 and	 CV	 events	 or	 death.	 In	 this	 thesis,	 I	
present	novel	 findings	 from	human	mechanistic	 studies	 to	 support	my	original	
hypothesis	that	hypoglycaemia	induces	durable	activation	of	the	innate	immune	
system	which	 can	 accelerate	 atherosclerosis.	 Furthermore,	 I	 developed	 for	 the	
first	 time	 a	 murine	 model	 of	 recurrent	 hypoglycaemia	 and	 combined	
atherosclerosis	to	explore	in	more	detail	this	relationship.	My	animal	model	can	
be	 developed	 further	 to	 test	 more	 definitively	 the	 consequences	 of	
hypoglycaemia	 on	 the	 plaque.	 Also,	 further	 investigation	 in	 humans	 with	
diabetes	 in	 warranted	 to	 first	 dissect	 further,	 and	 then	 potentially	
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Context: Hypoglycemia is emerging as a risk for cardiovascular events in diabetes. We hypothesized
that hypoglycemia activates the innate immune system, which is known to increase cardiovascular risk.
Objective: To determine whether hypoglycemia modifies subsequent innate immune system responses.
Design and Setting: Single-blinded, prospective study of three independent parallel groups.
Participants and Interventions: Twenty-four healthy participants underwent either a hyperinsulinemic-
hypoglycemic (2.5mmol/L), euglycemic (6.0mmol/L), or sham-saline clamp (n = 8 for each group). After
48 hours, all participants received low-dose (0.3 ng/kg) intravenous endotoxin.
Main Outcome Measures: We studied in-vivo monocyte mobilization and monocyte-platelet
interactions.
Results: Hypoglycemia increased total leukocytes (9.98 6 1.14 3 109/L vs euglycemia 4.38 6 0.53 3
109/L,P,0.001; vs sham-saline 4.766 0.363 109/L,P,0.001) (mean6 SEM),mobilizedproinflammatory
intermediatemonocytes (42.206 7.52/mL vs euglycemia 20.666 3.43/mL, P, 0.01; vs sham-saline 26.206
3.86/mL, P, 0.05), andnonclassicmonocytes (36.166 4.66/mL vs euglycemia 12.726 2.42/mL, P, 0.001; vs
sham-saline 19.056 3.81/mL, P, 0.001). Following hypoglycemia vs euglycemia, platelet aggregation to
agonist (area under the curve) increased (73.87 6 7.30 vs 52.50 6 4.04, P , 0.05) and formation of
monocyte-platelet aggregates increased (96.056 14.51/mL vs 49.326 6.41/mL,P,0.05).Withinmonocyte
subsets, hypoglycemia increased aggregation of intermediatemonocytes (10.516 1.42/mL vs euglycemia
4.196 1.08/mL,P,0.05; vs sham-saline 3.816 1.42/mL,P,0.05) andnonclassicmonocytes (9.536 1.08/mL
vs euglycemia 2.866 0.72/mL, P, 0.01; vs sham-saline 3.086 1.01/mL, P, 0.05), with platelets compared
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with controls. Hypoglycemia led to greater leukocyte mobilization in response to subsequent low-dose
endotoxin challenge (10.96 6 0.97 vs euglycemia 8.21 6 0.85 3 109/L, P , 0.05).
Conclusions:Hypoglycemiamobilizes monocytes, increases platelet reactivity, promotes interaction
between platelets and proinflammatory monocytes, and potentiates the subsequent immune
response to endotoxin. These changes may contribute to increased cardiovascular risk observed in
people with diabetes. (J Clin Endocrinol Metab 104: 1187–1199, 2019)
Hypoglycemia is associated with a greater propensityto adverse cardiovascular (CV) outcomes in diabetes
(1–3). To determine whether such outcomes were de-
pendent on changes in innate immune responses, we
devised a model whereby subjects were challenged with a
hypoglycemic clamp, and then the durable effects on the
innate immune system were probed by an in vivo en-
dotoxin challenge 48 hours later.
Iatrogenic hypoglycemia remains a major barrier to
effective treatment of insulin-treated diabetes (4). The
Action to Control Cardiovascular Risk in Diabetes trial
showed that intensive glucose control, during which
patients were exposed to significantly more hypoglyce-
mia (5), was associated with excess CVmortality. Despite
the evidence confirming an association between hypo-
glycemia and mortality, cause and effect has not been
established. Trial evidence suggests that the relationship
is, at least in part, explained by confounding, that is, that
hypoglycemia identifies patients with comorbidities who
are both vulnerable to hypoglycemia and more likely to
die for other reasons (6). Nevertheless, a recent large
meta-analysis (7) suggested that comorbidities alone are
unlikely to explain this relationship. Furthermore, there
is a growing body of evidence highlighting a number of
mechanisms whereby hypoglycemia may lead to CV
events (8, 9).
Hypoglycemia has proinflammatory consequences,
including increases in levels of factor VIII and von
Willebrand factor and impaired fibrinolysis (10–12). In
addition, hypoglycemia has been shown to increase
proinflammatory cytokines (12–14) and promote rises in
the levels of proatherogenic cell adhesion molecules (12).
Repeated episodes of hypoglycemia have also been re-
ported to impair nitric oxide–mediated vasodilation (15).
Monocytes are phagocytes that are central to the
etiology of atherosclerosis (16) and play a role in pre-
cipitating acute CV events by promoting plaque de-
stabilization and rupture (17). The extent to which
monocytosis and monocyte activation are modified by
hypoglycemia remains uncertain. Recent studies
have also determined that monocytes can be classi-
fied into three distinct subsets, called classic mono-
cytes (CMs: CD14++ CD162, and Mon1), intermediate
monocytes (IMs: CD14++ CD16+,Mon2), and nonclassic
monocytes (NCMs: CD14+ CD16++, Mon3) (18, 19). A
number of observational studies indicate that IMsmay be
particularly proatherogenic. Elevated levels of IMs are
associatedwith adverseCVoutcomes (20–23), independently
predict future CV events (22), and have been associated with
coronary plaque vulnerability in patients with angina (24).
Elevated levels of CMs may also independently predict CV
events (25).
Acute myocardial infarction results in monocytosis,
mediated by sympathetic nervous system activation (26).
In humans, CD16+ monocytes selectively mobilize, in a
catecholamine-dependent fashion, after exercise (27).
Because epinephrine is the key counterregulatory hormone
produced in response to hypoglycemia, we hypothesized
that hypoglycemia would also exert significant effects on
monocytes. We further hypothesized that we would see
additional synergistic changes in monocyte and platelet
activation, as revealed by formation of monocyte-
platelet aggregates (MPAs), which are increased after
acute myocardial infarction (20, 28). In large pro-
spective studies, CV events did not appear to occur
during the hypoglycemic episode per se, but there was
an increased risk of events in the weeks andmonths after
the episode (29–31). Therefore, we hypothesized that
acute hypoglycemia may prime the innate immune
system, leading to a more pronounced inflammatory
response to a subsequent inflammatory stimulus down-
stream from the initial episode of hypoglycemia. It is also
relevant to note that people with diabetes experience
increased incidences of acute and chronic infections that
will further activate innate immunity. To reveal whether
hypoglycemia modulated monocyte function in the hu-
man in vivo, we chose to combine a classic hypoglycemic
stimulus with a subsequent in vivo systemic stimulus of
the innate immune system. To do so, we combined
hyperinsulinemic-hypoglycemic, euglycemic, and sham-
saline clamps with low-dose intravenous endotoxin
challenge 48 hours later in healthy participants. Endo-
toxin, otherwise known as gram-negative bacterial
lipopolysaccharide, was used because it induces a short-
lived, sterile inflammation that is both safe and repro-
ducible (32).











Study design and participants
This was a single-blinded, prospective study of three in-
dependent parallel groups (hyperinsulinemic-hypoglycemia,
euglycemia, and sham-saline controls) conducted in a ran-
dom group order at the Clinical Research Facility, Northern
General Hospital, Sheffield, United Kingdom between January
2015 and April 2016. We therefore had three groups that had
euglycemia with insulin, hypoglycemia with insulin, or saline.
Each then received endotoxin. Baseline values at the start
of endotoxin administration were studied in all groups, pro-
viding a set of data obtained before endotoxin. A total of 24
healthy participants without diabetes were recruited from the
University of Sheffield and Sheffield Teaching Hospitals, with
written informed consent in accordance with a protocol ap-
proved by Yorkshire and the Humber-Sheffield Research
Ethics Committee (REC 14/YH/1264). All participants had a
HbA1c ,6.5% (,48 mmol/mol), measured with ion exchange
high-performance liquid chromatography, and none had im-
paired glucose tolerance based on HbA1c as judged by the
American Diabetes Association criteria (33, 34). Participants
were in good health, as determined by amedical history, physical
examination, vital signs, and clinical laboratory test results in-
cluding full blood count and renal and liver function. Those with
an intercurrent illness in the previous 4 weeks were excluded.
Participants taking beta-blockers, QT interval–prolonging agents,
and anticoagulant, antiplatelet, or anti-inflammatory medica-
tions were also excluded. Female participants were on secure
contraception and also had negative urinary pregnancy tests on
the morning of the clamp and endotoxin studies.
Clamp studies
All participants attended at 0800 hours after an overnight
fast and were blinded to their group allocation. Participants
were instructed to avoid caffeine, alcohol, and vigorous exercise
24 hours before the study visit. An intravenous cannula was
inserted into the antecubital fossa of the nondominant arm for
insulin and dextrose infusion. A second intravenous cannula
was inserted into the antecubital fossa of the dominant arm for
all blood measurements except glucose. After application of a
local anesthetic cream (lidocaine/prilocaine; Astra-Zeneca,
Macclesfield, UK) to the dorsal hand or wrist of the non-
dominant arm, a retrograde cannula was inserted and the hand
placed in a warming chamber (The Sheffield Hand Warmer,
Sheffield, UK) at 55°C to allow arterialization of venous blood
for glucose measurement. In the hypoglycemia and euglycemia
study groups, a primed continuous insulin (Human Actrapid;
Novo Nordisk Pharmaceuticals LT, Crawley, UK) infusion was
administered at a rate of 90 mU/m2/min, with total insulin
exposure matched between groups. A 20% dextrose (Baxter
Healthcare Ltd., Thetford, UK) variable-rate infusion was
administered simultaneously and the rate adjusted according to
arterialized whole blood glucose concentrationsmeasured every
5 minutes with a glucose oxidase method (Yellow Springs In-
strument 2300 STAT, Yellow Springs, Ohio). After a brief
(30-minute) euglycemic phase in both groups, blood glucosewas
lowered to 2.5 mmol/L in the hypoglycemia group and main-
tained for 60 minutes at this level. In the euglycemia group,
blood glucose was maintained at 6 mmol/L for 60 minutes.
Participants in the sham-saline group were investigated identi-
cally but did not receive insulin/dextrose infusions and instead
received a slow intravenous infusion of 0.9% NaCl (Baxter,
Baxter Healthcare Ltd.) at a predetermined fixed rate. Thus,
participants in the sham-saline groupwere under normoglycemic
conditions, allowing us to control for the effects of insulin and
dextrose. Blood was sampled at baseline and at 60 minutes.
Members of staff processing assays were blinded to glucose
group allocation.
Endotoxin challenge
Endotoxin challenge is a safe and well-studied model of
innate immune activation in vivo (35). Forty-eight hours after
the clamp, participants reattended at 0800 hours, having fasted
overnight and refrained from caffeine, alcohol, and vigorous
exercise since the clamp visit. An intravenous cannula was
inserted into the antecubital fossa of the nondominant arm for
administration of endotoxin and a second cannula inserted into
the contralateral antecubital fossa for blood sampling. All
participants received 0.3 ng/kg Escherichia coli O:113 lipo-
polysaccharide (Clinical Centre Reference Endotoxin; National
Institutes of Health, Bethesda, MD). Endotoxin powder was
reconstituted in 1 mL sterile 0.9% NaCl to form a solution at
a concentration of 1000 ng/mL, which was vortexed for
60 minutes. The weight-adjusted dosage of endotoxin was
obtained from this solution, added to 5 mL of 0.9% NaCl, and
administered as a slow bolus injection over 1 minute. An in-
travenous infusion of 500mL of 0.9%NaCl (Baxter Healthcare
Ltd.) then continued for 4 hours after endotoxin to avoid
hypotension. Venous blood was sampled at baseline and 2, 4,
and 6 hours after endotoxin. All laboratory measurements were
performed by staff blinded to glucose group allocation.
Biochemical analysis
To measure epinephrine, venous forearm blood was col-
lected into chilled lithium heparin tubes and centrifuged at 4°C,
1000g for 10 minutes. The resulting supernatant was stored
at 280°C until assayed by high-performance liquid chroma-
tography. To determine insulin levels, EDTA-anticoagulated
blood was centrifuged at 3000g for 10 minutes, and free insulin
levels were measured in the resulting plasma with an immu-
noassay (Roche Cobas; Roche Diagnostics, Burgess Hill, West
Sussex, UK). Venous blood was centrifuged at 3000g for
10 minutes, and the resulting serum was used to measure
cortisol and GH with an immunoradiometric assay (Roche
Cobas). Sample collection for cortisol and GH was controlled
for time of day across the three study groups.
Cell counts and flow cytometry
Total and differential white blood cell (WBC) and platelet
counts in EDTA-anticoagulated blood were determined with an
automated clinical grade Sysmex cell counter (XN-9000; Sys-
mex, Milton Keynes, UK). For the clamp visit, alternative WBC
counting methods were piloted for the first two subjects in each
group, but these were later deemed less accurate than the
Sysmex cell counter. Data shown in Figs. 2, 3, and 4a, 4c, 4d,
4e, and 4f are Sysmex data from n = 6 in each study group. Flow
cytometry was used to determine MPAs: blood was collected
into tubes containing trisodium citrate dihydrate (3.13% w/v)
and incubated in a heat block at 37°C for 10 minutes; eryth-
rocytes were lysed with fluorescence-activated cell sorting
(FACS) lyse solution (BD, Oxford, UK) and stained with
fluorescein isothiocyanate–conjugated CD16 (BioLegend, London,
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UK), allophycocyanin-conjugated CD14 (BioLegend), and phyco-
erythrin (PE)-conjugated CD42a (BD) in addition to matched
isotype controls. Cells were fixedwith FACS Fix (BD) and analyzed
with flow cytometry (Accuri C6 multicolor flow cytometer; BD)
within a consistent time frame for all subjects. Monocytes were
gated based on morphology and CD14 expression. Neutrophils
were gated on morphology and through exclusion of monocytes.
Monocyte-platelet aggregation was determined by measuring
monocytemean fluorescence of the platelet-specific marker CD42a.
To phenotype and enumerate monocyte subsets, anticoagulated
blood was stained with fluorescein isothiocyanate–conjugated
CD16 (BioLegend), allophycocyanin-conjugated CD14 (BioL-
egend), PE-conjugated CD66c (BD), PE-Cy7-conjugated CD11b
(BioLegend), and (PerCP)-eFluor® 710-conjugated CX3C
chemokine receptor 1 (CX3CR1; eBioscience, Altrincham,
UK). Matched isotype controls and a “fluorescence minus
one” strategy optimized compensation. Stained whole blood
was lysed with FACS lyse as above and the pellet resuspended
in PBS before fixation with 1% w/v formaldehyde. Samples
were immediately processed for analysis with flow cytometry
(LSRII; BD). Monocytes were gated based on morphologi-
cal characteristics and through the exclusion of neutrophils
with CD66c. Monocyte subsets were identified based on
relative expression of CD14 and CD16. Flow cytometry data
were analyzed with FlowJo version 10 (FlowJo LLC, Ash-
land, OR).
Platelet aggregation
Platelet aggregation was measured with impedance aggreg-
ometry (Multiplate®; Verum Diagnostica GmBH, Munich,
Germany). Aliquots of 300 mL saline and 300 mL hirudin-
anticoagulated blood were added to the cuvette and incubated
at 37°C for 3 minutes. Then 20 mL ADP (at a final concentration
of 6.45 mM) was added as agonist, and the assay commenced.
The area under the curve was measured, which represents the
level of platelet aggregation.
Statistical analysis
Our pilot data indicated that a sample size of seven par-
ticipants per group would have 90% power to detect a 50%
relative difference in mobilization of monocytes between hy-
poglycemia and controls. Eight subjects were recruited per
group to allow for a 13% dropout rate. Mean baseline mea-
surements of glucose were compared between groups with
ANOVA. Mean measurements of glucose, insulin, and epi-
nephrine at 60 minutes after clamp were compared, adjusting
for clamp baseline measurement, with analysis of covariance. In
the event of unequal variance between groups, a log transform
was applied and the analysis repeated. Longitudinal and between-
group comparisons were made for postendotoxin measure-
ments with mixed effects linear models. For models examining
between-group differences, the baseline endotoxin measure-
ment was included as a covariate. For all mixed-effects linear
models, an autoregressive correlation structure was used to
allow for the correlation between multiple measurements on
the same person. Planned contrasts were made with baseline
and between groups at equivalent time points with Sidak
correction for multiple comparisons. All data are expressed as
mean 6 SEM, unless otherwise specified, and a P , 0.05 was
deemed statistically significant. Analysis was performed in
SPSS version 22.0 (IBM, Chicago, IL).
Results
Participants
Study participants across the three groups were well
matched for age, sex, body mass index, HbA1c, and total
WBC count, with no significant differences at screen-
ing (Table 1). Participant numbers at each stage of study
are illustrated in a flow diagram (Supplemental Flow
Diagram).
Clamp studies
Glucose, insulin, and counterregulatory hormones
Arterialized blood glucose values are shown in Fig. 1a.
The glucose values were 2.516 0.11 mmol/L and 6.046
0.16 mmol/L at the end of the hypoglycemia and
euglycemia clamps, respectively. Glucose values at the
end of the sham-saline clamp were 4.64 6 0.09 mmol/L.
A counterregulatory response to hypoglycemia was ev-
ident, with epinephrine levels during hypoglycemia
(1.87 6 0.25 nmol/L) being significantly higher (P ,
0.001) than those during euglycemia (0.076 0.01 nmol/L)
and sham-saline (0.10 6 0.04 nmol/L) (Fig. 1b). Free in-
sulin levels at the end of clamp were similar between the
hypoglycemia (968.5 6 149.1 pmol/L) and euglycemia
groups (1025.4 6 81.4 pmol/L, P = 0.996) but signif-
icantly higher (P, 0.001) than those in the sham-saline
(31.3 6 6.3 pmol/L) group (Fig. 1c). Serum cortisol and
Table 1. Comparison of Participant Characteristics at Baseline
Parameter Hypoglycemia Euglycemia Sham-Saline P
Total (n = 24) 8 8 8 N/A
Sex, M/F 4/4 4/4 4/4 N/A
Age, y 21 (19–22) 21 (20–23) 21.5 (21–26) 0.299
Body mass index, kg/m2 24 6 2 23 6 2 24 6 4 0.638
HbA1c
% 5.2 6 0.31 5.2 6 0.26 5.1 6 0.14 0.792
mmol/mol 34 6 3.6 33.5 6 2.8 32.6 6 1.4 0.616
Total WBCs, 3109/L 6.26 6 1.42 4.83 6 0.91 4.50 6 1.69 0.102
Data are mean 6 SD or median (interquartile range). P values indicate comparisons between study groups via parametric or nonparametric testing.
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GHwere significantly higher in the hypoglycemia group
than in the euglycemia and sham-saline groups (Fig. 1d
and 1e).
Total and differential leukocyte count
We determined whether hypoglycemia results in
changes in circulating leukocytes. Hypoglycemia sig-
nificantly increased the total number of WBCs com-
pared with controls (Fig. 2a). There was an increase
across all classes of leukocytes studied, including neutro-
phils (Fig. 2b), lymphocytes (Fig. 2c), and total monocytes
(Fig. 3a).
Monocyte subsets
We sought to determine whether hypoglycemia exerted
specific effects on monocyte subsets associated with car-
diac pathology. Hypoglycemia increased the absolute
number of all three circulating monocyte subsets com-
pared with euglycemia and sham-saline (Fig. 3b–3d). The
number of circulating NCMs after 60 minutes of hypo-
glycemia compared with baseline (17.6 6 2.9 cells/mL)
increased twofold. IM numbers after 60 minutes of hy-
poglycemia compared with baseline (23.2 6 4.5 cells/mL)
increased by a factor of 1.81, and CMs after 60 minutes of
hypoglycemia comparedwithbaseline (442.46 55.3 cells/mL)
increased by a factor of 1.29. There were no significant dif-
ferences in the baseline values of all three monocyte subsets
between the study groups.
Platelet count, aggregation, and MPAs
Activation of platelets and generation of platelet-
leukocyte aggregates contribute to leukocyte mobiliza-
tion and inflammation in the vasculature (36). We
therefore studied platelet number and function and their
Figure 1. Glucose, insulin, and counterregulatory hormones in clamp studies. (a) Arterialized whole blood glucose values during hyperinsulinemic
hypoglycemic, euglycemic, and sham-saline clamps, (b) epinephrine, (c) free insulin, (d) cortisol, and (e) GH values after 60 min of hypoglycemia,
euglycemia, or sham-saline injection. Data are mean (SEM). *P , 0.05; **P , 0.01; ***P , 0.001; ns-nonsignificant; P values are provided for
comparison between study groups. Black circles (and dashed line 1a), hypoglycemia group; open circles, euglycemia group; black triangles (and solid
line 1a), sham-saline group.
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interaction with leukocytes. Total platelet count in-
creased in hypoglycemia compared with euglycemia and
sham-saline controls (Fig. 4a). ADP-induced platelet
aggregation increased after 60 minutes of hypoglycemia
vs euglycemia (P = 0.014), and numerically (but not
statistically significantly) higher platelet aggregation was
detected in the hypoglycemia group compared with the
sham-saline group (P = 0.064) (Fig. 4b). The total
number of MPAs increased after 60 minutes of hy-
poglycemia compared with euglycemia (Fig. 4c). Al-
though total MPAs were not significantly higher in the
hypoglycemia group compared with sham-saline
controls at 60 minutes (Fig. 4c), we observed specific
increases in NCM-MPAs and IM-MPAs (Fig. 4d and 4e).
CM-MPAs appeared to increase after 60 minutes of
hypoglycemia vs euglycemia and sham-saline, but this
increase was not statistically significant (P = 0.054)
(Fig. 4f).
Cell surface markers
To further explore the activation state of monocytes
after hypoglycemia, we studied expression levels of
chemokine receptor CX3CR1 and integrin CD11b. Hy-
poglycemia did not alter the expression of CX3CR1 or
CD11b (Supplemental Fig. 1a and 1b).
Endotoxin challenge
To determine whether previous hypoglycemia af-
fected the subsequent response to a classic immune ac-
tivator and thus to reveal whether hypoglycemia had any
longer-lasting effects on the innate immune system, we
performed a low-dose intravenous endotoxin challenge
48 hours after the hypoglycemic challenge in all subjects.
Consistent with the low-dose model used, no fever or
significant change in mean arterial blood pressure was
recorded after endotoxin challenge across the study
groups.
Epinephrine, cortisol, and GH
In contrast to the stress response induced by hypo-
glycemia, epinephrine levels were not significantly dif-
ferent between study groups 6 hours after endotoxin
administration (Fig. 5a). In the hypoglycemia group,
epinephrine levels were 0.15 6 0.04 nmol/L vs 0.06 6
0.01 nmol/L in euglycemia group and 0.096 0.01 nmol/L
in sham-saline group. There were also no differences
detected between groups in serum cortisol and GH levels
after endotoxin administration (Fig. 5b and 5c).However, a
rise compared with baseline in the stress hormone cortisol
was evidentwhereby serum cortisol levels peaked at 4 hours
after endotoxin challenge in all study groups (P = 0.005)
(Fig. 5b).
Total and differential leukocyte count
We observed that antecedent hypoglycemia modu-
lated the subsequent WBC response to endotoxin. Total
Figure 2. Peripheral total WBC, neutrophil, and lymphocyte kinetics
in experimental hypoglycemia and controls. Number of circulating
(a) total WBCs, (b) neutrophils, and (c) lymphocytes after 60 min of
hypoglycemia, euglycemia, or sham-saline injection. Data are mean
(SEM). **P , 0.01; ***P , 0.001; P values are provided for
comparison between study groups. Black circles, hypoglycemia
group; open circles, euglycemia group; black triangles, sham-saline
group.
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number of WBCs increased significantly after endotoxin
in all study groups (Fig. 6a). The peak WBC response
occurred at 4 hours after endotoxin, and this level was
significantly higher in the hypoglycemia group at
10.96 6 0.97 3 109/L vs 8.21 6 0.85 3 109/L in the
euglycemia group (P = 0.012) (Fig. 6a). TotalWBC count
4 hours after endotoxin in the sham-saline group was
10.65 6 0.64 3 109/L, and this level was significantly
higher than in the euglycemia group (P = 0.033) but not
the hypoglycemia group (P = 0.974). The rise in WBC
was mainly a consequence of an increase in neutrophil
count (Fig. 6b). The lymphocyte count decreased after
endotoxin (Fig. 6c), and the monocyte count initially
decreased before recovery 6 hours after endotoxin (Fig. 7a).
There was a trend toward a higher total monocyte count
in the hypoglycemia group 4 hours after endotoxin
compared with euglycemia, but this comparison did not
reach statistical significance (P = 0.085). The absolute
number of circulating monocyte subsets did not differ
significantly between study groups (Fig. 7b, 7c, and 7d).
NCM and IM numbers decreased significantly after
endotoxin compared with baseline values in all groups
(P , 0.001) (Fig. 7b and 7c). Compared with baseline,
CM numbers significantly declined at 2 hours (P ,
0.001), before rising and reaching a peak at 6 hours (P,
0.001) (Fig. 7d).
Cell surface markers
We examined monocyte activation after endotoxin
exposure by measuring cell surface marker CX3CR1
expression. Endotoxin administration caused a signifi-
cant decline in expression of this marker across all study
groups compared with baseline (P , 0.001) (Supple-
mental Fig. 2a). This decline was accompanied by an
increase in the concentration of CX3C chemokine ligand
1 in plasma at 4 and 6 hours compared with baseline in
all groups (P, 0.001) (Supplemental Fig. 2e). Activation
of monocytes was also revealed by increased expression
of CD11b expression at 4 and 6 hours after endotoxin
compared with baseline in all groups (P , 0.001)
(Supplemental Fig. 3a). In addition, the percentage of
total monocytes that were positive for CD11b expression
was higher in hypoglycemia group than in the euglycemia
group at 2 hours after endotoxin (P = 0.007) (Supple-
mental Fig. 3b).
Discussion
Hypoglycemia may contribute to exacerbations of ische-
mic CV disease. We aimed to investigate the effect of acute
experimental hypoglycemia and subsequent low-dose
endotoxemia on aspects of the innate immune response
(total leukocytes, leukocyte subsets, and specifically mono-
cyte subsets), thrombosis (platelet aggregation), and crosstalk
Figure 3. Total monocyte count and monocyte subset kinetics in experimental hypoglycemia groups and controls. Absolute circulating numbers
of (a) total monocytes and monocyte subsets (b) NCM, (c) IM, and (d) CM after 60 min of hypoglycemia, euglycemia, or sham-saline injection.
Data are mean (SEM). *P , 0.05; **P , 0.01; ***P , 0.001; P values are provided for comparison between study groups. Black circles,
hypoglycemia group; open circles, euglycemia group; black triangles, sham-saline group.
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between inflammation and thrombosis (MPAs). Our main
findings were that hypoglycemia increased the number
of all three circulating monocyte subsets, in association
with a stress response characterized by increased plasma
epinephrine levels; hypoglycemia increased platelet re-
activity, promoted formation of MPAs, and promoted
aggregate formation between proinflammatory mono-
cytes and platelets; leukocyte mobilization to the stress
response of low-dose endotoxin was independent of
epinephrine; and antecedent hypoglycemia resulted in a
significantly higher inflammatory leukocyte response to
low-dose endotoxin administered 48 hours later.
As shown previously (13, 37), we confirm that
hypoglycemia results in leukocytosis. In addition, we
present the effect of hypoglycemia on monocyte subset
kinetics and demonstrate an increase in the absolute
number of all three circulating monocyte subsets. The
largest increase was observed in numbers of circulating
NCMs (twofold) and IMs (1.8-fold), with a modest in-
crease in the number of CMs (1.3-fold). These data are
in keeping with an observed selective mobilization of
CD16+ monocytes in response to exercise (27, 38) and
epinephrine infusion (39). Ratter et al. (37) also recently
determined that hypoglycemia might modify selective
monocyte mobilization. However, they did not pheno-
type monocyte subsets but rather measured total levels of
CD16 on peripheral blood mononuclear cells isolated
from both healthy participants and those with type 1
Figure 4. Platelet reactivity and MPA formation in experimental hypoglycemia and controls. (a) Total platelet count, (b) platelet aggregation to
ADP 6.45 mM, (c) total MPA formation, and MPA formation within monocyte subsets (d) NCM-MPA, (e) IM-MPA, and (f) CM-MPA after 60 min
of hypoglycemia, euglycemia, or sham-saline injection. Data are mean (SEM). *P , 0.05; **P , 0.01; ns, nonsignificant; P values are provided
for comparison between study groups. Black circles, hypoglycemia group; open circles, euglycemia group; black triangles, sham-saline group.
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diabetes in experimental hypoglycemia settings. Our data
identify specific changes in monocyte subsets that have
been previously linked to monocyte activation and
atherogenesis. Because observational data support the
notion of CD16+ monocytes being proatherogenic (20,
22–24), and adrenergic modulation of monocytes induces
Figure 5. Changes in epinephrine, cortisol, and GH response after
endotoxin challenge. (a) Epinephrine, (b) cortisol, and (c) GH responses
2, 4, and 6 h after low-dose (0.3 ng/kg) intravenous endotoxin
challenge in participants who underwent hypoglycemia, euglycemia, or
a sham-saline clamp 48 h earlier. Data are mean (SEM). **P , 0.01;
ns, nonsignificant; P value on dashed line in (b) represents change in
cortisol at 4 h compared with baseline in all groups; solid horizontal
lines represent significance for comparison between study groups.
Dashed line in (a) illustrates the mean epinephrine response in the
hypoglycemia clamp group. Black circles, hypoglycemia group; open
circles, euglycemia group; black triangles, sham-saline group.
Figure 6. Peripheral total WBC, neutrophil, and lymphocyte kinetics
after endotoxin challenge. Number of circulating (a) total WBCs,
(b) neutrophils, and (c) lymphocytes 2, 4, and 6 h after low-dose
(0.3 ng/kg) intravenous endotoxin challenge in participants who
underwent hypoglycemia, euglycemia, or a sham-saline clamp 48 h
earlier. Data are mean (SEM). *P , 0.05; ns, nonsignificant; P
values are provided for comparison between study groups; solid
horizontal line in (c) represents significance for comparison between
study groups. Black circles, hypoglycemia group; open circles,
euglycemia group; black triangles, sham-saline group.
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proinflammatory changes (40), an increase in the cir-
culating number of these cells after hypoglycemia may
increase CV risk in diabetes.
Previous studies investigating effects of hypoglycemia
on platelet biology have suggested an increase in platelet
reactivity; however, this increase was in the context of
hypoglycemic stimulus as part of an insulin stress test
(41). An older investigation into the effect of hypogly-
cemia on monocyte-platelet interactions in type 1 di-
abetes and healthy controls also suggested a trend toward
increased MPA formation, but these data were not
conclusive, with little difference between euglycemic and
hypoglycemic conditions (42). Our study also recapitulates
and extends previous findings that hypoglycemia is pro-
thrombotic, as evidenced by an increased platelet count and
increased platelet reactivity to ADP (43). We have con-
clusively demonstrated an overall increase in formation of
MPAs in hypoglycemia in comparison with euglycemia.
Furthermore, we provide data demonstrating MPA
formation within monocyte subsets in experimental
hypoglycemia. MPA formation is a highly sensitive
marker of both monocyte and platelet activation (44,
45). MPA formation promotes monocyte release of the
proinflammatory cytokines TNFa, C-X-C motif che-
mokine ligand 8, and C-Cmotif chemokine ligand 2 (46,
47) and increases adhesive properties of monocytes
(48), thereby representing a bridge between inflammation
and thrombosis that may increase CV risk. In acute
coronary syndromes, MPA formation correlates with
troponin elevation, risk of in-hospital cardiac events in-
cluding death, and risk of future cardiac events (20, 49).
We have also shown that NCMs and IMs aggregate more
readily with platelets in response to hypoglycemia com-
pared with CMs. A similar observation of proportionally
higher IM-MPA and NCM-MPA formation has been
reported in patients after an ST elevation myocardial in-
farction, with higher IM-MPAs in particular being a poor
prognostic indicator at 6 weeks after ST-elevation myo-
cardial infarction (20). Thus, our data suggest that hy-
poglycemia not only increased circulating numbers of
CD16+ monocytes but also promoted increased in-
teraction between these proinflammatory monocyte sub-
sets and platelets.
We wanted to determine whether antecedent hypo-
glycemia modulated responses to low-dose endotoxin.
We chose a low-dose endotoxin model because we
thought it was the safest way to combine the clamp and
endotoxin human models, because future extension to
the study of human diabetes would be more feasible with
this model, and because patients with diabetes are often
exposed to chronic low-grade infections through foot
ulceration and periodontitis, which might further increase
Figure 7. Total monocyte count and monocyte subset kinetics after endotoxin challenge. Absolute circulating numbers of (a) total monocytes
and monocyte subsets (b) NCM, (c) IM, and (d) CM 2, 4, and 6 hours after low-dose (0.3 ng/kg) intravenous endotoxin challenge in participants
who underwent hypoglycemia, euglycemia, or a sham-saline clamp 48 h earlier. Data are mean (SEM). ***P , 0.001; ns, nonsignificant; P value
on dashed line in (b) represents change in number of NCMs at 2, 4, and 6 hours compared with baseline in all study groups. P value on dashed
line in (c) represents change in number of IMs at 2, 4, and 6 h compared with baseline in all study groups. P values on dashed lines in (d)
represent change in number of CMs at 2 and 6 h compared with baseline in all study groups. Solid horizontal lines represent significance for
comparison between study groups. Black circles, hypoglycemia group; open circles, euglycemia group; black triangles, sham-saline group.
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the risk of CV mortality (50, 51). In our model, we ob-
served in all groups that monocytes were activated even in
response to low-dose endotoxin, as indicated by upre-
gulation of systemic levels of the CX3CR1 ligand, CX3C
chemokine ligand 1, and upregulation of the adhesion
molecule CD11b on the monocytes themselves. In-
terestingly, compared with euglycemia, hypoglycemia
resulted in greater leukocyte mobilization in response to
low-dose intravenous endotoxemia 48 hours later. Fur-
thermore, we noted a nonsignificant trend toward a higher
total monocyte count in the hypoglycemia group 4 hours
after endotoxin compared with euglycemia. The per-
centage of monocytes that were CD11b positive was also
higher in the hypoglycemia group compared with the
euglycemia group at 2 hours after endotoxin. Levels of
leukocyte mobilization were similar between groups who
received previous sham-saline or hypoglycemia. These
data suggest that euglycemia with insulin suppressed
leukocyte mobilization in response to endotoxin 48 hours
later, consistent with the known anti-inflammatory actions
of insulin (52, 53), and that the physiological stress of
hypoglycemia overcame this insulin-mediated suppression
of inflammatory responses. Our data show that drivers for
differential leukocyte mobilization to endotoxin are un-
likely to be due to differences between groups in epi-
nephrine, cortisol, and GH levels after endotoxin because
these levels were not significantly different. Our obser-
vation that a single episode of hypoglycemia compared
with euglycemia invokes a stronger proinflammatory re-
sponse to endotoxin up to 2 days later is of potential
clinical relevance given that trial data suggest downstream
mortality after hypoglycemia (29–31).
The strengths of our study include use of a human
experimental model and detailed flow cytometric anal-
ysis that allowed us to comprehensively describe immune
cell kinetics and activation status in response to experi-
mental hypoglycemia and endotoxin challenge in vivo.
The separation of clamp and endotoxin studies by 48 hours
allowed us to probe the longitudinal effects of hypoglycemia
on innate immunity. Moreover, by using a sham-saline
group, we specifically controlled for the immunological
effects of insulin, thereby robustly investigating proin-
flammatory changes in response to hypoglycemia.
One limitation was our decision to study a small
number of young, healthy participants, which limits the
applicability of our findings to older patients with di-
abetes, established CV risk factors, and atherosclerosis.
For ethical and safety reasons, we decided to examine our
experimental model initially in healthy participants. We
also specifically adopted a low-dose endotoxin model,
with future translatability in older, higher-risk partici-
pants in mind. Future studies should therefore confirm
our findings in patients with diabetes. In addition, it is
worth noting that we studied cell numbers, phenotypic
changes, and activation status in circulating immune cells,
and these data may not necessarily reflect the functional
capacity of these cells in an atherosclerotic plaque. An
animal model of combined experimental hypoglycemia
and atherosclerosis may help resolve these questions.
In conclusion, hypoglycemia mobilized proathero-
genic monocyte subsets and induced prothrombotic changes
by increasing platelet reactivity. In addition, hypoglycemia
amplified interactions between platelets and monocytes
by promoting MPA formation with increased aggre-
gation of proinflammatory monocytes with platelets.
Hypoglycemia may also prime the innate immune sys-
tem to respond more robustly to stimuli such as en-
dotoxin. This finding implies proinflammatory consequences
of hypoglycemia beyond the acute episode. These data pro-
vide mechanistic insights into how hypoglycemia could
increase CV risk through upregulation of inflammatory
responses.
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